Treatment and prevention of metabolic diseases
Inhibiting IL-11 signaling with specific agents addresses the inadequacies of current treatments for metabolic diseases, effectively reducing inflammation and liver fibrosis, and muscle wasting, offering therapeutic benefits for conditions like obesity and nonalcoholic steatohepatitis.
Patent Information
- Application Number
- JP2021564913
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2020-02-14
- Filing Date
- 2020-05-01
- Publication Date
- 2024-12-06
- Estimated Expiration
- 2040-05-01
AI Technical Summary
Current treatments for metabolic diseases such as obesity, type 2 diabetes, nonalcoholic steatohepatitis, and wasting diseases are inadequate, with no broadly effective therapies available, particularly for conditions like nonalcoholic steatohepatitis and wasting, which are associated with liver fibrosis and muscle loss.
Inhibition of interleukin-11 (IL-11)-mediated signaling using agents that block or reduce IL-11 binding to its receptor, including antibodies, decoy receptors, and oligonucleotides, to treat or prevent metabolic diseases by targeting IL-11-mediated pathways.
The inhibition of IL-11 signaling effectively addresses metabolic diseases by reducing inflammation, liver fibrosis, and muscle wasting, providing therapeutic benefits for conditions like obesity, diabetes, and nonalcoholic steatohepatitis, and improving patient prognosis.
Smart Images

Figure 0007595028000006 
Figure 0007595028000007 
Figure 0007595028000008
Abstract
Description
[Technical Field]
[0001] This application claims priority to UK Patent Publication No. 1906291.8, filed May 3, 2019, UK Patent Publication No. 1906597.8, filed May 10, 2019, UK Patent Publication No. 2001013.8, filed January 24, 2020, UK Patent Publication No. 2001896.6, filed February 12, 2020, and UK Patent Publication No. 2002030.1, filed February 14, 2020, the contents and elements of which are incorporated by reference for all purposes as if they were part of this specification.
[0002] The present invention relates to the diagnosis, treatment and prevention of metabolic diseases. [Background technology]
[0003] Obesity, diabetes and related conditions Obesity, as defined by the WHO, is the accumulation of excess fat that can impair health and is defined as a weight of 30 kg / m 2A BMI of 0.05 or higher is diagnostic for obesity. Obesity significantly increases the risk of metabolic diseases (including type 2 diabetes (T2D) and fatty liver disease), cardiovascular diseases (including hypertension, myocardial infarction, and stroke), musculoskeletal diseases (e.g., osteoarthritis), Alzheimer's disease, depression, and several types of cancer (breast cancer, ovarian cancer, prostate cancer, liver cancer, kidney cancer, and colon cancer). See, for example, Bluher, et al., Nat Rev Endocrinol. (2019) 15:288-298 and Prospective Studies Collaboration, Lancet. (2009) 373(9669):1083-96. Obesity can also lead to reduced quality of life, unemployment, reduced productivity, and social disadvantage (Berrington de Gonzalez et al., N Engl J Med (2010) 363:2211-2219). Furthermore, obesity is associated with a reduced life expectancy, estimated at 5 to 20 years depending on the severity of the condition and comorbidities (Fontaine et al., JAMA (2003) 289: 187-193).
[0004] The prevalence of obesity has increased to pandemic levels over the past 50 years. The global prevalence of obesity has also increased at an alarming rate among children and adolescents, increasing from 0.7% to 5.6% among boys and from 0.9% to 7.8% among girls between 1975 and 2016 (NCD-RisC, Lancet (2017) 390(10113):26227-2642). Westernized lifestyles and high-calorie foods are considered to be the main causes of obesity.
[0005] One of the most significant threats to human health worldwide is the increasing incidence of type 2 diabetes associated with obesity. Menke et al. (JAMA (2015) 314: 1021-1029) examined diabetes trends by BMI classification and found that diabetes increased only among obese subjects (18.0%-20.1%), suggesting that the majority of the increase in diabetes prevalence is attributable to the increasing prevalence of obesity. The high prevalence of diabetes in Asians is particularly concerning; despite having a lower BMI than Caucasians, Asians have a 30%-50% higher incidence of diabetes (Lee et al., Diabetes Care (2011) 34, 353-357).
[0006] The therapeutic efficacy of metformin has been demonstrated, and it is used as a first-line treatment for diabetes in addition to adopting a healthy lifestyle, including regular exercise, to achieve anti-obesity effects (Yerevanian et al., Curr Obes Rep (2019)). Recently, it has been shown that low-grade inflammation in type 2 diabetes can be regulated by utilizing interleukin-1 as a therapeutic target for diabetes (Kataria et al., Semin Immunopathol. (2010)).
[0007] Nonalcoholic steatohepatitis (NASH) The global prevalence of nonalcoholic fatty liver disease (NAFLD) is estimated to be 25% (Friedman et al., Nat Med. (2018) 24(7): 908-922). Although NAFLD is reversible, it can progress to nonalcoholic steatohepatitis (NASH), which is characterized by steatosis-induced inflammation, hepatocyte death, and liver fibrosis, ultimately leading to liver failure. Hepatic stellate cells (HSCs) play a crucial role in the pathogenesis of NASH, and up to 95% of hepatic myofibroblasts arise from them (Mederacke et al. Nat Commun (2013) 4:2823), which are responsible for most of the key pathologies of NASH, including liver fibrosis, inflammation, and liver parenchymal dysfunction (Friedman, Physiol Rev (2008) 88:125-172; Friedman, J Biol Chem (2000) 275:2247-2250; Higashi et al., Adv Drug Deliv Rev (2017) 121:27-42).
[0008] Various factors are involved in the activation and transformation of hepatic stellate cells, including the common profibrotic factors transforming growth factor β1 (TGFβ1) and platelet-derived growth factor (PDGF; Hellerbrand J Hepatol (1999) 30:77-87; Tsuchida and Friedman Nat Rev Gastroenterol Hepatol (2017) 14:397-411), as well as proinflammatory factors such as CCL2, TNFα, and CCL5 (Friedman, J Biol Chem (2000) 275:2247-2250; Tsuchida and Friedman Nat Rev Gastroenterol Hepatol (2017) 14:397-411; Kim et al., Sci Rep (2018) 8:7499). Perhaps reflecting this complexity and potential redundancy, treatments targeting single upstream factors in NASH pathogenesis have failed, and there are no approved drugs for the treatment of NASH. While several drugs are currently being tested in clinical trials for NASH, many of these target metabolism, and it is unclear whether they improve liver fibrosis, which predicts clinical outcome (Friedman et al., Nat Med. (2018) 24(7): 908-922; Banini et al., Curr Opin Gastroenterol (2017) 33:134-141).
[0009] Quiescent hepatic stellate cells (HSCs) are vitamin A-storing cells that differ significantly from fibroblasts. However, common factors activate both HSCs and fibroblasts, promoting their transformation into myofibroblasts, which share common characteristics (Mederacke et al. Nat Commun (2013) 4:2823; Iwaisako et al., Proc Natl Acad Sci USA 2014;111:E3297-305). Recently, IL-11 has been identified as a key factor involved in the transformation of fibroblasts into myofibroblasts in the cardiovascular and pulmonary systems (Schafer et al., Nature 2017;552:110-115; Cook et al., (2018) https: / / doi.org / 10.1101 / 336537). Although knowledge about IL-11 in the liver is very limited, recombinant human IL-11 has been shown to have a protective effect when injected at very high doses in rodents (Zhu et al., PLoS One (2015) 10:e0126296; Yu et al., Clin Res Hepatol Gastroenterol (2016) 40:562-570). Recombinant human IL-11 has also been tested in human clinical trials to reduce inflammation in advanced hepatitis (Lawitz et al., Am J Gastroenterol 2004;99:2359-2364).
[0010] Wasting diseases Wasting can be defined as muscle loss accompanied by a loss of fat mass, which can manifest as weight loss. Various acute and chronic illnesses and aging are often associated with wasting. Wasting can lead to poor nutritional status, loss of muscle mass and function, reduced quality of life, and increased risk of morbidity and mortality. While muscle wasting is the most common feature of wasting, adipose tissue wasting can occur independently of or simultaneously with muscle wasting. Examples of wasting disorders include cachexia, sarcopenia (e.g., age-related or disuse-related loss of skeletal muscle mass and strength), anorexia (reduced or lost appetite), myopenia (a term proposed to broadly describe muscle wasting), lipodystrophy (wasting of fat deposits in specific areas), and lipoatrophy. The current widely accepted definition of cachexia is "a multifactorial syndrome characterized by a persistent loss of skeletal muscle mass (with or without loss of fat mass) that cannot be fully reversed by conventional nutritional support and leads to progressive functional disability" (Evans et al. Clin Nutr. 2008 (6):793-9).
[0011] Wasting is highly prevalent in patients in the later stages of chronic illness. According to the Society on Sarcopenia, Cachexia, and Wasting Disorders (SCWS), approximately 5–15% of patients with chronic heart failure or chronic obstructive pulmonary disease experience wasting, and 60–80% of patients with advanced cancer experience wasting. Cachexia is the direct cause of 20% of cancer deaths (Skipworth et al, Clin Nutr. 2007; 26:667–76). Wasting has also been observed in patients with infectious diseases such as HIV / AIDS, malaria, and tuberculosis, as well as in patients with chronic diseases such as cystic fibrosis, liver cirrhosis, renal failure, Crohn's disease, rheumatoid arthritis, stroke, and neurodegenerative disorders. Additionally, trauma, post-surgery, weightlessness, chronic alcoholism, and sepsis are also associated with the development of wasting (Farkas et al. J Cachexia Sarcopenia Muscle (2013) 4:173-178).
[0012] Wasting and wasting disorders often have a negative impact on treatment of the underlying disease, can reduce a patient's response to treatment of the underlying disease, impair the immune system, and exacerbate symptoms of the underlying condition. Therefore, treatments that improve wasting may improve the effectiveness of treatment of the underlying disease / condition and improve patient outcomes.
[0013] For example, cachexia associated with advanced cancer often leads to poor prognosis in anticancer treatment. When weight-loss cancer patients attempt or undergo chemotherapy, they receive lower initial doses and more frequently experience severe dose-limiting toxicities than weight-stable patients. Therefore, they may receive significantly less treatment or be excluded from treatment plans from the onset (Vaughan et al. J Cachexia Sarcopenia Muscle (2013) 4:95-109). Effective treatment of wasting weight can provide positive outcomes for these patients.
[0014] Current treatments for wasting include appetite stimulants and exercise to increase muscle mass. However, nutritional supplementation and pharmacological appetite stimulation alone are often ineffective in reversing wasting, especially in severe or late-stage disease. Eicosapentaenoic acid (EPA; an omega-3 fatty acid extracted from fish oil) has been tested for its ability to improve cachexia in cancer patients, but clinical trials have yielded mixed results (Jatoi et al., J Clin Oncol. 2004; 22:2469-76). Antioxidants and nonsteroidal anti-inflammatory drugs are also being tested. For example, combinations of these therapies with EPA, oxidative stress inhibitors, and / or appetite stimulants appear promising for the treatment of wasting. Inhibition of the ubiquitin proteolytic pathway (UPP) is of particular interest. Inhibition by muscle inhibitors such as myostatin has not been successful in clinical trials.
[0015] The multifactorial nature of wasting associated with underlying conditions means that there are no widely effective or widely accepted treatments, not even approved pharmacological therapies, for wasting. Indeed, it is generally recognized that the only cure for wasting associated with underlying conditions is to cure the underlying disease (Vaughan et al. J Cachexia Sarcopenia Muscle (2013) 4:95-109). Therefore, new treatments for wasting are needed. Summary of the Invention [Means for solving the problem]
[0016] The present invention provides agents capable of inhibiting interleukin-11 (IL-11)-mediated signaling for use in methods for the treatment or prevention of metabolic diseases.
[0017] Also provided is the use of an agent capable of inhibiting interleukin-11 (IL-11)-mediated signaling in the manufacture of a medicament for use in a method for treating or preventing metabolic disease.
[0018] Further provided is a method for treating or preventing a metabolic disease, comprising administering to a subject a therapeutically or prophylactically effective amount of an agent capable of inhibiting interleukin-11 (IL-11)-mediated signaling.
[0019] In some embodiments, the metabolic disease is or comprises obesity, type 2 diabetes (T2D), type 1 diabetes (T1D), prediabetes, overweight, metabolic syndrome, pregnancy-associated hyperglycemia, cholestatic liver disease, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, wasting, cachexia, chemotherapy-associated weight loss, pancreatic insufficiency, pancreatitis, acute pancreatitis, chronic pancreatitis, steatosis, lipotoxicity, non-alcoholic fatty liver disease (NAFLD), non-alcoholic fatty liver (NAFL), non-alcoholic steatohepatitis (NASH), lipodystrophy, lipohypertrophy, lipoatrophy, insulin resistance, or hyperglucagonemia.
[0020] In some embodiments, the agent is an agent capable of blocking or reducing the binding of interleukin-11 (IL-11) to the interleukin-11 receptor (IL-11R).
[0021] In some embodiments, the agent is capable of binding to interleukin-11 (IL-11) or interleukin-11 receptor (IL-11R).
[0022] In some embodiments, the agent is selected from the group consisting of an antibody or antigen-binding fragment thereof, a polypeptide, a peptide, a nucleic acid, an oligonucleotide, an aptamer, and a small molecule.
[0023] In some embodiments, the agent is an antibody or an antigen-binding fragment thereof.
[0024] In some embodiments, the agent is a decoy receptor.
[0025] In some embodiments, the agent is an anti-IL-11 antagonist antibody or antigen-binding fragment thereof directed against IL-11-mediated signaling. In some embodiments, the agent is an anti-IL-11Rα antagonist antibody or antigen-binding fragment thereof directed against IL-11-mediated signaling.
[0026] In some embodiments, the agent is a decoy receptor for IL-11. In some embodiments, the decoy receptor for IL-11 comprises (i) an amino acid sequence corresponding to the cytokine binding module of gp130 and (ii) an amino acid sequence corresponding to the cytokine binding module of IL-11Rα.
[0027] In some embodiments, the agent is a mutein of IL-11. In some embodiments, the mutein of IL-11 is a mutein having a W147A substitution.
[0028] In some embodiments, the agent is an agent capable of blocking or reducing expression of interleukin-11 (IL-11) or interleukin-11 receptor (IL-11R).
[0029] In some embodiments, the agent is an oligonucleotide or a small molecule.
[0030] In some embodiments, the agent is an antisense oligonucleotide capable of inhibiting or reducing IL-11 expression. In some embodiments, the antisense oligonucleotide capable of inhibiting or reducing IL-11 expression is an IL-11-targeted siRNA comprising the sequence of SEQ ID NO: 12, 13, 14, or 15. In some embodiments, the agent is an antisense oligonucleotide capable of inhibiting or reducing IL-11Rα expression. In some embodiments, the antisense oligonucleotide capable of inhibiting or reducing IL-11Rα expression is an IL-11Rα-targeted siRNA comprising the sequence of SEQ ID NO: 16, 17, 18, or 19.
[0031] In some embodiments, the interleukin-11 receptor is or comprises IL-11Rα.
[0032] In some embodiments, the method comprises administering the agent to a subject in which expression of interleukin-11 (IL-11) or IL-11 receptor (IL-11R) is upregulated.
[0033] In some embodiments, the method comprises administering the agent to a subject identified as having upregulated expression of interleukin-11 (IL-11) or IL-11 receptor (IL-11R).
[0034] In some embodiments, the method includes determining whether expression of interleukin-11 (IL-11) or IL-11 receptor (IL-11R) is upregulated in a subject, and administering the agent to a subject in which expression of interleukin-11 (IL-11) or IL-11 receptor (IL-11R) is upregulated. DETAILED DESCRIPTION OF THE INVENTION
[0035] Interleukin-11 and IL-11 receptor Interleukin-11 (IL-11), also known as adipogenic inhibitory factor, is a pleiotropic cytokine and a member of the IL-6 cytokine family, which also includes IL-6, IL-11, IL-27, IL-31, oncostatin, leukemia inhibitory factor (LIF), cardiotrophin-1 (CT-1), cardiotrophin-like cytokine (CLC), ciliary neurotrophic factor (CNTF), and neuropoietin (NP-1).
[0036] Interleukin-11 (IL-11) is expressed in various mesenchymal cells. The IL-11 genomic sequence has been mapped to the centromeric region of chromosome 7 and chromosome 19. IL-11 is transcribed with a classical signal peptide, which ensures efficient secretion from cells. The activator protein complex (cJun / AP-1) within the IL-11 gene promoter is important for basal transcriptional regulation of IL-11 (Du and Williams, Blood 1997, Vol 89: 3897-3908). The human IL-11 precursor is a 199-amino acid polypeptide, and the mature IL-11 is a 178-amino acid protein (Garbers and Scheller, Biol. Chem. 2013; 394(9):1145-1161). The amino acid sequence of human IL-11 is available under UniProt accession number P20809 (P20809.1 GI:124294; SEQ ID NO: 1). Recombinant human IL-11 (oprelvekin) is also commercially available. Several IL-11s from other species, including mouse, rat, pig, cow, several species of bony fish, and primates, have also been cloned and sequenced.
[0037] As used herein, "IL-11" refers to IL-11 derived from any biological species, including isoforms, fragments, variants, or homologs of IL-11 obtained from any biological species. In a preferred embodiment, the biological species is human (Homo sapiens). IL-11 isoforms, fragments, variants, or homologs may be characterized by having at least 70%, preferably 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% amino acid sequence identity with the amino acid sequence of IL-11 precursor or mature IL-11 derived from a given biological species (e.g., human). An isoform, fragment, variant, or homolog of IL-11 may be characterized by its ability to bind to IL-11Rα (preferably from the same species) and thereby stimulate signaling in cells expressing IL-11Rα and gp130 (e.g., as described in Curtis et al. Blood, 1997, 90(11) or Karpovich et al. Mol. Hum. Reprod. 2003 9(2):75-80). The length of an IL-11 fragment may be any length (in amino acids), but may be at least 25% of the length of mature IL-11, and may be up to 50%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of the length of mature IL-11. The length of the IL-11 fragment may be a minimum of 10 amino acids and a maximum of 15, 20, 25, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, or 195 amino acids.
[0038] IL-11 signals via the ubiquitously expressed homodimer of glycoprotein 130 (gp130; also known as glycoprotein 130, IL-6ST, IL-6-β, or CD130). gp130 is a transmembrane protein and a receptor subunit that associates with the IL-6 receptor family to form type I cytokine receptors. Specificity is exerted by the individual interleukin-11 receptor α subunit (IL-11Rα). Although the IL-11α receptor does not directly participate in signal transduction, upon cytokine binding to the α receptor, it associates with gp130 to form the final complex.
[0039] Human gp130 (including a 22-amino acid signal peptide) is a 918-amino acid protein; its mature form is 866 amino acids long, containing a 597-amino acid extracellular domain, a 22-amino acid transmembrane domain, and a 277-amino acid intracellular domain. The extracellular domain of human gp130 contains the gp130 cytokine binding module (CBM). The gp130 CBM contains the Ig-like domain D1 and the gp130 fibronectin type III domains D2 and D3. The amino acid sequence of human gp130 is available under UniProt accession number P40189-1 (SEQ ID NO: 2).
[0040] Human IL-11Rα is a 422-amino acid polypeptide (UniProt Q14626; SEQ ID NO: 3) with approximately 85% nucleotide and amino acid sequence identity to murine IL-11Rα. Two isoforms of IL-11Rα, each with a distinct intracellular domain, have been reported (Du and Williams, supra). The IL-11 receptor α chain (IL-11Rα) shares many structural and functional similarities with the IL-6 receptor α chain (IL-6Rα). The extracellular domains of IL-11Rα and IL-6Rα share 24% amino acid identity and contain the characteristic conserved Trp-Ser-X-Trp-Ser (WSXWS) motif. The short intracellular domains (34 amino acids long) of IL-11Rα and IL-6α lack the Box1 and Box2 regions required for activation of the JAK / STAT signaling pathway.
[0041] The receptor binding site of mouse IL-11 has been mapped, and three sites (site I, site II, and site III) have been identified. Substitutions in site II and site III reduce binding to gp130. Site III mutations have no detectable agonist activity but exhibit antagonist activity against IL-11Rα (Cytokine Inhibitors Chapter 8; Gennaro Ciliberto and Rocco Savino, co-editors, Marcel Dekker, Inc. 2001).
[0042] As used herein, IL-11 receptor (IL-11R) refers to a polypeptide or polypeptide complex capable of binding to IL-11. In some embodiments, the IL-11 receptor is capable of binding to IL-11 and inducing signal transduction in cells expressing the IL-11 receptor.
[0043] The IL-11 receptor may be derived from any species, including isoforms, fragments, variants, or homologs of the IL-11 receptor from any species. In a preferred embodiment, the species is human (Homo sapiens).
[0044] In some embodiments, the IL-11 receptor may be IL-11Rα. In some embodiments, the IL-11 receptor may be a polypeptide complex comprising IL-11Rα. In some embodiments, the IL-11 receptor may be a polypeptide complex comprising IL-11Rα and gp130. In some embodiments, the IL-11 receptor may be gp130 or a gp130-containing complex to which IL-11 binds.
[0045] Isoforms, fragments, variants, or homologs of IL-11Rα may be characterized by having at least 70%, preferably 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% amino acid sequence identity with the amino acid sequence of IL-11Rα from a given species (e.g., human). Isoforms, fragments, variants, or homologs of IL-11Rα may also be characterized by the ability to bind IL-11 (preferably from the same species) and thereby stimulate signaling in cells expressing IL-11Rα and gp130 (e.g., as described in Curtis et al. Blood, 1997, 90(11) or Karpovich et al. Mol. Hum. Reprod. 2003 9(2):75-80). The length of the IL-11 receptor fragment may be any length (in amino acids), but may be at least 25% of the length of mature IL-11Rα and may be up to 50%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of the length of mature IL-11Rα. The length of a fragment of an IL-11 receptor may be a minimum of 10 amino acids, and a maximum of 15, 20, 25, 30, 40, 50, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 250, 300, 400, or 415 amino acids.
[0046] IL-11 signaling IL-11 binds to IL-11Rα with low affinity (Kd = approximately 10 nmol / L), and the interaction between these binding partners alone is insufficient to transduce biological signals. Coexpression of IL-11Rα and gp130 is required to form a receptor capable of binding with high affinity (Kd = approximately 400-800 pmol / L) and transducing signals (Curtis et al. Blood 1997; 90 (11):4403-12; Hilton et al., EMBO J 13:4765, 1994; Nandurkar et al., Oncogene 12:585, 1996). Binding of IL-11 to cell surface IL-11Rα induces heterodimerization, tyrosine phosphorylation, activation of gp130, and downstream signaling, primarily via the mitogen-activated protein kinase (MAPK) cascade and the Janus kinase / signal transducer and activator of transcription (Jak / STAT) pathway (Garbers and Scheller, supra).
[0047] Furthermore, because soluble IL-11Rα can, in principle, bind to IL-11 to form a biologically active soluble complex (Pflanz et al., 1999 FEBS Lett, 450, 117-122), it is conceivable that, like IL-6, IL-11 may bind to soluble IL-11Rα before binding to cell surface gp130 (Garbers and Scheller, supra). Curtis et al. (Blood 1997 Dec 1; 90 (11):4403-12) reported that they expressed a soluble mouse IL-11 receptor α chain (sIL-11R) and examined signal transduction in gp130-expressing cells. In this study, we reported that in the presence of gp130 but the absence of transmembrane IL-11R, soluble IL-11R induced IL-11-dependent differentiation of M1 leukemia cells and proliferation of Ba / F3 cells, as well as early intracellular events (e.g., phosphorylation of gp130, STAT3, and SHP2), similar to signaling via transmembrane IL-11R. Activation of membrane-bound gp130-mediated signaling by IL-11 bound to soluble IL-11Rα has recently been demonstrated (Lokau et al., 2016 Cell Reports 14, 1761-1773). This so-called IL-11 trans-signaling may be important in disease pathogenesis, but its role in human disease remains to be explored.
[0048] As used herein, "IL-11 trans-signaling" refers to signaling initiated by the further binding of IL-11 bound to IL-11Rα to gp130. IL-11 can bind to IL-11Rα non-covalently to form a complex. gp130 is membrane-bound and expressed by cells, and signaling occurs when the IL-11:IL-11Rα complex binds to gp130. In some embodiments, IL-11Rα may be soluble IL-11Rα. In some embodiments, soluble IL-11Rα is a soluble (secreted) isoform of IL-11Rα (e.g., lacking the transmembrane domain). In some embodiments, soluble IL-11Rα is a product liberated by proteolysis of the extracellular domain of membrane-bound IL-11Rα. In some embodiments, IL-11Rα may be membrane-bound, and gp130-mediated signaling may be initiated by IL-11 binding to membrane-bound IL-11Rα. This is referred to as "IL-11 cis-signaling." In a preferred embodiment, inhibition of IL-11-mediated signaling is achieved by disrupting IL-11-mediated cis-signaling.
[0049] IL-11-mediated signaling has been shown to stimulate hematopoiesis and thrombopoiesis, stimulate osteoclast activity, stimulate neurogenesis, inhibit adipogenesis, reduce the expression of pro-inflammatory cytokines, regulate extracellular matrix (ECM) metabolism, and mediate normal growth control of gastrointestinal epithelial cells (Du and Williams, supra).
[0050] The physiological role of interleukin-11 (IL-11) remains unclear. IL-11 has been most strongly associated with hematopoietic cell activation and platelet production. IL-11 has also been shown to confer protective effects against graft-versus-host disease, inflammatory arthritis, and inflammatory bowel disease, suggesting that IL-11 is an anti-inflammatory cytokine (Putoczki and Ernst, J Leukoc Biol 2010, 88(6):1109-1117). However, IL-11 has also been shown to be both pro- and anti-inflammatory, proangiogenic, and important in tumorigenesis. Recent studies have demonstrated that IL-11 is readily detectable in virus-induced inflammation in mouse arthritis models and cancer, suggesting that IL-11 expression is induced by pathological stimuli. Furthermore, IL-11 has been reported to be involved in Stat3-dependent activation of tumor-promoting target genes in neoplastic gastrointestinal epithelium (Putoczki and Ernst, supra).
[0051] As used herein, "IL-11 signal transduction" and "IL-11-mediated signal transduction" refer to signal transduction mediated by the binding of IL-11 to the IL-11 receptor, or by the binding of an IL-11 fragment having the function of the mature IL-11 molecule to the IL-11 receptor. It will also be appreciated that "IL-11 signal transduction" and "IL-11-mediated signal transduction" refer to signal transduction initiated by IL-11 or a functional fragment thereof, for example, via binding to the IL-11 receptor. Thus, "signal transduction" refers to signal transduction and other cellular processes that regulate cellular activity.
[0052] metabolic disease The present invention relates to the treatment and / or prevention of metabolic diseases.
[0053] As used herein, "metabolic disease" refers to any disease or condition caused by or characterized by a metabolic abnormality. In the context of this specification, "metabolism" refers to the conversion / processing of energy sources (e.g., substances that can be ingested to provide nutrients) into energy and / or the conversion / processing of energy sources for storage in the body.
[0054] "Normal metabolism" may be the metabolism of a healthy subject not suffering from a disease, e.g., a healthy subject not suffering from a metabolic disease, or a healthy subject without symptoms / correlates of a metabolic disease.
[0055] A subject with a metabolic disease may be a subject who exhibits metabolic abnormality.A subject with a metabolic disease may be a subject who has symptoms / correlations of metabolic abnormality.A subject with a metabolic disease may be a subject who has been diagnosed with a metabolic disease.A subject may be a subject who meets the diagnostic criteria for diagnosing a metabolic disease.
[0056] In some embodiments, the metabolic disease is or comprises (e.g., is characterized by) obesity, type 2 diabetes (T2D), type 1 diabetes (T1D), prediabetes, overweight, metabolic syndrome, pregnancy-associated hyperglycemia (i.e., gestational diabetes), cholestatic liver disease, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, wasting, cachexia, chemotherapy-associated weight loss, pancreatic insufficiency, pancreatitis, acute pancreatitis, chronic pancreatitis, steatosis, lipotoxicity, non-alcoholic fatty liver disease (NAFLD), non-alcoholic fatty liver (NAFL), non-alcoholic steatohepatitis (NASH), lipodystrophy, lipohypertrophy, lipoatrophy, insulin resistance, or hyperglucagonemia.
[0057] Aspects of the present invention relate to the treatment and / or prevention of abnormalities and / or malfunctions of cells / tissues / organs / organ systems that play a role in metabolism. In particular, the treatment and / or prevention of abnormalities and / or malfunctions of pancreatic cells / tissue / pancreas is contemplated herein, as is the treatment and / or prevention of abnormalities and / or malfunctions of hepatocytes / liver tissue / liver.
[0058] In some embodiments, the metabolic disorder is or includes obesity. Obesity is characterized by excess body fat. Diagnosis of obesity is reviewed, for example, in Orzano and Scott, J Am Board Fam Pract (2004) 17(5): 359-369, which is incorporated herein by reference in its entirety. An obese subject is defined as having a weight of 30 kg / m or more. 2 In some embodiments, the metabolic disorder is or comprises being overweight. Overweight is defined as a BMI of 25 kg / m or greater. 2 and more than 30 kg / m 2 Obesity and overweight are often caused by a combination of excessive food intake, lack of physical activity, and genetic susceptibility.
[0059] In some embodiments, the metabolic disease is or includes diabetes mellitus (often simply referred to as "diabetes"). Diabetes mellitus (Diabetes mellitus) is a group of metabolic disorders characterized by prolonged hyperglycemia (Diabetes Fact Sheet No. 312, WHO, 2013). The American Diabetes Association (ADA) diagnoses diabetes by detecting a hemoglobin A1c level of 6.5% or higher, a fasting plasma glucose (FPG) level of 126 mg / dL (7.0 mmol / L) or higher (measured after an 8-hour fast), or a plasma glucose level of 200 mg / dL (11.1 mmol / L) or higher 2 hours after ingestion of a 75-g oral glucose load, or a random plasma glucose level of 200 mg / dL (11.1 mmol / L) or higher in patients with classic symptoms of hyperglycemia or hyperglycemic emergency (American Diabetes Association, Diabetes Care (2010) 33(Suppl 1): S62-S69). Symptoms of diabetes include frequent urination, increased thirst, and increased hunger. The underlying cause of diabetes is generally the insufficient production of insulin by the pancreas or the inability of the body's cells to respond appropriately to the insulin that is produced.
[0060] There are three main types of diabetes, as described, for example, in Diabetes Fact Sheet No. 312 (WHO (2013)). Type 1 diabetes (T1D) results from pancreatic insufficiency, which results in an insufficient number of insulin-producing pancreatic islet beta cells, resulting in an inability to produce sufficient amounts of insulin. Type 1 diabetes and its diagnosis are reviewed, for example, in Kahanovitz et al., Point Care. (2017) 16(1): 37-40 (incorporated herein by reference in its entirety). Type 2 diabetes (T2D) occurs when a subject's body's cells no longer respond appropriately to insulin, and as the condition progresses, insulin production may become insufficient. Type 2 diabetes is most often caused by overweight and physical inactivity. Type 2 diabetes is reviewed in DeFronzo, Nature Reviews Disease Primers (2015) 1:15019 (incorporated herein by reference in its entirety). Gestational diabetes (also known as pregnancy-associated hyperglycemia) occurs when a pregnant woman's blood glucose levels become elevated. Gestational diabetes is caused by pregnancy-related insulin resistance, which increases the insulin demand during pregnancy and outpaces insulin production. Gestational diabetes is reviewed, for example, in Kampmann et al., World J Diabetes. (2015) 6(8):1065-1072, which is incorporated herein by reference in its entirety.
[0061] In some embodiments, the metabolic disease is or comprises insulin deficiency. In some embodiments, the metabolic disease is or comprises insulin resistance. In some embodiments, the metabolic disease is or comprises hyperglycemia. In some embodiments, the metabolic disease is or comprises type 2 diabetes (T2D). In some embodiments, the metabolic disease is or comprises type 2 diabetes (T2D). In some embodiments, the metabolic disease is or comprises type 1 diabetes (T1D). In some embodiments, the metabolic disease is or comprises pregnancy-associated hyperglycemia.
[0062] In some embodiments, the metabolic disease is or includes prediabetes. Prediabetes refers to a hyperglycemic state in which blood glucose levels remain elevated for a prolonged period but remain below the level required for diagnosing diabetes. Prediabetes and its diagnosis are reviewed, for example, in Bansal World J Diabetes. (2015) 6(2):296-303, which is incorporated herein by reference in its entirety. The WHO defines prediabetes as a moderately hyperglycemic state, diagnosed by a fasting plasma glucose (FPG) level of 6.1-6.9 mmol / L (110-125 mg / dL) and a plasma glucose level of 7.8-11.0 mmol / L (140-200 mg / dL) two hours after ingestion of a 75 g oral glucose load. The ADA diagnosis of prediabetes requires a plasma glucose level of 7.8 to 11.0 mmol / L (140 to 200 mg / dL) 2 hours after ingestion of a 75-g oral glucose load, a fasting plasma glucose (FPG) level of 100 to 125 mg / dL, and a hemoglobin A1c level of 5.7% to 6.4%.
[0063] In some embodiments, the metabolic disease is or includes metabolic syndrome. Metabolic syndrome is, for example, reviewed in Rochlani et al., Cardiovascular Disease (2017) 215-225 (which is incorporated herein by reference in its entirety). According to the WHO definition, metabolic syndrome refers to the presence of any two of the following: obesity, hyperlipidemia (hypertriglyceridemia or low high-density lipoprotein (HDL) cholesterol), hypertension, and microalbuminuria, plus insulin resistance (impaired fasting blood glucose, impaired glucose tolerance, or type 2 diabetes). There are several other definitions of metabolic syndrome, which are summarized in Table 1 of Rochlani et al., supra.
[0064] In some embodiments, the metabolic disease is or includes cholestasis. Cholestasis refers to a decrease in bile flow from the liver to the duodenum. In some embodiments, the metabolic disease is or includes cholestatic liver disease. Cholestatic liver disease is caused by insufficient bile synthesis, insufficient bile secretion through the bile duct, and / or insufficient bile flow through the bile duct. Cholestatic liver disease is, for example, reviewed in Jansen et al., Hepatology (2017) 65(2):722-738 and Pollock and Minuk, J Gastroenterol Hepatol (2017) 32(7):1303-1309 (these documents are incorporated herein by reference in their entirety). Cholestatic liver diseases include primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC).
[0065] In some embodiments, the metabolic disease is or includes hyperlipidemia. Hyperlipidemia refers to an elevated level of lipids or lipoproteins in the blood. Hyperlipidemia includes hypertriglyceridemia, hypercholesterolemia, and combined hyperlipidemia (a combination of hypertriglyceridemia and hypercholesterolemia). Hyperlipidemia is associated with, for example, atherosclerosis and cardiovascular disease.
[0066] In some embodiments, the metabolic disorder is or includes hypertriglyceridemia, which is described, for example, in Berglund et al., J. Clin. Endocrinol. Metab. (2012) 97(9):2969-89, and is defined as blood triglyceride levels of 150 mg / dL or higher (1.7 mmol / L or higher).
[0067] In some embodiments, the metabolic disease is or includes hypercholesterolemia. Hypercholesterolemia is described, for example, in Bhatnagar et al., BMJ (2008) 337:a993. The UK NHS defines hypercholesterolemia as a blood total cholesterol level of 5 mmol / L or higher, or a blood low-density lipoprotein (LDL) level of 3 mmol / L or higher. The US NIH defines hypercholesterolemia as a blood total cholesterol level of 240 mg / dL or higher.
[0068] In some embodiments, the metabolic disorder is or includes pancreatic insufficiency. Pancreatic insufficiency may be endocrine or exocrine insufficiency. Pancreatic endocrine insufficiency may be characterized by insufficient production of one or more of insulin, amylin, glucagon, somatostatin, ghrelin, and pancreatic polypeptide (PP). Pancreatic exocrine insufficiency may be characterized by insufficient production of one or more of pancreatic juices, digestive enzymes, trypsinogen, chymotrypsinogen, elastase, carboxypeptidase, pancreatic lipase, nuclease, and amylase, and the resulting inability to properly digest food. Pancreatic insufficiency is usually caused by the loss of pancreatic cells that produce these related factors, for example, in the case of endocrine insufficiency, this occurs due to the loss of islet cells, and in the case of exocrine insufficiency, this occurs due to the loss of acinar cells. Pancreatic exocrine insufficiency is described, for example, in Struyvenberg et al., BMC Med (2017) 15:29, which is incorporated herein by reference in its entirety. The most common cause of pancreatic insufficiency is pancreatitis, but it can also be caused by cystic fibrosis, surgery, celiac disease, and diabetes.
[0069] In some embodiments, the metabolic disease is or includes a pancreatic disorder. As used herein, "disorder" refers to damage to the associated organ and / or tissue or damage to the cells of the associated organ. Cell / tissue / organ damage may result from injury to these cells / tissues / organs, for example, due to a chemical or physical treatment / experience. In some embodiments, for example, in the case of a drug-induced disorder, the damage may result from a chemical injury. In some embodiments, the damage may result from a physical injury, for example, due to a surgical injury that may occur during surgery for disease treatment and / or transplantation (e.g., the damage may be iatrogenic). In some embodiments, the damage may result from hypoxia, for example, due to ischemia or reperfusion. In some embodiments, the damage may result from an infection, an immune response to an infection, cancer, and / or autoimmunity. The damage may be reversible or irreversible. Cell / tissue / organ damage may be characterized by an alteration in the structure and / or function of the cell / tissue / organ. For example, cell / tissue / organ damage may be characterized by a decrease in the amount of a correlate of normal cell / tissue / organ function and / or an increase in a correlate of impaired cell / tissue / organ function. Cell / tissue / organ damage may also be characterized by cell death, e.g., the death of cells in the damaged organ / tissue. Such cell death may result from apoptosis (i.e., programmed cell death) or necrosis (premature cell death due to injury).
[0070] In some embodiments, the metabolic disorder is or includes pancreatitis. Pancreatitis is characterized by inflammation of the pancreas. Pancreatitis may be acute or chronic. Acute pancreatitis is reviewed, for example, in Shah et al., J Inflamm Res (2018) 11:77-85 (incorporated herein by reference in its entirety). Acute pancreatitis is most often caused by gallstones, but may also be caused by alcoholic or metabolic disorders. Chronic pancreatitis is reviewed, for example, in Pham et al. Version 1. F1000Res (2018) 7: F1000 Faculty Rev-607 (incorporated herein by reference in its entirety). Chronic pancreatitis is a syndrome involving chronic inflammation, fibrosis, and loss of acinar and islet cells, and may manifest as exocrine and endocrine insufficiency.
[0071] In some embodiments, the metabolic disorder is or includes steatosis. Steatosis refers to the abnormal accumulation of lipids in cells / tissues / organs. Steatosis may be macrodroplet steatosis or microdroplet steatosis.
[0072] In some embodiments, the metabolic disorder is characterized by the accumulation of molecules (or derivatives thereof) that include lipid moieties in non-adipose tissue, hi some embodiments, the metabolic disorder is lipotoxic, includes lipotoxicity, is characterized by lipotoxicity, or is associated with lipotoxicity.
[0073] As used herein, "lipotoxicity" refers to cell / tissue damage, dysfunction, and / or death caused by the accumulation of molecules containing lipid moieties (or derivatives thereof) in non-adipose tissue. According to the present disclosure, in some embodiments, the lipotoxicity is lipotoxicity in liver, kidney, heart, and / or skeletal muscle cells. In some embodiments, the lipotoxicity is lipotoxicity in liver cells (e.g., hepatocytes).
[0074] The metabolic disease characterized by lipotoxicity or the metabolic disease associated with lipotoxicity includes, for example, non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).The lipid accumulation in hepatocyte and the association between lipid accumulation in hepatocyte and NAFLD (particularly NASH) are described in Friedman et al., Nat. Med. (2018) 24(7):908-922 and Farrell et al., Adv. Exp. Med. Biol. (2018) 1061: 19-44 (these documents are incorporated herein by reference in their entirety).
[0075] NASH and other NAFLDs are thought to result from lipotoxicity to hepatocytes. Lipotoxic factors are thought to include free (unesterified) cholesterol, saturated free fatty acids (e.g., palmitic acid), diacylglycerol, lysophosphatidylcholine, sphingolipids, and ceramides. Hepatocytes are unable to sequester these chemically reactive lipid molecules, resulting in mitochondrial damage, endoplasmic reticulum (ER) stress, and autophagy. Lipotoxicity induces hepatocyte apoptosis and necrosis (necroptosis and pyroptosis) of hepatocytes, activating the innate immune system and triggering the expression of pro-inflammatory factors. The expression of pro-inflammatory cytokines and chemokines recruits inflammatory cells such as macrophages and neutrophils.
[0076] The Examples herein (particularly Example 5) demonstrate that autocrine IL-11-mediated signaling is an important component of lipotoxic signaling (e.g., in hepatocytes) and that antagonism of IL-11-mediated signaling can suppress lipotoxicity (and its downstream effects). Thus, according to aspects of the present disclosure, lipotoxicity or diseases characterized by or associated with lipotoxicity can be treated / prevented through antagonism of IL-11-mediated signaling.
[0077] Importantly, as shown in Example 5.3.5 herein, it has been demonstrated that IL-11-mediated signaling in hepatocytes is an important factor in the lipotoxicity associated with NAFL and causes NASH via a pathway separate from IL-11-mediated activation of hepatic stellate cells prior to their transformation into myofibroblasts. Thus, according to aspects of the present disclosure, NAFLD (e.g., NASH) can be treated / prevented by suppressing lipotoxicity in hepatocytes through antagonism of IL-11-mediated signaling.
[0078] In some embodiments, the metabolic disease is nonalcoholic fatty liver disease (NAFLD). NAFLD is generally described in, for example, Benedict and Zhang, World J Hepatol. (2017) 9(16): 715-732 and Albhaisi et al., Version 1. F1000Res. (2018) 7: F1000 Faculty Rev-720 (these documents are incorporated herein by reference in their entirety). NAFLD is characterized by fatty degeneration of the liver (particularly hepatocytes). NAFLD includes nonalcoholic fatty liver (NAFL) and nonalcoholic steatohepatitis (NASH). NAFL is characterized by fatty degeneration that occupies more than 5% of the liver parenchyma, without hepatocellular damage. NAFL can progress to NASH, which is fatty degeneration (steatohepatitis) accompanied by inflammation and / or fibrosis.
[0079] In some embodiments, the metabolic disease is or includes lipodystrophy. Lipodystrophy is reviewed, for example, in Fiorenza et al., Nature Reviews Endocrinology (2011) 7: 137-150, which is incorporated herein by reference in its entirety. Lipodystrophy refers to the inability to produce and / or maintain normal adipose tissue, resulting in complete or partial loss of adipose tissue (lipoatrophy), which may be accompanied by pathological accumulation of adipose tissue (lipohypertrophy). Lipodystrophy can be hereditary or acquired, although hereditary lipodystrophy syndromes are rare. In some embodiments, the metabolic disease is or includes lipoatrophy. In some embodiments, the metabolic disease is or includes lipohypertrophy.
[0080] In some embodiments, the metabolic disorder is or includes hyperglucagonemia, as described, for example, in Wewer Albrechtsen et al., Biomark Med. (2016) (11):1141-1151, which is incorporated herein by reference in its entirety.
[0081] In some embodiments, the metabolic disorder is or includes wasting. As used herein, "waste" refers to unintentional weight loss, which may be progressive and / or degenerative. Wasting can be defined as a loss of muscle mass, sometimes accompanied by a loss of fat mass. Generally, significant, unintentional weight loss (including skeletal muscle) is usually observed, and may be accompanied by adipose tissue loss. In some cases, adipose tissue wasting may occur in isolation, as seen in lipodystrophic disorders. Wasting may be characterized by protein and energy deficiencies induced by various combinations of reduced food intake and metabolic abnormalities (Fearon et al., Lancet Oncol. (2011) 12(5):489-95). Wasting can lead to progressive functional impairment, decreased quality of life, and increased risk of morbidity and mortality. Wasting can also lead to asthenia (abnormal physical weakness or lack of energy) and / or anemia (a lack of red blood cells or hemoglobin in the blood). The wasting may not be fully reversible by conventional nutritional supplementation or currently attempted therapeutic interventions, and death usually occurs when a patient loses 30% of their stable pre-existing weight (Tisdale, Nature Reviews Cancer, 2, 862-871 (2002)).
[0082] Diseases / conditions characterized by wasting include cachexia (age-unrelated muscle loss), sarcopenia (muscle loss: e.g., age-related muscle loss, disuse-related muscle loss, space travel-related muscle loss, or denervation-related muscle loss), eating disorders (protein-energy malnutrition), muscular dystrophy, lipodystrophy (e.g., abnormal or degenerative conditions of adipose tissue), lipoatrophy (age-related loss of subcutaneous fat in the face and other tissues), and myopenia (muscle wasting in any chronic disease; proposed by Fearon et al. J Cachexia Sarcopenia Muscle. 2011;2:1-3). Herein, diseases / conditions characterized by wasting are also referred to as "wasting diseases." In some embodiments, the wasting disease according to the present disclosure is cachexia, pre-cachexia, refractory cachexia, sarcopenia, anorexia, lipodystrophy, lipoatrophy, and / or myopenia. In some embodiments according to various aspects described herein, the wasting disease is cachexia, pre-cachexia and / or refractory cachexia.
[0083] Wasting disorders resulting from chronic illness include "mild muscle wasting disorders" (which may be associated with frailty), "moderate muscle wasting disorders" (which may be associated with frailty; also known as "pre-cachexia"), or "severe muscle wasting disorders" (which may be associated with frailty; also known as "cachexia" and often associated with frailty).
[0084] Cachexia is a complex inflammatory / metabolic syndrome associated with underlying disease (acute or chronic) and characterized by wasting. The hallmark clinical features of cachexia are weight loss (normalized for body fluid volume) in adults and failure to thrive (excluding endocrine disorders) in children. Furthermore, anorexia, inflammation, insulin resistance, increased muscle protein breakdown, and an increased basal metabolic rate are commonly observed in cachexia. Patients with cachexia also exhibit reduced lipid levels and hepatic steatosis, suggesting a role for hepatic metabolism in the pathogenesis of cachexia. Therefore, therapeutic strategies targeting the liver to prevent hepatic steatosis, liver injury, or liver metabolism may have direct implications for cachexia. Cachexia is distinct from starvation, age-related muscle loss, primary depression, malabsorption, and hyperthyroidism, and is associated with increased morbidity (Evans et al. Clin Nutr. 2008 (6):793-9).
[0085] Cachexia is defined as an involuntary weight loss of more than 5% from a stable pre-existing weight, a body mass index (BMI) of 20 kg / m (in people under 65 years of age), 2 Less than or (in people aged 65 years or older) 22 kg / m 2 Sarcopenia is defined as having a skeletal muscle mass index of less than 10% and a weight loss of more than 2%, or having a skeletal muscle mass index that is diagnosed as sarcopenia and a weight loss of more than 2%. Cachexia patients may also have a body fat percentage of less than 10% and / or a low blood albumin level of less than 35 g / L. These criteria may be useful in identifying populations at risk for developing wasting diseases (Fearon et al. Lancet Oncol. 2011; 12(5):489-95).
[0086] A three-stage classification of cachexia has been proposed, in which severity is classified according to the degree of deficiency in energy stores and body protein (BMI) in combination with the degree of ongoing weight loss. 1. Pre-cachexia - Patient has lost less than 5% of their body weight and has not developed severe complications. 2. Cachexia - Complex inflammatory / metabolic syndrome is ongoing and weight loss is greater than 5%, but is treatable. 3. Refractory cachexia - Cachexia is no longer responsive to treatment or the burdens and risks of treatment outweigh the benefits (Fearon et al., supra). The refractory period is often determined by the overall stage of the underlying disease and the condition of the patient, as discussed below.
[0087] The metabolic disease may be in an acute phase or a chronic phase. Aspects of the present invention can treat / prevent diseases / conditions associated with metabolic diseases. Diseases / conditions associated with metabolic diseases include diseases / conditions that show a positive correlation with the onset of metabolic diseases. In some embodiments, the diseases / conditions associated with metabolic diseases are diseases / conditions that may cause metabolic diseases, diseases / conditions that cause metabolic diseases, or diseases / conditions that have caused metabolic diseases (i.e., diseases / conditions that may cause metabolic diseases, diseases / conditions that cause metabolic diseases, or diseases / conditions that have caused metabolic diseases).
[0088] Furthermore, diseases / conditions associated with metabolic diseases include diseases / conditions caused by metabolic diseases and / or diseases / conditions exacerbated by metabolic diseases (diseases / conditions exacerbated by metabolic diseases, diseases / conditions progressed by metabolic diseases, and / or diseases / conditions complicated with metabolic diseases). In some embodiments, diseases / conditions associated with metabolic diseases may be those that show a positive association with the onset of metabolic diseases or may be those that are exacerbated by metabolic diseases. "Associated" diseases / conditions may be diseases / conditions that include pathologies associated with metabolic diseases.
[0089] In embodiments of the present invention, the metabolic disease or metabolic disease-related disease / condition may be present in or affect any organ / tissue, such as the heart, liver, kidney, brain, skin, muscular system, stomach, small intestine, large intestine, pancreas, oral cavity, salivary glands, pharynx, esophagus, gallbladder, trachea, larynx, bladder, ovaries, uterus, testes, endocrine glands (e.g., pituitary gland or thyroid gland), lymphatic system (e.g., spleen), etc.
[0090] In embodiments of the present invention, the disease / condition associated with metabolic disease may be one or more of cancer, heart disease, kidney disease, lung disease, liver disease, chronic infection, neurodegenerative disease, acute injury, trauma, post-operative condition or aging / senescence.
[0091] In some embodiments, a metabolic disease may be detected / identified / diagnosed using one or more biomarkers or correlates of the metabolic disease.
[0092] Drugs that can suppress the action of IL-11 Aspects of the present invention include the inhibition of IL-11 mediated signaling.
[0093] As used herein, "inhibition" refers to a decrease, lowering, or reduction compared to a control condition. For example, inhibition of the action of IL-11 by an agent capable of inhibiting IL-11-mediated signaling refers to a decrease, lowering, or reduction in the intensity / degree of IL-11-mediated signaling in the absence of the agent and / or in the presence of an appropriate control agent.
[0094] As used herein, "inhibition" may also refer to neutralization or antagonism. That is, an agent capable of inhibiting IL-11-mediated signal transduction (e.g., interaction, signal transduction, or other activity mediated by IL-11 or an IL-11-containing complex) may be said to be a "neutralizing" or "antagonizing" agent for the relevant function or process. For example, an agent capable of inhibiting IL-11-mediated signal transduction may be referred to as an agent capable of neutralizing IL-11-mediated signal transduction, or as an antagonist of IL-11-mediated signal transduction.
[0095] The IL-11 signaling pathway has multiple routes that can inhibit IL-11 signaling. An agent that can inhibit IL-11-mediated signaling may inhibit IL-11 signaling, for example, by inhibiting the action of one or more factors involved in signaling via the IL-11 receptor or the action of one or more factors required for signaling via the IL-11 receptor.
[0096] For example, inhibition of IL-11 signaling may be achieved by disrupting the interaction between IL-11 (or an IL-11-containing complex, e.g., a complex consisting of IL-11 and IL-11Rα) and an IL-11 receptor (e.g., IL-11Rα, a receptor complex containing IL-11Rα, gp130, or a receptor complex containing IL-11Rα and gp130). In some embodiments, inhibition of IL-11-mediated signaling is achieved by suppressing gene or protein expression of, for example, one or more of IL-11, IL-11Rα, and gp130.
[0097] In another embodiment, inhibition of IL-11-mediated signaling is achieved by disrupting IL-11-mediated cis signaling without disrupting IL-11-mediated trans signaling, e.g., by inhibiting a gp130-mediated cis complex containing membrane-bound IL-11Rα. In another embodiment, inhibition of IL-11-mediated signaling is achieved by disrupting IL-11-mediated trans signaling without disrupting IL-11-mediated cis signaling, i.e., by inhibiting a gp130-mediated trans signaling complex, such as IL-11 bound to soluble IL-11Rα or IL-6 bound to soluble IL-6R. In another embodiment, inhibition of IL-11-mediated signaling is achieved by disrupting IL-11-mediated cis signaling and IL-11-mediated trans signaling. Any of the agents described herein may be used to inhibit IL-11-mediated cis signaling and / or IL-11-mediated trans signaling.
[0098] In another example, inhibition of IL-11 signaling may be achieved by disrupting the signaling pathway downstream of IL-11 / IL-11Rα / gp130. That is, in some embodiments, the inhibition / antagonism of IL-11-mediated signaling includes the inhibition of the signaling pathway / signaling process / signaling factor downstream of signaling mediated by the complex consisting of IL-11 and the IL-11 receptor.
[0099] In some embodiments, the inhibition / antagonism of IL-11-mediated signaling comprises the inhibition of signaling through an intracellular signaling pathway activated by a complex consisting of IL-11 and the IL-11 receptor. In some embodiments, the inhibition / antagonism of IL-11-mediated signaling comprises the inhibition of one or more factors whose expression / activity is upregulated by signaling through a complex consisting of IL-11 and the IL-11 receptor.
[0100] In some embodiments, the methods of the present invention use agents capable of inhibiting JAK / STAT signaling. In some embodiments, agents capable of inhibiting JAK / STAT signaling can inhibit the action of JAK1, JAK2, JAK3, TYK2, STAT1, STAT2, STAT3, STAT4, STAT5A, STAT5B, and / or STAT6. For example, agents capable of inhibiting JAK / STAT signaling can inhibit the activation of a JAK / STAT protein, inhibit the interaction between a JAK protein or a STAT protein and a cell surface receptor (e.g., IL-11Rα or gp130), inhibit the phosphorylation of a JAK protein, inhibit the interaction between a JAK protein and a STAT protein, inhibit the phosphorylation of a STAT protein, inhibit the dimerization of a STAT protein, inhibit the transport of a STAT protein to the cell nucleus, inhibit the binding of a STAT protein to DNA, and / or promote the degradation of a JAK protein and / or a STAT protein. In some embodiments, the JAK / STAT inhibitor is selected from the group consisting of ruxolitinib (Jakafi / Jakavi; Incyte), tofacitinib (Xeljanz / Jakvinus; NIH / Pfizer), oclacitinib (Apoquel), baricitinib (Olumient; Incyte / Eli Lilly), filgotinib (G-146034 / GLPG-0634; Galapagos NV), gandotinib (LY-2784544; Eli Lilly), lestaurtinib (CEP-701; Teva), momelotinib (GS-0387 / CYT-387; Gilead Sciences), pacritinib (SB1518; CTI), PF-04965842 (Pfizer), upadacitinib (ABT-494; AbbVie), peficitinib (ASP015K / JNJ-54781532; Astellas), fedratinib (SAR302503; Celgene), cucurbitacin I (JSI-124), and CHZ868.
[0101] In some embodiments, the methods of the present invention use agents capable of inhibiting MAPK / ERK signaling. In some embodiments, the agents capable of inhibiting MAPK / ERK signaling can inhibit the action of GRB2, the action of RAF kinase, the action of MEK protein, the activation of MAP3K / MAP2K / MAPK and / or Myc, and / or the phosphorylation of STAT protein. In some embodiments, the agents capable of inhibiting ERK signaling can inhibit ERK p42 / 44. In some embodiments, the ERK inhibitor is selected from SCH772984, SC1, VX-11e, DEL-22379, sorafenib (Nexavar; Bayer / Onyx), SB590885, PLX4720, XL281, RAF265 (Novartis), encorafenib (LGX818 / Biraftovi; Array BioPharma), dabrafenib (Tafinlar; GSK), vemurafenib (Zelboraf; Roche), cobimetinib (Cotellic; Roche), CI-1040, PD0325901, binimetinib (MEK162 / Mektovi; Array BioPharma), selumetinib (AZD6244; Array / AstraZeneca), and trametinib (GSK1120212 / Mekinist; Novartis). In some embodiments, the methods of the present invention utilize an agent capable of inhibiting c-Jun N-terminal kinase (JNK) signaling / activity. In some embodiments, the agent capable of inhibiting JNK signaling / activity can inhibit the action and / or phosphorylation of JNK (e.g., JNK1, JNK2, etc.). In some embodiments, the JNK inhibitor is selected from SP600125, CEP 1347, TCS JNK 6o, c-JUN peptide, SU3327, AEG 3482, TCS JNK 5a, BI78D3, IQ3, SR3576, IQ1S, JIP-1(153-163), and CC401 dihydrochloride.
[0102] In the examples of the present invention, the inventors demonstrated that signaling via IL-11 / IL-11Rα / gp130 upregulated the expression and activity of NOX4. NOX4 is an NADPH oxidase and a source of reactive oxygen species (ROS). Nox4 expression was upregulated in transgenic mice expressing IL-11 specifically in hepatocytes, and stimulation of human primary hepatocytes with IL-11 also upregulated NOX4 expression.
[0103] In some embodiments, the present invention uses an agent capable of suppressing NOX4 expression (gene or protein expression) or its function. In some embodiments, the present invention uses an agent capable of suppressing IL-11-mediated upregulation of NOX4 expression / function. An agent capable of suppressing NOX4 expression or its function is sometimes referred to herein as a NOX4 inhibitor. For example, a NOX4 inhibitor may be capable of reducing NOX4 expression (e.g., gene and / or protein expression), reducing the expression level of RNA encoding NOX4, reducing the expression level of NOX4 protein, and / or reducing the activity level of NOX4 (e.g., reducing NOX4-mediated NADPH oxidase activity and / or reducing NOX4-mediated ROS production).
[0104] NOX4 inhibitors include molecules that bind to NOX4 and molecules that can reduce the expression of NOX4. Inhibitors that bind to NOX4 include peptide / nucleic acid aptamers, antibodies (and antibody fragments), and fragments of NOX4 interaction partners that act as antagonists to the function of NOX4, as well as small molecule inhibitors of NOX4. Molecules that can reduce the expression of NOX4 include NOX4 antisense RNA (e.g., siRNA, shRNA, etc.). In some embodiments, the NOX4 inhibitor is selected from the NOX4 inhibitors described in Altenhofer et al., Antioxid Redox Signal. (2015) 23(5): 406-427 or Augsburder et al., Redox Biol. (2019) 26: 101272, such as GKT137831.
[0105] Binding Agents In some embodiments, an agent capable of inhibiting IL-11-mediated signaling may bind to IL-11. In some embodiments, an agent capable of inhibiting IL-11-mediated signaling may bind to an IL-11 receptor (e.g., IL-11Rα, gp130, or a complex comprising IL-11Rα and / or gp130). When such an agent binds to IL-11 or the IL-11 receptor, the ability of IL-11 to bind to the IL-11 receptor may be reduced / inhibited, thereby inhibiting IL-11-mediated signaling, and as a result, downstream signaling may be inhibited. Alternatively, when such an agent binds to IL-11 or the IL-11 receptor, the ability of IL-11 to bind to the IL-11 receptor (e.g., IL-11Rα and / or gp130) may be reduced / inhibited, thereby inhibiting IL-11-mediated cis signaling and / or IL-11-mediated trans signaling, and as a result, downstream signaling may be inhibited. The agent may bind to a trans-signaling complex, such as a complex consisting of IL-11 and soluble IL-11Rα, and inhibit gp130-mediated signaling.
[0106] The agent capable of binding to IL-11 or an IL-11-containing complex or an IL-11 receptor may be of any type, but in some embodiments, the agent may be an antibody, an antigen-binding fragment thereof, a polypeptide, a peptide, a nucleic acid, an oligonucleotide, an aptamer, or a small molecule. The agent may be provided in isolated or purified form, or may be formulated as a pharmaceutical composition or medicament.
[0107] Antibodies and antigen-binding fragments In some embodiments, the agent capable of binding to IL-11 or an IL-11-containing complex or an IL-11 receptor is an antibody or an antigen-binding fragment thereof. In some embodiments, the agent capable of binding to IL-11 or an IL-11-containing complex or an IL-11 receptor is a polypeptide, such as a decoy receptor molecule. In some embodiments, the agent capable of binding to IL-11 or an IL-11-containing complex or an IL-11 receptor may be an aptamer.
[0108] In some embodiments, the agent capable of binding to IL-11 or an IL-11-containing complex, or an IL-11 receptor is an antibody or an antigen-binding fragment thereof. As used herein, the term "antibody" is used in the broadest sense to encompass monoclonal antibodies, polyclonal antibodies, monospecific antibodies, multispecific antibodies (e.g., bispecific antibodies), and antibody fragments that exhibit binding to relevant target molecules.
[0109] Recent advances in monoclonal antibody technology have made it possible to generate antibodies against most antigens. The antigen-binding portion may be a portion of an antibody (e.g., a Fab fragment) or a synthetic antibody fragment (e.g., a single-chain Fv fragment [ ScFv). Monoclonal antibodies against a selected antigen may be produced by known techniques, such as those described in "Monoclonal Antibodies: A manual of techniques" by H. Zola (CRC Press, 1988) or "Monoclonal Hybridoma Antibodies: Techniques and Applications" by J. G. R. Hurrell (CRC Press, 1982). Chimeric antibodies have also been reported by Neuberger et al. (1988, 8th International Biotechnology Symposium Part 2, 792-799). Monoclonal antibodies (mAbs) are particularly useful in the methods of the present invention. A monoclonal antibody (mAb) is a homogeneous antibody population that specifically targets a single epitope on an antigen.
[0110] Polyclonal antibodies are also useful in the methods of the invention. Monospecific polyclonal antibodies are preferred. Suitable polyclonal antibodies can be produced using methods well known in the art.
[0111] Antigen-binding fragments of antibodies, such as Fab fragments and Fab2 fragments, may be used / provided, as well as recombinant antibodies and recombinant antibody fragments. H ) region and the light chain variable (V L The α-terminal region of the ribosomal RNA (RIR) is known to be involved in antigen recognition, a finding first made in early protease digestion experiments and confirmed by experiments in which rodent antibodies were "humanized." Rodent-derived variable regions can be fused to human-derived constant regions to generate antibodies that retain the antigen specificity of the parent rodent antibody (Morrison et al (1984) Proc. Natl. Acad. Sd. USA 81, 6851-6855).
[0112] The antibodies and antigen-binding fragments according to the present disclosure comprise complementarity determining regions (CDRs) of an antibody capable of binding to the relevant target molecule (ie, IL-11 / IL-11-containing complex / IL-11 receptor).
[0113] Examples of antibodies capable of binding to IL-11 include the monoclonal mouse anti-human IL-11 antibody clone #22626; catalogue no. MAB218 (R&D Systems, Minnesota, USA), clone 6D9A (Abbiotec), clone KT8 (Abbiotec), clone M3103F11 (BioLegend), clone 1F1 (Abnova Corporation), clone 3C6 (Abnova Corporation), clone GF1 (LifeSpan Biosciences), clone 13455 (Source BioScience), 11h3 / 19.6.1 (Hermann et al., Arthritis Rheum. (1998) 41(8):1388-97), AB-218-NA (R&D Systems), and X203 (Ng et al., Sci Transl Med. (2019) 11(511) pii: eaaw1237) and the anti-IL-11 antibodies disclosed in U.S. Patent Publication Nos. 2009 / 0202533(A1), WO99 / 59608(A2), WO2018 / 109174(A2) and WO 2019 / 238882(A1).
[0114] In particular, the anti-IL-11 antibody clone 22626 (also known as MAB218) has been shown to be an antagonist of IL-11-mediated signaling, for example, in Schaefer et al., Nature (2017) 552(7683):110-115. Hermann et al., Arthritis Rheum. (1998) 41(8):1388-97 discloses that the monoclonal antibody 11h3 / 19.6.1 is an anti-IL-11 IgG1 neutralizing antibody. AB-218-NA from R&D Systems, used in, for example, McCoy et al., BMC Cancer (2013) 13:16, is another example of an anti-IL-11 neutralizing antibody. WO 2018 / 109174(A2) and WO 2019 / 238882(A1) disclose further examples of anti-IL-11 antagonist antibodies against IL-11-mediated signaling. Also, X203 (also referred to as Enx203), disclosed in Ng, et al., "IL-11 is a therapeutic target in idiopathic pulmonary fibrosis." bioRxiv 336537; doi: https: / / doi.org / 10.1101 / 336537 and WO 2019 / 238882 (A1), is an anti-IL11 antagonist antibody against IL-11-mediated signaling, and comprises a VH region represented by SEQ ID NO: 92 in WO 2019 / 238882(A1) (SEQ ID NO: 22 in the present disclosure) and a VL region represented by SEQ ID NO: 94 in WO 2019 / 238882(A1) (SEQ ID NO: 23 in the present disclosure). Humanized X203 is described in WO 2019 / 238882(A1), including hEnx203, which comprises a VH region set forth in SEQ ID NO: 117 in WO 2019 / 238882(A1) (SEQ ID NO: 30 in the present disclosure) and a VL region set forth in SEQ ID NO: 122 in WO 2019 / 238882(A1) (SEQ ID NO: 31 in the present disclosure).Enx108A is yet another example of an anti-IL-11 antagonist antibody against IL-11-mediated signaling, and comprises a VH region set forth in SEQ ID NO: 8 in WO 2019 / 238882(A1) (SEQ ID NO: 26 in the present disclosure) and a VL region set forth in SEQ ID NO: 20 in WO 2019 / 238882(A1) (SEQ ID NO: 27 in the present disclosure).
[0115] Examples of antibodies capable of binding to IL-11Rα include monoclonal antibody clone 025 (Sino Biological), clone EPR5446 (Abcam), clone 473143 (R&D Systems), clones 8E2, 8D10, and 8E4 described in U.S. Patent Publication No. 2014 / 0219919(A1), and affinity matured variants of 8E2, a monoclonal antibody described in Blanc et al. (J. Immunol Methods. 2000 Jul 31;241(1-2);43-59), and X209 (reported in Widjaja et al., Gastroenterology (2019) 157(3):777-792, Widjaja, et al., "IL-11 neutralizing therapies target hepatic stellate cell-induced liver inflammation and fibrosis in NASH." bioRxiv 470062; doi: https: / / doi.org / 10.1101 / 470062), WO2014121325(A1) and U.S. Patent Publication No. 2013 / 0302277(A1), as well as the anti-IL-11Rα antibodies disclosed in U.S. Patent Publication No. 2009 / 0202533(A1), WO99 / 59608(A2), WO2018 / 109170(A2) and WO 2019 / 238884(A1).
[0116] In particular, anti-IL-11Rα antibody clone 473143 (also known as MAB1977) has been shown to be an antagonist of IL-11-mediated signaling, for example, in Schaefer et al., Nature (2017) 552(7683):110-115. U.S. Patent Publication No. 2014 / 0219919(A1) provides the sequences of anti-human IL-11Rα antibody clones 8E2, 8D10, and 8E4, and discloses that these anti-human IL-11Rα antibody clones have antagonistic activity against IL-11-mediated signaling (see, for example, paragraphs
[0489] to
[0490] of U.S. Patent Publication No. 2014 / 0219919(A1)). Furthermore, U.S. Patent Publication No. 2014 / 0219919(A1) also provides sequence information for 62 affinity matured variants of clone 8E2, and discloses that 61 of them have antagonistic activity against IL-11-mediated signaling (see Table 3 in U.S. Patent Publication No. 2014 / 0219919(A1)). WO 2018 / 109170(A2) and WO 2019 / 238884(A1) disclose further examples of anti-IL-11Rα antagonist antibodies against IL-11-mediated signaling. Also, X209 (also referred to as Enx209), disclosed in Widjaja, et al., "IL-11 neutralizing therapies target hepatic stellate cell-induced liver inflammation and fibrosis in NASH," bioRxiv 470062; doi: https: / / doi.org / 10.1101 / 470062 and WO 2019 / 238884(A1), is an anti-IL-11Rα antagonist antibody against IL-11-mediated signaling, and comprises a VH region represented by SEQ ID NO: 7 in WO 2019 / 238884(A1) (SEQ ID NO: 24 in the present disclosure) and a VL region represented by SEQ ID NO: 14 in WO 2019 / 238884(A1) (SEQ ID NO: 25 in the present disclosure).Humanized X209 is described in WO 2019 / 238884(A1), including hEnx209, which comprises a VH region set forth in SEQ ID NO: 11 in WO 2019 / 238884(A1) (SEQ ID NO: 32 in the present disclosure) and a VL region set forth in SEQ ID NO: 17 in WO 2019 / 238884(A1) (SEQ ID NO: 33 in the present disclosure).
[0117] Those skilled in the art will be familiar with techniques for generating antibodies suitable for therapeutic use in a given species / subject. For example, procedures for generating antibodies suitable for therapeutic use in humans are described in Park and Smolen Advances in Protein Chemistry (2001) 56: 369-421, which is incorporated herein by reference in its entirety.
[0118] Antibodies against a given target protein (e.g., IL-11 or IL-11Rα) can be generated in model species (e.g., rodents or rabbits) and then genetically modified to improve suitability for therapeutic use in a given species / subject. For example, one or more amino acid substitutions in a monoclonal antibody generated by immunization of a model species can be used to obtain an antibody sequence that more closely resembles the sequence of human germline immunoglobulins (thus reducing the likelihood of an immune response due to anti-xenoantibodies in human subjects treated with the antibody). Modifications of antibody variable domains can be focused on the framework regions to preserve the antibody paratope. Antibody humanization is routine in the field of antibody technology and is reviewed, for example, in Almagro and Fransson, Frontiers in Bioscience (2008) 13:1619-1633, Safdari et al., Biotechnology and Genetic Engineering Reviews (2013) 29(2): 175-186, and Lo et al., Microbiology Spectrum (2014) 2(1), all of which are incorporated herein by reference in their entireties. Antibody humanization can be omitted by generating antibodies against a given target protein (e.g., IL-11 or IL-11Rα) in a transgenic model species expressing human immunoglobulin genes to obtain a fully human antibody (e.g., as described in Bruggemann et al., Arch Immunol Ther Exp (Warsz) (2015) 63(2):101-108, which is incorporated herein by reference in its entirety).
[0119] Phage display technology may also be used to identify antibodies against a predetermined target protein (e.g., IL-11 or IL-11Rα), and this method is well known to those skilled in the art. The identification of fully human antibodies against human target proteins using phage display is reviewed, for example, in Hoogenboom, Nat. Biotechnol. (2005) 23, 1105-1116 and Chan et al., International Immunology (2014) 26(12): 649-657 (these documents are incorporated herein by reference in their entirety).
[0120] The antibody / fragment may be an antagonist antibody / fragment that inhibits or reduces the biological activity of IL-11. The antibody / fragment may be a neutralizing antibody that neutralizes the biological effect of IL-11, for example, a neutralizing antibody that neutralizes the ability of IL-11 to stimulate protein synthesis signaling via the IL-11 receptor. Neutralizing activity may be measured by assessing the neutralizing ability against IL-11-induced proliferation in the T11 mouse plasmacytoma cell line (Nordan, RP et al. (1987) J. Immunol. 139:813).
[0121] Antibodies that bind IL-11 or IL-11Rα can be assessed for their antagonistic effect on IL-11-mediated signaling using assays described, for example, in U.S. Patent Publication No. 2014 / 0219919(A1) or Blanc et al. (J. Immunol Methods. 2000 Jul 31;241(1-2);43-59). Briefly, antibodies that bind IL-11 and IL-11Rα can be assessed in vitro for their ability to inhibit proliferation of Ba / F3 cells expressing IL-11Rα and gp130 from an appropriate species in response to stimulation with IL-11 from the appropriate species. In another method, antibodies that bind IL-11 and antibodies that bind IL-11Rα can be analyzed in vitro for their ability to inhibit fibroblast-to-myofibroblast conversion by assessing αSMA expression after stimulation of fibroblasts with TGFβ1 (e.g., as described in WO 2018 / 109174(A2) (Example 6) and WO 2018 / 109170(A2) (Example 6) and Ng et al., Sci Transl Med. (2019) 11(511) pii: eaaw1237 and Widjaja et al., Gastroenterology (2019) 157(3):777-792).
[0122] Antibodies typically contain six CDRs: three CDRs in the light chain variable region (VL) (LC-CDR1, LC-CDR2, and LC-CDR3) and three CDRs in the heavy chain variable region (VH) (HC-CDR1, HC-CDR2, and HC-CDR3). These six CDRs together define the antibody paratope, which refers to the portion of the antibody that binds to the target molecule. The VH and VL regions contain framework regions (FR) on both ends of each CDR, which provide a scaffold for the CDRs. The structure of the VH region comprises, from the N-terminus to the C-terminus, N-terminus-[HC-FR1]-[HC-CDR1]-[HC-FR2]-[HC-CDR2]-[HC-FR3]-[HC-CDR3]-[HC-FR4]-C-terminus, and the structure of the VL region comprises, from the N-terminus to the C-terminus, N-terminus-[LC-FR1]-[LC-CDR1]-[LC-FR2]-[LC-CDR2]-[LC-FR3]-[LC-CDR3]-[LC-FR4]-C-terminus.
[0123] There are several conventional methods for defining the CDRs and FRs of antibodies, including, for example, the methods described in Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD (1991) and Chothia et al., J. Mol. Biol. 196:901-917 (1987), and VBASE2 described in Retter et al., Nucl. Acids Res. (2005) 33 (suppl 1): D671-D674. The CDRs and FRs of the VH and VL regions of the antibodies described herein are defined according to the Kabat system.
[0124] In some embodiments, the antibody or antigen-binding fragment thereof according to the present disclosure is derived from an antibody that specifically binds to IL-11 (e.g., Enx108A, Enx203, or hEnx203). In some embodiments, the antibody or antigen-binding fragment thereof according to the present disclosure is derived from an antibody that specifically binds to IL-11Rα (e.g., Enx209 or hEnx209).
[0125] Preferably, antibodies and antigen-binding fragments according to the present disclosure inhibit IL-11-mediated signaling. Such antibodies / antigen-binding fragments may be described as being antagonists of IL-11-mediated signaling and / or as having the ability to neutralize IL-11-mediated signaling.
[0126] In some embodiments, the antibody / antigen-binding fragment comprises the CDRs of an antibody that binds IL-11. In some embodiments, the antibody / antigen-binding fragment comprises the CDRs of or derived from the CDRs of an antibody that binds IL-11 described herein (e.g., Enx108A, Enx203, or hEnx203).
[0127] In some embodiments, the antibody / antigen-binding fragment comprises: (1) HC-CDR1 having the amino acid sequence of SEQ ID NO: 34; HC-CDR2 having the amino acid sequence of SEQ ID NO: 35, and HC-CDR3 having the amino acid sequence of SEQ ID NO: 36, or Variants in which one, two or three amino acids are replaced with other amino acids in one or more of HC-CDR1, HC-CDR2 or HC-CDR3. It contains a VH region incorporating
[0128] In some embodiments, the antibody / antigen-binding fragment comprises: (2) LC-CDR1 having the amino acid sequence of SEQ ID NO: 37; LC-CDR2 having the amino acid sequence of SEQ ID NO: 38, and an LC-CDR3 having the amino acid sequence of SEQ ID NO: 39, or Variants in which one, two or three amino acids are substituted with other amino acids in one or more of LC-CDR1, LC-CDR2 or LC-CDR3 It contains a VL region incorporating
[0129] In some embodiments, the antibody / antigen-binding fragment comprises: (3) HC-CDR1 having the amino acid sequence of SEQ ID NO: 40; HC-CDR2 having the amino acid sequence of SEQ ID NO: 41, and HC-CDR3 having the amino acid sequence of SEQ ID NO: 42, or Variants in which one, two or three amino acids are replaced with other amino acids in one or more of HC-CDR1, HC-CDR2 or HC-CDR3. It contains a VH region incorporating
[0130] In some embodiments, the antibody / antigen-binding fragment comprises: (4) LC-CDR1 having the amino acid sequence of SEQ ID NO: 43; LC-CDR2 having the amino acid sequence of SEQ ID NO: 44, and LC-CDR3 having the amino acid sequence of SEQ ID NO: 45, or Variants in which one, two or three amino acids are substituted with other amino acids in one or more of LC-CDR1, LC-CDR2 or LC-CDR3 It contains a VL region incorporating
[0131] In some embodiments, the antibody / antigen-binding fragment comprises a VH region incorporating the CDR described in (1) and a VL region incorporating the CDR described in (2). In some embodiments, the antibody / antigen-binding fragment comprises a VH region incorporating the CDR described in (3) and a VL region incorporating the CDR described in (4).
[0132] In some embodiments, the antibody / antigen-binding fragment comprises the VH and VL regions of an antibody that binds IL-11. In some embodiments, the antibody / antigen-binding fragment comprises the VH and VL regions of, or derived from, an antibody that binds IL-11 described herein (e.g., Enx108A, Enx203, or hEnx203).
[0133] In some embodiments, the antibody / antigen-binding fragment comprises a VH region comprising an amino acid sequence having at least 70% sequence identity, more preferably at least 75%, at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or at least 100% sequence identity to the amino acid sequence of SEQ ID NO:26. In some embodiments, the antibody / antigen-binding fragment comprises a VL region comprising an amino acid sequence having at least 70% sequence identity, more preferably at least 75%, at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or at least 100% sequence identity to the amino acid sequence of SEQ ID NO:27. In some embodiments, the antibody / antigen-binding fragment has an amino acid sequence having at least 70% sequence identity, more preferably at least 75%, at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or at least 100% sequence identity to the amino acid sequence of SEQ ID NO:26. and a VL region comprising an amino acid sequence having at least 70% sequence identity, more preferably at least 75%, at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or at least 100% sequence identity, to the amino acid sequence of SEQ ID NO:27.
[0134] In some embodiments, the antibody / antigen-binding fragment comprises a VH region comprising an amino acid sequence having at least 70% sequence identity, more preferably at least 75%, at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or at least 100% sequence identity to the amino acid sequence of SEQ ID NO: 22. In some embodiments, the antibody / antigen-binding fragment comprises a VL region comprising an amino acid sequence having at least 70% sequence identity, more preferably at least 75%, at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or at least 100% sequence identity to the amino acid sequence of SEQ ID NO:23. In some embodiments, the antibody / antigen-binding fragment has an amino acid sequence having at least 70% sequence identity, more preferably at least 75%, at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or at least 100% sequence identity to the amino acid sequence of SEQ ID NO:22. and a VL region comprising an amino acid sequence having at least 70% sequence identity, more preferably at least 75%, at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or at least 100% sequence identity, to the amino acid sequence of SEQ ID NO:23.
[0135] In some embodiments, the antibody / antigen-binding fragment comprises a VH region comprising an amino acid sequence having at least 70% sequence identity, more preferably at least 75%, at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or at least 100% sequence identity to the amino acid sequence of SEQ ID NO: 30. In some embodiments, the antibody / antigen-binding fragment comprises a VL region comprising an amino acid sequence having at least 70% sequence identity, more preferably at least 75%, at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or at least 100% sequence identity to the amino acid sequence of SEQ ID NO: 31. In some embodiments, the antibody / antigen-binding fragment has an amino acid sequence having at least 70% sequence identity, more preferably at least 75%, at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or at least 100% sequence identity to the amino acid sequence of SEQ ID NO: 30. and a VL region comprising an amino acid sequence having at least 70% sequence identity, more preferably at least 75%, at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or at least 100% sequence identity, to the amino acid sequence of SEQ ID NO: 31.
[0136] In some embodiments, the antibody / antigen-binding fragment comprises the CDRs of an antibody that binds to IL-11Rα, ie, the antibody / antigen-binding fragment comprises the CDRs of, or derived from, the CDRs of, an antibody that binds to IL-11Rα described herein (e.g., Enx209 or hEnx209).
[0137] In some embodiments, the antibody / antigen-binding fragment comprises: (5) HC-CDR1 having the amino acid sequence of SEQ ID NO: 46; HC-CDR2 having the amino acid sequence of SEQ ID NO: 47, and HC-CDR3 having the amino acid sequence of SEQ ID NO: 48, or Variants in which one, two or three amino acids are replaced with other amino acids in one or more of HC-CDR1, HC-CDR2 or HC-CDR3. It contains a VH region incorporating
[0138] In some embodiments, the antibody / antigen-binding fragment comprises: (6) LC-CDR1 having the amino acid sequence of SEQ ID NO: 49; LC-CDR2 having the amino acid sequence of SEQ ID NO: 50, and LC-CDR3 having the amino acid sequence of SEQ ID NO: 51, or Variants in which one, two or three amino acids are substituted with other amino acids in one or more of LC-CDR1, LC-CDR2 or LC-CDR3 It contains a VL region incorporating
[0139] In some embodiments, the antibody / antigen-binding fragment comprises a VH region incorporating the CDR described in (5) and a VL region incorporating the CDR described in (6).
[0140] In some embodiments, the antibody / antigen-binding fragment comprises the VH and VL regions of an antibody that binds to IL-11Rα. In some embodiments, the antibody / antigen-binding fragment comprises the VH and VL regions of, or derived from, an antibody that binds to IL-11Rα described herein (e.g., Enx209 or hEnx209).
[0141] In embodiments of the invention in which one or more amino acids of a reference amino acid sequence (e.g., a CDR sequence, VH region sequence, or VL region sequence described herein) are substituted with another amino acid, the substitution may be a conservative substitution, for example, according to the following table: In some embodiments, the substitution is between amino acids in the same box in the middle column. In some embodiments, the substitution is between amino acids in the same box in the right column. [Table 1]
[0142] In some embodiments, substitutions may be functionally conservative, i.e., in some embodiments, substitutions may not affect (or may not substantially affect) one or more functional properties (e.g., target binding) of the antibody / fragment containing the substitution when compared to the same molecule without the substitution.
[0143] In some embodiments, substitutions to a reference VH or VL region sequence may be made by focusing on one or more specific regions of the VH or VL region sequence, for example, by focusing on one or more framework regions (FR1, FR2, FR3, and / or FR4) of the reference VH or VL region sequence.
[0144] Antibodies and antigen-binding fragments according to the present disclosure may be designed and prepared using the sequence of a monoclonal antibody (mAb) capable of binding to the relevant target molecule. Antigen-binding regions of antibodies, such as single-chain variable fragments (scFv), Fab fragments, Fab2 fragments, etc., may also be used / provided. An "antigen-binding region" or "antigen-binding fragment" is an antibody fragment capable of binding to the target for which the original antibody is specific.
[0145] In some embodiments, the antibody / fragment comprises the VL and VH regions of an antibody capable of binding to IL-11, an IL-11-containing complex, or an IL-11 receptor. The VL and VH regions, which are present in the antigen-binding region of the antibody, together constitute an Fv region. In some embodiments, the antibody / fragment comprises or consists of an Fv region of an antibody capable of binding to IL-11, an IL-11-containing complex, or an IL-11 receptor. The Fv region may be expressed as a single chain comprising the VH and VL regions covalently linked, for example, by a flexible oligopeptide. Thus, the antibody / fragment may comprise or consist of an scFv comprising the VL and VH regions of an antibody capable of binding to IL-11, an IL-11-containing complex, or an IL-11 receptor.
[0146] The light chain variable region (VL) and light chain constant region (CL) and the heavy chain variable region (VH) and heavy chain constant region 1 (CH1) in the antigen-binding region of the antibody together constitute a Fab region. In some embodiments, the antibody / fragment comprises or consists of a Fab region of an antibody capable of binding to IL-11, an IL-11-containing complex, or an IL-11 receptor.
[0147] In some embodiments, the antibody / fragment comprises or consists of a full-length antibody capable of binding to IL-11, an IL-11-containing complex, or an IL-11 receptor. A "full-length antibody" refers to an antibody having a structure substantially similar to that of an immunoglobulin (Ig). For example, Schroeder and Cavacini J Allergy Clin Immunol. (2010) 125(202): S41-S52 (incorporated herein by reference in its entirety) describes various types of immunoglobulins and their structures. Immunoglobulin G (i.e., IgG) is a glycoprotein of approximately 150 kDa comprising two heavy chains and two light chains. From the N-terminus to the C-terminus, the heavy chain comprises a heavy chain variable region (VH) followed by a heavy chain constant region comprising three constant regions (CH1, CH2, and CH3). Similarly, the light chain comprises a light chain variable region (VL) followed by a light chain constant region (CL). Immunoglobulins may be classified according to the type of heavy chain as IgG (e.g., IgG1, IgG2, IgG3, IgG4), IgA (e.g., IgA1, IgA2), IgD, IgE, or IgM. Light chains may be kappa chains or lambda chains.
[0148] In some embodiments, the antibody / antigen-binding fragment of the present disclosure comprises the sequence of an immunoglobulin heavy chain constant region. In some embodiments, the sequence of the immunoglobulin heavy chain constant region may be the sequence of a human immunoglobulin heavy chain constant region. In some embodiments, the sequence of the immunoglobulin heavy chain constant region may be the sequence of a heavy chain constant region of IgG (e.g., IgG1, IgG2, IgG3, IgG4), IgA (e.g., IgA1, IgA2), IgD, IgE, or IgM, such as human IgG (e.g., hIgG1, hIgG2, hIgG3, hIgG4), hIgA (e.g., hIgA1, hIgA2), hIgD, hIgE, or hIgM, or may be a sequence derived from the sequence of the heavy chain constant region of these antibodies. In some embodiments, the sequence of the immunoglobulin heavy chain constant region is the sequence of a heavy chain constant region of a human IgG1 allotype (e.g., G1m1, G1m2, G1m3, or G1m17) or is a sequence derived from the sequence of a heavy chain constant region of a human IgG1 allotype.
[0149] In some embodiments, the sequence of the immunoglobulin heavy chain constant region is the constant region sequence of the human immunoglobulin G1 constant region (IGHG1; UniProt: P01857-1, v1) or a sequence derived from the constant region sequence of the constant region of human immunoglobulin G1. In some embodiments, the sequence of the immunoglobulin heavy chain constant region is the constant region sequence of the human immunoglobulin G1 constant region (i.e., allotype G1m3) (IGHG1; UniProt: P01857-1, v1) comprising the K214R, D356E, and L358M substitutions or a sequence derived from this human immunoglobulin G1 constant region. In some embodiments, the antibody / antigen-binding fragment comprises an amino acid sequence having at least 70% sequence identity, more preferably at least 75%, at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or at least 100% sequence identity to the amino acid sequence of SEQ ID NO: 52.
[0150] In some embodiments, the sequence of the immunoglobulin heavy chain constant region is the constant region sequence of the human immunoglobulin G4 constant region (IGHG4; UniProt:P01861, v1) or a sequence derived from the constant region sequence of the human immunoglobulin G4 constant region. In some embodiments, the sequence of the immunoglobulin heavy chain constant region is the constant region sequence of the human immunoglobulin G4 constant region (IGHG4; UniProt:P01861, v1) containing an S241P substitution and / or an L248E substitution or a sequence derived from this human immunoglobulin G4 constant region sequence. The S241P mutation stabilizes the hinge, and the L248E mutation further reduces the already low ADCC effector function of IgG4 (Davies and Sutton, Immunol Rev. 2015 Nov;268(1):139-159; Angal et al. Mol Immunol. 1993 Jan;30(1):105-8). In some embodiments, the antibody / antigen-binding fragment comprises an amino acid sequence having at least 70% sequence identity, more preferably at least 75%, at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or at least 100% sequence identity to the amino acid sequence of SEQ ID NO: 53.
[0151] In some embodiments, the antibody / antigen-binding fragment of the present disclosure comprises an immunoglobulin light chain constant region sequence. In some embodiments, the immunoglobulin light chain constant region sequence may be a human immunoglobulin light chain constant region sequence. In some embodiments, the immunoglobulin light chain constant region sequence may be a κ or λ light chain sequence, or may be a sequence derived from a κ or λ light chain. Examples of kappa or lambda light chains include the human immunoglobulin constant region kappa chain (IGKC; Cκ; UniProt: P01834-1, v2) or the human immunoglobulin constant region lambda chain (IGLC; Cλ), such as IGLC1 (UniProt: P0CG04-1, v1), IGLC2 (UniProt: P0DOY2-1, v1), IGLC3 (UniProt: P0DOY3-1, v1), IGLC6 (UniProt: P0CF74-1, v1) or IGLC7 (UniProt: A0M8Q6-1, v3).
[0152] In some embodiments, the antibody / antigen-binding fragment comprises an immunoglobulin light chain constant region sequence. In some embodiments, the immunoglobulin light chain constant region sequence is the sequence of a human immunoglobulin constant region kappa chain (IGKC; Cκ; UniProt:P01834-1, v2; SEQ ID NO:90) or a sequence derived from the human immunoglobulin constant region kappa chain. In some embodiments, the immunoglobulin light chain constant region sequence is the sequence of a human immunoglobulin constant region lambda chain (IGLC; Cλ), such as the sequence of IGLC1, IGLC2, IGLC3, IGLC6, or IGLC7. In some embodiments, the antibody / antigen-binding fragment comprises an amino acid sequence having at least 70% sequence identity, more preferably at least 75%, at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or at least 100% sequence identity to the amino acid sequence of SEQ ID NO: 54. In some embodiments, the antibody / antigen-binding fragment comprises an amino acid sequence having at least 70% sequence identity, more preferably at least 75%, at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or at least 100% sequence identity to the amino acid sequence of SEQ ID NO: 55.
[0153] In some embodiments, the antibody / antigen-binding fragment comprises: (i) a polypeptide comprising, or consisting of, an amino acid sequence having at least 70% amino acid sequence identity, preferably 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity, to the amino acid sequence of SEQ ID NO: 28; and (ii) a polypeptide comprising, or consisting of, an amino acid sequence having at least 70% amino acid sequence identity, preferably 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity, to the amino acid sequence of SEQ ID NO: 29.
[0154] In some embodiments, the antibody / antigen-binding fragment comprises: (i) a polypeptide comprising, or consisting of, an amino acid sequence having at least 70% amino acid sequence identity, preferably 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity, to the amino acid sequence of SEQ ID NO: 56; and (ii) a polypeptide comprising, or consisting of, an amino acid sequence having at least 70% amino acid sequence identity, preferably 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity, to the amino acid sequence of SEQ ID NO: 57.
[0155] In some embodiments, the antibody / antigen-binding fragment comprises: (i) a polypeptide comprising, or consisting of, an amino acid sequence having at least 70% amino acid sequence identity, preferably 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity, to the amino acid sequence of SEQ ID NO: 58; and (ii) a polypeptide comprising, or consisting of, an amino acid sequence having at least 70% amino acid sequence identity, preferably 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity, to the amino acid sequence of SEQ ID NO: 59.
[0156] Fab, Fv, scFv and dAb antibody fragments can all be expressed in E. coli and secreted, and therefore can be easily mass-produced.
[0157] Full-length antibodies and F(ab')2 fragments are "bivalent." By "bivalent," we mean that full-length antibodies and F(ab')2 fragments have two antigen-binding sites. In contrast, Fab, Fv, scFv, and dAb fragments are monovalent because they have only one antigen-binding site. Synthetic antibodies capable of binding to IL-11, IL-11-containing complexes, or IL-11 receptor can also be generated using phage display techniques well known in the art.
[0158] Antibodies may also be prepared by affinity maturation techniques to generate modified antibodies with improved affinity for an antigen compared to the unmodified parent antibody. Affinity matured antibodies may be prepared by techniques known in the art, and techniques for producing affinity matured antibodies are described, for example, in Marks et al., Rio / Technology 10:779-783 (1992); Barbas et al., Proc Nat. Acad. Sci. USA 91:3809-3813 (1994); Schier et al., Gene 169:147-155 (1995); Yelton et al., J. Immunol. 155:1994-2004 (1995); Jackson et al., J. Immunol. 154(7):331 0-15 9 (1995); and Hawkins et al., J. Mol. Biol. 226:889-896 (1992).
[0159] Antibodies / fragments include bispecific antibodies, which are composed of, for example, two fragments derived from two antibodies, thereby capable of binding to two different antigens. Bispecific antibodies include the antibodies / fragments described herein that can bind to IL-11, IL-11-containing complexes, or IL-11 receptors. Bispecific antibodies may also contain another fragment with affinity for a second antigen, which may be any desired antigen. Techniques for producing bispecific antibodies are well known in the art; see, for example, Mueller, D. et al. (2010 Biodrugs 24 (2): 89-98), Wozniak-Knopp, G. et al. (2010 Protein Eng Des 23 (4): 289-297), and Baeuerle, PA. et al. (2009 Cancer Res 69 (12): 4941-4944). Bispecific antibodies and bispecific antigen-binding fragments may be provided in any suitable form, for example, as described in Kontermann MAbs 2012, 4(2): 182-197, which is incorporated herein by reference in its entirety. For example, bispecific antibodies or bispecific antigen-binding fragments may be provided as bispecific antibody complexes (e.g., IgG2, F(ab')2, or CovX-Body), bispecific IgG or IgG-like molecules (e.g., IgG, scFv4-Ig, IgG-scFv, scFv-IgG, DVD-Ig, IgG-sVD, sVD-IgG, 2 in 1-IgG, mAb 2 or Tandemab with a shared light chain (LC), asymmetric bispecific IgG or IgG-like molecules (e.g., kih IgG, kih IgG with a shared light chain (LC), CrossMab, kih IgG-scFab, mAb-Fv, charge-paired IgG, or SEED-body), small bispecific antibody molecules (e.g., Diabody (Db), dsDb, DART, scDb, tandAb, tandem scFv (taFv), tandem dAb / VHH, triple body, triple head, Fab-scFv, or F(ab')2-scFv2), bispecific Fc-C H3. Fusion proteins (e.g., taFv-Fc, Di-diabody, scDb-C) H 3. scFv-Fc-scFv, HCAb-VHH, scFv-kih-Fc or scFv-kih-C H 3), or bispecific fusion proteins (e.g., scFv2-albumin, scDb-albumin, taFv-toxin, DNL-Fab3, DNL-Fab4-IgG, DNL-Fab4-IgG-cytokine 2). See Figure 2 in Kontermann MAbs 2012, 4(2): 182-19 for details.
[0160] Methods for producing bispecific antibodies include chemically crosslinking antibodies or antibody fragments, for example, via a reducible disulfide bond or a non-reducible thioether bond, as described in, for example, Segal and Bast, 2001. Production of Bispecific Antibodies. Current Protocols in Immunology. 14:IV:2.13:2.13.1-2.13.16 (which is incorporated herein by reference in its entirety). For example, N-succinimidyl-3-(2-pyridyldithio)propionate (SPDP) can be used to chemically crosslink, for example, Fab fragments via SH groups in the hinge region to produce disulfide-linked bispecific F(ab)2 heterodimers.
[0161] Another method for producing bispecific antibodies is to fuse antibody-producing hybridomas, for example, using polyethylene glycol, to produce quadroma cells capable of secreting bispecific antibodies, as described, for example, in DM and Bast, BJ 2001. Production of Bispecific Antibodies. Current Protocols in Immunology. 14:IV:2.13:2.13.1-2.13.16.
[0162] Bispecific antibodies and bispecific antigen-binding fragments can also be produced by recombinant techniques; for example, bispecific antibodies and bispecific antigen-binding fragments can be expressed from nucleic acid constructs encoding the polypeptides of the antigen-binding molecules, as described, for example, in Chapter 40: Production of Bispecific Antibodies: Diabodies and Tandem scFv (Hornig and Farber-Schwarz) in Antibody Engineering: Methods and Protocols, Second Edition (Humana Press, 2012), or French, How to make bispecific antibodies, Methods Mol. Med. 2000; 40:333-339.
[0163] For example, a DNA construct encoding the light and heavy chain variable regions of two antigen-binding regions (i.e., encoding the light and heavy chain variable regions of an antigen-binding region capable of binding to IL-11, an IL-11-containing complex, or an IL-11 receptor, and the light and heavy chain variable regions of an antigen-binding region capable of binding to another target protein) and containing a sequence encoding a suitable linker or dimerization region linking these antigen-binding regions can be prepared by molecular cloning techniques. This DNA construct can then be expressed (e.g., in vitro) in a suitable host cell (e.g., a mammalian host cell) to produce a recombinant bispecific antibody, and the expressed recombinant bispecific antibody can be purified as needed.
[0164] Decoy receptor Peptide- or polypeptide-based agents capable of binding to IL-11 or IL-11-containing complexes may be based on the IL-11 receptor, for example, based on an IL-11-binding fragment of the IL-11 receptor.
[0165] In some embodiments, the binding agent may comprise an IL-11-binding fragment of the IL-11Rα chain, which may preferably be soluble and / or may not comprise one or more transmembrane domains, or may not comprise any transmembrane domains at all. In some embodiments, the binding agent may comprise an IL-11-binding fragment of gp130, which may preferably be soluble and / or may not comprise one or more transmembrane domains, or may not comprise any transmembrane domains at all. Such molecules may be referred to as decoy receptors. Binding of such agents to IL-11 may reduce / inhibit the ability of IL-11 to bind to an IL-11 receptor (e.g., IL-11Rα or gp130), thereby inhibiting IL-11-mediated cis- and / or trans-signaling, and thereby inhibiting downstream signaling.
[0166] Curtis et al. (Blood 1997 Dec 1; 90 (11):4403-12) reported that the soluble murine IL-11 receptor α chain (sIL-11R) was able to antagonize the activity of IL-11 when tested on cells expressing the transmembrane IL-11R and gp130. It has been proposed that the antagonism of sIL-11R against IL-11 observed in this study depends on the number of available gp130 molecules on cells already expressing the transmembrane IL-11R.
[0167] The use of soluble decoy receptors for signaling inhibition and therapeutic intervention has also been reported for other signaling molecule-receptor pairs, such as VEGF and its receptor (De-Chao Yu et al., Molecular Therapy (2012); 20 5, 938-947; Konner and Dupont Clin Colorectal Cancer 2004 Oct;4 Suppl 2:S81-5).
[0168] Thus, in some embodiments, the binding agent may be a decoy receptor, for example, a soluble receptor for IL-11 and / or IL-11-containing complexes. It has been reported that decoy receptors compete for IL-11 and / or IL-11-containing complexes and exert antagonistic effects against IL-11 (Curtis et al., supra). IL-11 decoy receptors are also described in WO 2017 / 103108(A1) and WO 2018 / 109168(A1), which are incorporated herein by reference in their entireties.
[0169] Preferably, the decoy receptor for IL-11 can inhibit the binding of IL-11 and / or IL-11-containing complexes to gp130, IL-11Rα, and / or gp130:IL-11Rα receptors by binding to IL-11 and / or IL-11-containing complexes. In this manner, the decoy receptor for IL-11 acts as a "decoy" receptor for IL-11 and IL-11-containing complexes in a manner very similar to that of etanercept, which acts as a decoy receptor for TNFα. IL-11-mediated signaling is reduced compared to signaling in the absence of the decoy receptor.
[0170] Preferably, the decoy receptor for IL-11 binds to IL-11 via one or more cytokine binding modules (CBM). The CBM is the CBM of a natural IL-11 receptor molecule, is derived from the CBM of a natural IL-11 receptor molecule, or is homologous to the CBM of a natural IL-11 receptor molecule. For example, the decoy receptor for IL-11 may comprise one or more CBMs of gp130 and / or IL-11Rα, consist of one or more CBMs of gp130 and / or IL-11Rα, comprise one or more CBMs derived from the CBM of gp130 and / or IL-11Rα, consist of one or more CBMs derived from the CBM of gp130 and / or IL-11Rα, comprise one or more CBMs homologous to the CBM of gp130 and / or IL-11Rα, or consist of one or more CBMs homologous to the CBM of gp130 and / or IL-11Rα.
[0171] In some embodiments, the decoy receptor for IL-11 may comprise an amino acid sequence corresponding to the cytokine binding module of gp130, or may consist of an amino acid sequence corresponding to the cytokine binding module of gp130. In some embodiments, the decoy receptor for IL-11 may comprise an amino acid sequence corresponding to the cytokine binding module of IL-11Rα. As used herein, an amino acid sequence "corresponding to" a reference region or reference sequence of a given peptide / polypeptide has at least 60% sequence identity with the amino acid sequence of this reference region / reference sequence, for example, at least 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity with the amino acid sequence of this reference region / reference sequence.
[0172] In some embodiments, the decoy receptor may be capable of binding to IL-11 with a binding affinity of, for example, at least 100 μM or less, or may bind to IL-11 with a binding affinity of 10 μM or less, 1 μM or less, 100 nM or less, or about 1 to 100 nM. In some embodiments, the decoy receptor may comprise the entire IL-11-binding domain or a portion thereof, or may lack the entire transmembrane domain or a portion thereof. The decoy receptor may be fused to an immunoglobulin constant region (e.g., an IgG Fc region).
[0173] inhibitors The present invention contemplates the use of inhibitor molecules that can bind to one or more of IL-11, IL-11-containing complexes, IL-11Rα, gp130, or complexes containing IL-11Rα and / or gp130, and inhibit IL-11-mediated signal transduction.
[0174] In some embodiments, the agent is a peptide- or polypeptide-based binding agent based on IL-11, e.g., a mutant, variant, or binding fragment of IL-11. Suitable peptide- or polypeptide-based agents may inhibit signaling initiation or result in insufficient signaling by binding to an IL-11 receptor (e.g., IL-11Rα, gp130, or a complex containing IL-11Rα and / or gp130). These types of IL-11 mutants may act as competitive inhibitors of endogenous IL-11.
[0175] For example, W147A is an IL-11 antagonist in which the 147th amino acid is mutated from tryptophan to alanine, thereby disrupting the so-called "site III" of IL-11. This mutant can bind to IL-11Rα but does not associate with gp130 homodimers, resulting in efficient blockage of IL-11 signaling (Underhill-Day et al., 2003; Endocrinology 2003 Aug;144(8):3406-14). Lee et al. (Am J respire Cell Mol Biol. 2008 Dec;39(6):739-746) also reported the creation of an IL-11 antagonist mutant ("mutein") that can specifically inhibit IL-11 binding to IL-11Rα. IL-11 muteins are also described in WO 2009 / 052588(A1).
[0176] Menkhorst et al. (Biology of Reproduction May 1, 2009 vol. 80 no. 5 920-927) reported that a pegylated IL-11 antagonist, PEGIL11A (CSL Limited, Parkville, Victoria, Australia), can effectively suppress the action of IL-11 in female mice.
[0177] Furthermore, Pasqualini et al. (Cancer (2015) 121(14):2411-2421) reported a ligand-targeted peptidomimetic, bone metastasis-targeting peptidomimetic-11 (BMTP-11), that can bind to IL-11Rα.
[0178] In some embodiments, a binding agent capable of binding to the IL-11 receptor may be provided in the form of a small molecule inhibitor of IL-11Rα, gp130, or a complex containing IL-11Rα and / or gp130. In some embodiments, the binding agent may be provided in the form of a small molecule inhibitor of IL-11 or an IL-11-containing complex, such as the IL-11 inhibitors described in Lay et al., Int. J. Oncol. (2012); 41(2): 759-764, which is incorporated herein by reference in its entirety.
[0179] Aptamers In some embodiments, the agent capable of binding to IL-11 or an IL-11-containing complex or an IL-11 receptor (e.g., IL-11Rα, gp130, or a complex containing IL-11Rα and / or gp130) is an aptamer. Aptamers, also called nucleic acid / peptide ligands, are nucleic acid or peptide molecules characterized by their ability to bind to target molecules with high specificity and high affinity. Most aptamers identified to date are non-natural molecules.
[0180] Aptamers that bind to a given target (e.g., IL-11, IL-11-containing complexes, or IL-11 receptors) are identified using Systematic Evolution of Ligands by EXponential enrichment (SELEX). TMAptamers may be identified and / or produced by the SELEX method, or by constructing SOMAmers (slow off-rate modified aptamers) (Gold L et al. (2010) PLoS ONE 5(12):e15004). Aptamers and the SELEX method have been reported by Tuerk and Gold (Science (1990) 249(4968):505-10) and are also described in WO91 / 19813. In the SELEX method and SOMAmer technology, for example, functional groups that mimic amino acid side chains are added to expand the chemical diversity of aptamers. As a result, aptamers with high affinity for a target can be enriched and identified.
[0181] Aptamers may be DNA molecules or RNA molecules, and may be single-stranded or double-stranded. Aptamers may also include chemically modified nucleic acids, such as nucleic acids with chemically modified sugars, phosphates, and / or bases. Such modifications may improve the stability of the aptamer or confer resistance to degradation, and may include modifications at the 2' position of the ribose.
[0182] Aptamer can be synthesized by methods well known to those skilled in the art. For example, aptamer can be chemically synthesized on a solid support. Solid-phase synthesis using the phosphoramidite method can also be used. Briefly, the immobilized nucleotide is detritylated, and then coupled with an appropriately activated nucleoside phosphoramidite to form a phosphite triester bond. Then, capping is performed, and the phosphite triester can be oxidized with an oxidizing agent (usually iodine). This cycle can be repeated to construct an aptamer (see, for example, Sinha, ND; Biernat, J.; McManus, J.; Koster, H. Nucleic Acids Res. 1984, 12, 4539; and Beaucage, SL; Lyer, RP (1992). Tetrahedron 48 (12): 2223).
[0183] The lower limit of the length of a suitable nucleic acid aptamer may be any of 10 nucleotides, 11 nucleotides, 12 nucleotides, 13 nucleotides, 14 nucleotides, 15 nucleotides, 16 nucleotides, 17 nucleotides, 18 nucleotides, 19 nucleotides, 20 nucleotides, 21 nucleotides, 22 nucleotides, 23 nucleotides, 24 nucleotides, 25 nucleotides, 26 nucleotides, 27 nucleotides, 28 nucleotides, 29 nucleotides, 30 nucleotides, 31 nucleotides, 32 nucleotides, 33 nucleotides, 34 nucleotides, 35 nucleotides, 36 nucleotides, 37 nucleotides, 38 nucleotides, 39 nucleotides, and 40 nucleotides. Suitable upper limits for the length of nucleic acid aptamers are 20 nucleotides, 21 nucleotides, 22 nucleotides, 23 nucleotides, 24 nucleotides, 25 nucleotides, 26 nucleotides, 27 nucleotides, 28 nucleotides, 29 nucleotides, 30 nucleotides, 31 nucleotides, 32 nucleotides, 33 nucleotides, 34 nucleotides, 35 nucleotides, 36 nucleotides, 37 nucleotides, 38 nucleotides, 39 nucleotides, 40 nucleotides, 41 nucleotides, 42 nucleotides, 43 nucleotides, 44 nucleotides, 45 nucleotides, 46 nucleotides, 47 nucleotides, 48 nucleotides, 49 nucleotides, 50 nucleotides, 51 nucleotides, 52 nucleotides, 53 nucleotides, 54 nucleotides, 55 nucleotides, 56 nucleotides, 57 nucleotides, 58 nucleotides, 59 nucleotides, 60 nucleotides, 61 nucleotides, 62 nucleotides, 63 nucleotides, 64 nucleotides, 65 nucleotides, 66 nucleotides, 67 nucleotides, 68 nucleotides, 69 nucleotides, 70 nucleotides, 71 nucleotides, 72 nucleotides, 73 nucleotides, 74 nucleotides, 75 nucleotides, 76 nucleotides, 77 nucleotides, 78 nucleotides, 79 nucleotides, 80 nucleotides, 81 nucleotides, 82 nucleotides, 83 nucleotides, 84 nucleotides, 85 nucleotides, 86 nucleotides, 87 nucleotides, 88 nucleotides, 89 nucleotides, 90 nucleotides, The length may be any of 0, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, or 80 nucleotides.Preferred lengths of nucleic acid aptamers are 10 nucleotides, 11 nucleotides, 12 nucleotides, 13 nucleotides, 14 nucleotides, 15 nucleotides, 16 nucleotides, 17 nucleotides, 18 nucleotides, 19 nucleotides, 20 nucleotides, 21 nucleotides, 22 nucleotides, 23 nucleotides, 24 nucleotides, 25 nucleotides, 26 nucleotides, 27 nucleotides, 28 nucleotides, 29 nucleotides, 30 nucleotides, 31 nucleotides, 32 nucleotides, 33 nucleotides, 34 nucleotides, 35 nucleotides, 36 nucleotides, 37 nucleotides, 38 nucleotides, 39 nucleotides, 40 nucleotides, 41 nucleotides, 42 nucleotides, 43 nucleotides, 44 nucleotides, 45 nucleotides, The length may be any of 46 nucleotides, 47 nucleotides, 48 nucleotides, 49 nucleotides, 50 nucleotides, 51 nucleotides, 52 nucleotides, 53 nucleotides, 54 nucleotides, 55 nucleotides, 56 nucleotides, 57 nucleotides, 58 nucleotides, 59 nucleotides, 60 nucleotides, 61 nucleotides, 62 nucleotides, 63 nucleotides, 64 nucleotides, 65 nucleotides, 66 nucleotides, 67 nucleotides, 68 nucleotides, 69 nucleotides, 70 nucleotides, 71 nucleotides, 72 nucleotides, 73 nucleotides, 74 nucleotides, 75 nucleotides, 76 nucleotides, 77 nucleotides, 78 nucleotides, 79 nucleotides, and 80 nucleotides.
[0184] Aptamer can be a peptide that is selected or constructed to bind to a specific target molecule.Peptide aptamer and its preparation and identification methods are reviewed in Reverdatto et al., Curr Top Med Chem.(2015)15(12):1082-101 (this document is incorporated herein by reference in its entirety).The lower limit of the length of peptide aptamer can be 2 amino acids, 3 amino acids, 4 amino acids, 5 amino acids, 6 amino acids, 7 amino acids, 8 amino acids, 9 amino acids, or 10 amino acids. The upper limit of the length of the peptide aptamer may be any of 15 amino acids, 16 amino acids, 17 amino acids, 18 amino acids, 19 amino acids, 20 amino acids, 21 amino acids, 22 amino acids, 23 amino acids, 24 amino acids, 25 amino acids, 26 amino acids, 27 amino acids, 28 amino acids, 29 amino acids, 30 amino acids, 31 amino acids, 32 amino acids, 33 amino acids, 34 amino acids, 35 amino acids, 36 amino acids, 37 amino acids, 38 amino acids, 39 amino acids, 40 amino acids, 41 amino acids, 42 amino acids, 43 amino acids, 44 amino acids, 45 amino acids, 46 amino acids, 47 amino acids, 48 amino acids, 49 amino acids, and 50 amino acids. The length of a suitable peptide aptamer may be any of 2 to 30 amino acids, 2 to 25 amino acids, 2 to 20 amino acids, 5 to 30 amino acids, 5 to 25 amino acids, and 5 to 20 amino acids.
[0185] Aptamers have K values in the nM or pM range. D and K D may be, for example, less than 500 nM, less than 100 nM, less than 50 nM, less than 10 nM, less than 1 nM, less than 500 pM, or less than 100 pM.
[0186] Properties of IL-11 binding agents An agent of the invention capable of binding to IL-11 or an IL-11 containing complex or IL-11 receptor may exhibit any one or more of the following properties: Specific binding to IL-11 or IL-11-containing complexes or IL-11 receptors K below 10 μM D , preferably 5 μM or less, 1 μM or less, 500 nM or less, 100 nM or less, 10 nM or less, 1 nM or less, or 100 pM or less. D Binding to IL-11 or IL-11-containing complexes or IL-11 receptors Inhibition of the interaction between IL-11 and IL-11Rα Inhibition of the interaction between IL-11 and gp130 Inhibition of the interaction between IL-11 and the IL-11Rα:gp130 receptor complex Inhibition of the interaction between the IL-11:IL-11Rα complex and gp130
[0187] These properties can be measured by analyzing the relevant factors in a suitable assay, which may include comparing performance to appropriate controls. Those skilled in the art can determine appropriate control conditions for a given assay.
[0188] For example, a suitable negative control for analyzing the binding ability of a test antibody / antigen-binding fragment to an IL-11 / IL-11-containing complex / IL-11 receptor may be an antibody / antigen-binding fragment against a non-target protein (i.e., an antibody / antigen-binding fragment that is not specific for IL-11 / IL-11-containing complex / IL-11 receptor). A suitable positive control may be a validated (e.g., commercially available) known antibody that binds to IL-11 or a known antibody that binds to IL-11 receptor. The control may be of the same isotype, e.g., have the same constant region, as the antibody / antigen-binding fragment that is expected to bind to an IL-11 / IL-11-containing complex or IL-11 receptor under analysis.
[0189] In some embodiments, the agent may be capable of specifically binding to IL-11, an IL-11-containing complex, or an IL-11 receptor (e.g., IL-11Rα, gp130, or a complex comprising IL-11Rα and / or gp130). Preferably, an agent that specifically binds to a given target molecule binds to the target molecule with higher affinity and / or longer duration than it binds to other non-target molecules.
[0190] In some embodiments, the agent may bind to IL-11 or an IL-11-containing complex with greater affinity than it binds to one or more other members of the IL-6 cytokine family (e.g., IL-6, leukemia inhibitory factor (LIF), oncostatin M (OSM), cardiotrophin-1 (CT-1), ciliary neurotrophic factor (CNTF), and cardiotrophin-like cytokine (CLC)). In some embodiments, the agent may bind to an IL-11 receptor (e.g., IL-11Rα, gp130, or a complex comprising IL-11Rα and / or gp130) with greater affinity than it binds to one or more other members of the IL-6 receptor family. In some embodiments, the agent may bind to IL-11Rα with greater affinity than it binds to one or more of IL-6Rα, leukemia inhibitory factor receptor (LIFR), oncostatin M receptor (OSMR), ciliary neurotrophic factor receptor α (CNTFRα), and cytokine receptor-like factor 1 (CRLF1).
[0191] In some embodiments, the extent of binding of a binding agent to a non-target molecule is less than about 10% of the extent of binding of the binding agent to a target molecule, as measured, for example, by ELISA, SPR, biolayer interferometry (BLI), microscale thermophoresis (MST), or radioimmunoassay (RIA). Alternatively, binding specificity may be reflected in binding affinity, where a binding agent has a K D at least 0.1 orders of magnitude (i.e., 0.1 × 10 n (n is an integer representing the number of digits) Small K DThe antibody binds to IL-11, an IL-11-containing complex, or an IL-11 receptor by an order of magnitude of at least 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.5, or 2.0.
[0192] The binding affinity of a given binding agent for a target is determined by its dissociation constant (K D Binding affinity can be measured by methods known in the art, such as ELISA, surface plasmon resonance (SPR; see, e.g., Hearty et al., Methods Mol Biol (2012) 907:411-442; or Rich et al., Anal Biochem. 2008 Feb 1; 373(1):112-20), biolayer interferometry (see, e.g., Lad et al., (2015) J Biomol Screen 20(4): 498-507; or Concepcion et al., Comb Chem High Throughput Screen. 2009 Sep; 12(8):791-800), microscale thermophoresis (MST) analysis (see, e.g., Jerabek-Willemsen et al., Assay Drug Dev Technol. 2011 Aug; 9(4): 342-353), or radiolabeled antigen binding assay (RIA).
[0193] In some embodiments, the agent has a K D , preferably 10 μM or less, 5 μM or less, 4 μM or less, 3 μM or less, 2 μM or less, 1 μM or less, 500 nM or less, 100 nM or less, 75 nM or less, 50 nM or less, 40 nM or less, 30 nM or less, 20 nM or less, 15 nM or less, 12.5 nM or less, 10 nM or less, 9 nM or less, 8 nM or less, 7 nM or less, 6 nM or less, 5 nM or less, 4 nM or less, 3 nM or less, 2 nM or less, 1 nM or less, 500 pM or less, 400 pM or less, 300 pM or less, 200 pM or less or 100 pM or less Dand capable of binding to IL-11, an IL-11-containing complex, or an IL-11 receptor.
[0194] In some embodiments, the agent has an EC 50 is 10,000ng / ml or less, preferably EC 50 or less, binds to IL-11, an IL-11-containing complex, or an IL-11 receptor with a binding affinity of 5,000 ng / ml or less, 1000 ng / ml or less, 900 ng / ml or less, 800 ng / ml or less, 700 ng / ml or less, 600 ng / ml or less, 500 ng / ml or less, 400 ng / ml or less, 300 ng / ml or less, 200 ng / ml or less, 100 ng / ml or less, 90 ng / ml or less, 80 ng / ml or less, 70 ng / ml or less, 60 ng / ml or less, 50 ng / ml or less, 40 ng / ml or less, 30 ng / ml or less, 20 ng / ml or less, 15 ng / ml or less, 10 ng / ml or less, 7.5 ng / ml or less, 5 ng / ml or less, 2.5 ng / ml or less, or 1 ng / ml or less. ELISA can be performed, for example, as described in Antibody Engineering, vol. 1 (2nd Edn), Springer Protocols, Springer (2010), Part V, pp. 657-665.
[0195] In some embodiments, the agent binds to IL-11 or an IL-11-containing complex in a region important for binding of the IL-11 receptor or IL-11-containing complex to its receptor (e.g., gp130 or IL-11Rα), thereby inhibiting the interaction between IL-11 or an IL-11-containing complex and the IL-11 receptor and / or inhibiting signaling through the IL-11 receptor. In some embodiments, the agent binds to the IL-11 receptor in a region important for binding to IL-11 or an IL-11-containing complex, thereby inhibiting the interaction between IL-11 or an IL-11-containing complex and the IL-11 receptor and / or inhibiting signaling through the IL-11 receptor.
[0196] The ability of a given binding agent (e.g., an agent capable of binding to IL-11 or an IL-11-containing complex or an IL-11 receptor) to inhibit the interaction between two proteins can be measured, for example, by analyzing the interaction between these interaction partners in the presence of the binding agent, or after incubating the binding agent with one or both of the interaction partners. Suitable assays for determining whether a given binding agent can inhibit the interaction between two interaction partners include competitive ELISA.
[0197] Binding agents capable of inhibiting a given interaction (e.g., the interaction between IL-11 and IL-11Rα, the interaction between IL-11 and gp130, the interaction between IL-11 and IL-11Rα:gp130, or the interaction between IL-11:IL-11Rα and gp130) are identified by a reduced / diminished extent of interaction between these interaction partners in the presence of the binding agent or after incubation of the binding agent with one or both of the interaction partners, compared to the extent of interaction in the absence of the binding agent (or in the presence of a suitable control binding agent). Suitable assays can be performed in vitro, for example, using recombinant interaction partners or cells expressing the interaction partners. Cells expressing the interaction partners may express the interaction partners endogenously or may express the interaction partners from nucleic acids introduced into the cells. For purposes of conducting such assays, one or both of the interaction partners and / or the binding agents may be labeled with a detectable substance or used in conjunction with such a label to detect and / or measure the extent of interaction. For example, the binding agent may be labeled with a radioactive atom, a dye molecule, a fluorescent molecule, or any other molecule that can be easily detected by any method. Suitable detectable molecules include fluorescent proteins, luciferase, enzyme substrates, and radioactive labels. The binding agent may be directly or indirectly labeled with a detectable label. For example, the binding agent may be unlabeled and may be detected using another labeled binding agent. Alternatively, the second binding agent may be bound to biotin, and labeled streptavidin may be bound to the biotin, thereby indirectly labeling the first binding agent.
[0198] The ability of a binding agent to inhibit an interaction between two binding partners can also be identified by analyzing the downstream functional consequences of such an interaction (e.g., IL-11-mediated signaling). For example, downstream functional consequences of the interaction between IL-11 and IL-11Rα:gp130 or between IL-11:IL-11Rα and gp130 may include, for example, IL-11-mediated processes, or, for example, collagen or IL-11 gene / protein expression.
[0199] Inhibition of the interaction between IL-11 or IL-11-containing complexes and the IL-11 receptor can be achieved by, for example, inhibiting the IL-11 receptor, as described in Curtis et al. Blood, 1997, 90(11) and Karpovich et al. Mol. Hum. Reprod. 2003 9(2): 75-80. 3 They can also be analyzed using a 3H-thymidine incorporation assay and / or a Ba / F3 cell proliferation assay. Ba / F3 cells co-express IL-11Rα and gp130.
[0200] In some embodiments, the binding agent may be capable of inhibiting the interaction between IL-11 and IL-11Rα to less than 100%, for example 99% or less, 95% or less, 90% or less, 85% or less, 75% or less, 70% or less, 65% or less, 60% or less, 55% or less, 50% or less, 45% or less, 40% or less, 35% or less, 30% or less, 25% or less, 20% or less, 15% or less, 10% or less, 5% or less, or 1% or less, compared to the extent of interaction between IL-11 and IL-11Rα in the absence of the binding agent (or in the presence of a suitable control binding agent). In some embodiments, the binding agent may be capable of inhibiting the interaction between IL-11 and IL-11Rα by less than 1-fold, for example 0.99-fold or less, 0.95-fold or less, 0.9-fold or less, 0.85-fold or less, 0.8-fold or less, 0.75-fold or less, 0.7-fold or less, 0.65-fold or less, 0.6-fold or less, 0.55-fold or less, 0.5-fold or less, 0.45-fold or less, 0.4-fold or less, 0.35-fold or less, 0.3-fold or less, 0.25-fold or less, 0.2-fold or less, 0.15-fold or less, or 0.1-fold or less, compared to the extent of interaction between IL-11 and IL-11Rα in the absence of the binding agent (or in the presence of a suitable control binding agent).
[0201] In some embodiments, the binding agent may be capable of inhibiting the interaction between IL-11 and gp130 to less than 100%, for example 99% or less, 95% or less, 90% or less, 85% or less, 75% or less, 70% or less, 65% or less, 60% or less, 55% or less, 50% or less, 45% or less, 40% or less, 35% or less, 30% or less, 25% or less, 20% or less, 15% or less, 10% or less, 5% or less, or 1% or less, compared to the extent of interaction between IL-11 and gp130 in the absence of the binding agent (or in the presence of a suitable control binding agent). In some embodiments, the binding agent may be capable of inhibiting the interaction between IL-11 and gp130 by less than 1-fold, for example 0.99-fold or less, 0.95-fold or less, 0.9-fold or less, 0.85-fold or less, 0.8-fold or less, 0.75-fold or less, 0.7-fold or less, 0.65-fold or less, 0.6-fold or less, 0.55-fold or less, 0.5-fold or less, 0.45-fold or less, 0.4-fold or less, 0.35-fold or less, 0.3-fold or less, 0.25-fold or less, 0.2-fold or less, 0.15-fold or less, or 0.1-fold or less, compared to the extent of interaction between IL-11 and gp130 in the absence of the binding agent (or in the presence of a suitable control binding agent).
[0202] In some embodiments, the binding agent may be capable of inhibiting the interaction between IL-11 and IL-11Rα:gp130 to less than 100%, for example 99% or less, 95% or less, 90% or less, 85% or less, 75% or less, 70% or less, 65% or less, 60% or less, 55% or less, 50% or less, 45% or less, 40% or less, 35% or less, 30% or less, 25% or less, 20% or less, 15% or less, 10% or less, 5% or less, or 1% or less, compared to the extent of interaction between IL-11 and IL-11Rα:gp130 in the absence of the binding agent (or in the presence of a suitable control binding agent). In some embodiments, the binding agent may be capable of inhibiting the interaction between IL-11 and IL-11Rα:gp130 by less than 1-fold, for example 0.99-fold or less, 0.95-fold or less, 0.9-fold or less, 0.85-fold or less, 0.8-fold or less, 0.75-fold or less, 0.7-fold or less, 0.65-fold or less, 0.6-fold or less, 0.55-fold or less, 0.5-fold or less, 0.45-fold or less, 0.4-fold or less, 0.35-fold or less, 0.3-fold or less, 0.25-fold or less, 0.2-fold or less, 0.15-fold or less, or 0.1-fold or less, compared to the extent of interaction between IL-11 and IL-11Rα:gp130 in the absence of the binding agent (or in the presence of a suitable control binding agent).
[0203] In some embodiments, the binding agent may be capable of inhibiting the interaction between the IL-11:IL-11Rα complex and gp130 to less than 100%, for example 99% or less, 95% or less, 90% or less, 85% or less, 75% or less, 70% or less, 65% or less, 60% or less, 55% or less, 50% or less, 45% or less, 40% or less, 35% or less, 30% or less, 25% or less, 20% or less, 15% or less, 10% or less, 5% or less, or 1% or less, compared to the extent of interaction between the IL-11:IL-11Rα complex and gp130 in the absence of the binding agent (or in the presence of a suitable control binding agent). In some embodiments, the binding agent is capable of inhibiting the interaction between the IL-11:IL-11Rα complex and gp130 by less than 1-fold, e.g., 0.99-fold or less, 0.95-fold or less, 0.9-fold or less, 0.85-fold or less, 0.8-fold or less, 0.75-fold or less, 0.7-fold or less, 0.65-fold or less, 0.6-fold or less, 0.55-fold or less, 0.5-fold or less, 0.45-fold or less, 0.4-fold or less, 0.35-fold or less, 0.3-fold or less, 0.25-fold or less, 0.2-fold or less, 0.15-fold or less, or 0.1-fold or less, compared to the extent of interaction between the IL-11:IL-11Rα complex and gp130 in the absence of the binding agent.
[0204] Agents that can reduce the expression of IL-11 or the IL-11 receptor In an embodiment of the present invention, an agent capable of suppressing IL-11-mediated signaling may be an agent capable of blocking or reducing the expression of one or more of IL-11, IL-11Rα and gp130.
[0205] The expression may be gene expression or protein expression and may be measured by the methods described herein or by methods in the art well known to those skilled in the art. The expression may be expression by a cell / tissue / organ / organ system in a subject.
[0206] Suitable agents may be of any type, but in some embodiments, agents capable of blocking or reducing the expression of one or more of IL-11, IL-11Rα, and gp130 may be small molecules or oligonucleotides.
[0207] An agent capable of inhibiting or reducing the expression of one or more of IL-11, IL-11Rα, and gp130 may inhibit or reduce the expression of one or more of IL-11, IL-11Rα, and gp130, for example, through inhibiting the transcription of a gene encoding IL-11, IL-11Rα, or gp130, inhibiting post-transcriptional processing of RNA encoding IL-11, IL-11Rα, or gp130, reducing the stability of RNA encoding IL-11, IL-11Rα, or gp130, promoting the degradation of RNA encoding IL-11, IL-11Rα, or gp130, inhibiting post-translational processing of an IL-11 polypeptide, IL-11Rα polypeptide, or gp130 polypeptide, reducing the stability of an IL-11 polypeptide, IL-11Rα polypeptide, or gp130 polypeptide, or promoting the degradation of an IL-11 polypeptide, IL-11Rα polypeptide, or gp130 polypeptide.
[0208] Taki et al. (Clin Exp Immunol (1998) Apr; 112(1): 133-138) reported that IL-11 expression was reduced in rheumatoid synovial cells treated with indomethacin, dexamethasone, or interferon gamma (IFNγ).
[0209] The present invention further contemplates the use of antisense nucleic acids to inhibit / reduce the expression of IL-11, IL-11Rα, or gp130. In some embodiments, agents capable of inhibiting or reducing the expression of IL-11, IL-11Rα, or gp130 may reduce said expression by RNA interference (RNAi).
[0210] In some embodiments, the agent may be an inhibitory nucleic acid, such as an antisense RNA or a small interfering RNA, including, but not limited to, an shRNA or an siRNA.
[0211] In some embodiments, the inhibitory nucleic acid is provided in a vector, e.g., in some embodiments, the agent may be a lentiviral vector encoding shRNA against one or more of IL-11, IL-11Rα, and gp130.
[0212] Oligonucleotide molecules (especially RNA) can be used to regulate gene expression.Such oligonucleotide molecules include antisense oligonucleotides; small interfering RNA (siRNA) targets mRNA degradation; post-transcriptional gene silencing (PTG); use microRNA (miRNA) to suppress the mRNA translation specific to developmentally regulated sequences; and targeted transcriptional gene silencing.
[0213] Antisense oligonucleotide is an oligonucleotide (preferably single-stranded oligonucleotide) that targets target oligonucleotide (for example, mRNA) and binds to it through complementary sequence binding.When target oligonucleotide is mRNA, antisense oligonucleotide binds to mRNA, thereby inhibiting the translation of mRNA and inhibiting the expression of gene product.Antisense oligonucleotide can be designed to bind to the sense strand of genomic nucleic acid and suppress the transcription of target nucleotide sequence.
[0214] The nucleic acid sequences of known IL-11, IL-11Rα, or gp130 (e.g., accession numbers: BC012506.1 GI:15341754 (human IL-11), BC134354.1 GI:126632002 (mouse IL-11), AF347935.1 GI:13549072 (rat IL-11), NM_001142784.2 GI:391353394 (human IL-11Rα), NM_001163401.1 GI:254281268 (mouse IL-11Rα), NM_139116.1 GI:20806172 (rat IL-11Rα), NM_001190981.1 Oligonucleotides that suppress or silence expression of IL-11, IL-11Rα or gp130 may be designed taking into account known mRNA sequences available from GenBank at GI:300244534 (human gp130), NM_010560.3 GI:225007624 (mouse gp130), NM_001008725.3 GI:300244570 (rat gp130).
[0215] Such oligonucleotides may be of any length, but are preferably short, e.g., less than 100 nucleotides in length, e.g., 10 to 40 nucleotides in length, or 20 to 50 nucleotides in length, and may contain a nucleotide sequence that is completely complementary or substantially complementary (e.g., 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% complementary) to a nucleotide sequence of a corresponding length in a target oligonucleotide (e.g., IL-11 mRNA, IL-11Rα mRNA or gp130 mRNA). The complementary region of the nucleotide sequence may be any length, but is preferably at least 5 nucleotides in length, and may be 50 nucleotides or less in length, for example, 6 nucleotides, 7 nucleotides, 8 nucleotides, 9 nucleotides, 10 nucleotides, 11 nucleotides, 12 nucleotides, 13 nucleotides, 14 nucleotides, 15 nucleotides, 16 nucleotides, 17 nucleotides, 18 nucleotides, 19 nucleotides, 20 nucleotides, 21 nucleotides, 22 nucleotides, 23 nucleotides, 24 nucleotides, 25 nucleotides, or less in length. The length may be any of 1 nucleotide, 26 nucleotides, 27 nucleotides, 28 nucleotides, 29 nucleotides, 30 nucleotides, 31 nucleotides, 32 nucleotides, 33 nucleotides, 34 nucleotides, 35 nucleotides, 36 nucleotides, 37 nucleotides, 38 nucleotides, 39 nucleotides, 40 nucleotides, 41 nucleotides, 42 nucleotides, 43 nucleotides, 44 nucleotides, 45 nucleotides, 46 nucleotides, 47 nucleotides, 48 nucleotides, 49 nucleotides, and 50 nucleotides.
[0216] Suppressing the expression of IL-11, IL-11Rα, or gp130 preferably reduces the amount of IL-11, IL-11Rα, or gp130 expressed by a cell / tissue / organ / organ system / subject. For example, suppressing IL-11, IL-11Rα, or gp130 in a given cell by administering an appropriate nucleic acid reduces the amount of IL-11, IL-11Rα, or gp130 expressed by the cell compared to untreated cells. Suppression may be partial. The degree of suppression is preferably at least 50%, and more preferably at least 60%, 70%, 80%, 85%, or 90%. Expression or function is considered to be "silenced" when the degree of suppression is 90% to 100%.
[0217] The role of the RNAi machinery and small RNAs in targeting heterochromatin complexes and epigenetic gene silencing at specific chromosomal loci has been demonstrated. Double-stranded RNA (dsRNA)-mediated posttranscriptional silencing, also known as RNA interference (RNAi), is a phenomenon in which dsRNA complexes can rapidly target and silence homologous regions of specific genes. RNAi acts as a signal to promote the degradation of mRNAs with sequence identity. 20-nt siRNAs are typically long enough to induce gene-specific silencing but short enough to circumvent a host response. Using several siRNA molecules, reduction of target gene product expression can be achieved with up to 90% silencing. RNAi-based therapeutics have progressed to phase I, II, and III clinical trials for a variety of indications (Nature 2009 Jan 22; 457(7228):426-433).
[0218] In the art, such RNA sequences are referred to as "short interfering RNAs" or "small interfering RNAs (siRNAs)" or "microRNAs (miRNAs)" depending on their origin. These RNA sequences can be used to downregulate gene expression by binding to complementary RNAs to induce mRNA elimination (RNAi), or by inhibiting mRNA-to-protein translation. siRNAs are obtained by processing long double-stranded RNAs, and natural siRNAs are usually exogenous. Microinterfering RNAs (miRNAs) are endogenously encoded small non-coding RNAs that are obtained by processing short hairpin structures. Both siRNAs and miRNAs can suppress the translation of mRNAs with partially complementary target sequences without cleaving the RNA, and can degrade mRNAs with completely complementary sequences.
[0219] siRNA ligands are typically double-stranded, and to optimize the effectiveness of this RNA in downregulating the function of a target gene, it is preferable to select the length of the siRNA molecule so that it is long enough to be accurately recognized by the RISC complex that mediates the recognition of the target mRNA by the siRNA, yet short enough to minimize the host response.
[0220] miRNA ligands are typically single-stranded and have a partially complementary region capable of forming a hairpin structure. miRNAs are RNA genes that are transcribed from DNA but not translated into protein. The DNA sequence encoding the miRNA gene is longer than the miRNA and contains the miRNA sequence and a nearly complementary reverse sequence. When this DNA sequence is transcribed into a single-stranded RNA molecule, a partially double-stranded RNA segment is formed from base pairs consisting of the miRNA sequence and its reverse complementary sequence. The design of microRNA sequences is reported in John et al., PLoS Biology, 11(2), 1862-1879, 2004.
[0221] The RNA ligands mimicking the effects of siRNA or miRNA are typically 10 to 40 ribonucleotides in length (or synthetic analogs thereof), more preferably 17 to 30 ribonucleotides in length, more preferably 19 to 25 ribonucleotides in length, and most preferably 21 to 23 ribonucleotides in length. In some embodiments of the present invention using double-stranded siRNA, the double-stranded siRNA molecule may have a symmetric 3'-end overhang, which may consist of, for example, one or two (ribo)nucleotides, typically a 3'-end UU or dTdT overhang. Based on the disclosure herein, those skilled in the art can easily design appropriate siRNA and miRNA sequences using libraries such as Ambion siRNA finder. siRNA and miRNA sequences can be synthetically produced and added exogenously to induce gene downregulation, or they can be produced using an expression system (e.g., a vector). In a preferred embodiment, the siRNA is synthetically produced.
[0222] Long double-stranded RNA may be processed intracellularly to produce siRNA (see, for example, Myers (2003) Nature Biotechnology 21:324-328). Long dsRNA molecules may have symmetric 3'- or 5'-end overhangs, which may consist of, for example, one or two (ribo)nucleotides, or they may have blunt ends. Long dsRNA molecules may be 25 nucleotides or longer in length. Long dsRNA molecules are preferably 25 to 30 nucleotides in length. Long dsRNA molecules are more preferably 25 to 27 nucleotides in length. Long dsRNA molecules are most preferably 27 nucleotides in length. dsRNAs 30 nucleotides or longer in length may be expressed using the pDECAP vector (Shinagawa et al., Genes and Dev., 17, 1340-5, 2003).
[0223] Another method involves expressing short hairpin RNA molecules (shRNAs) in cells. shRNAs are more stable than synthetic siRNAs. shRNAs consist of short inverted repeats linked by a short loop sequence. One of the inverted repeats is complementary to the target gene. In cells, shRNAs are processed by DICER to form siRNAs, which degrade the target gene's mRNA and suppress its expression. In a preferred embodiment, shRNAs are produced endogenously (intracellularly) by transcription from a vector. shRNAs may also be produced intracellularly by transfecting cells with a vector encoding the shRNA sequence under the control of an RNA polymerase III promoter (e.g., human H1 promoter or human 7SK promoter) or an RNA polymerase II promoter. Alternatively, shRNAs may be synthesized exogenously (in vitro) by transcription from a vector. The resulting shRNAs may then be directly introduced into cells. Preferably, shRNA molecules contain a partial sequence of IL-11, IL-11Rα, or gp130. The length of the shRNA sequence is preferably 40 to 100 base pairs, more preferably 40 to 70 base pairs. The length of the stem portion of the hairpin structure is preferably 19 to 30 base pairs. The stem portion may contain GU pairs to stabilize the hairpin structure.
[0224] The siRNA, long dsRNA, or miRNA molecule may be produced by recombinant techniques by transcription of a nucleic acid sequence (preferably incorporated into a vector). Preferably, the siRNA, long dsRNA, or miRNA molecule comprises a partial sequence of IL-11, IL-11Rα, or gp130.
[0225] In one embodiment, siRNA, long dsRNA or miRNA is produced endogenously (intracellularly) by transcription from vector.Vector can be introduced into cell by any method known in the art.The expression of these RNA sequences can be regulated as needed using tissue-specific promoters (for example, heart, liver or kidney-specific).In another embodiment, siRNA, long dsRNA or miRNA is produced exogenously (in vitro) by transcription from vector.
[0226] A suitable vector may be an oligonucleotide vector configured to express an oligonucleotide drug capable of inhibiting IL-11, IL-11Rα, or gp130. Such vectors may be viral or plasmid vectors. The oligonucleotide therapeutic may be incorporated into the genome of the viral vector and operably linked to a regulatory sequence (e.g., a promoter) that directs expression. "Operably linked" may also include a situation in which a selected nucleotide sequence and a regulatory nucleotide sequence are covalently linked such that the nucleotide sequence is expressed under the influence or control of the regulatory sequence. Thus, a regulatory sequence is operably linked to a selected nucleotide sequence if the regulatory sequence is capable of directing transcription of a nucleotide sequence that constitutes all or a portion of the selected nucleotide sequence.
[0227] Viral vectors encoding siRNA sequences whose expression is driven by a promoter are known in the art and have the advantage of being able to express oligonucleotide therapeutics for a long period of time.Viral vectors include lentivirus (Nature 2009 Jan 22; 457(7228):426-433), adenovirus (Shen et al., FEBS Lett 2003 Mar 27; 539(1-3)111-4) and retrovirus (Barton and Medzhitov PNAS November 12, 2002 vol.99, no.23 14943-14945).
[0228] In another embodiment, carriers configured to aid in the delivery of oligonucleotide therapeutics to sites where inhibition of IL-11, IL-11Rα, or gp130 expression is required may be used. Such carriers generally include positively charged carriers complexed with oligonucleotides (e.g., cell-permeable cationic peptides, cationic polymers, cationic dendrimers, and cationic lipids); small molecules (e.g., cholesterol, bile acids, and lipids), polymers, antibodies, and RNAs bound to oligonucleotides; or oligonucleotides encapsulated in nanoparticle formulations (Wang et al., AAPS J. 2010 Dec; 12(4): 492-503).
[0229] In one embodiment, the vector may contain nucleic acid sequences in both sense and antisense orientations such that when the nucleic acid sequences are expressed as RNA, the sense and antisense strand portions associate to form double-stranded RNA.
[0230] Alternatively, siRNA molecules may be synthesized using standard solid-phase or liquid-phase synthesis methods known in the art. The linkage between nucleotides may be a phosphodiester bond or other bond, such as P(O)S (thioate); P(S)S (dithioate); P(O)NR'2; P(O)R'; P(O)OR6; CO; or CONR'2 (wherein R is H (or a salt) or alkyl (C 1~12 ) and R6 is alkyl (C 1~9 )) is linked to the adjacent nucleotide via —O— or —S—.
[0231] In addition to natural bases, modified nucleotide bases can be used and may impart advantageous properties to siRNA molecules containing them.
[0232] For example, modified bases may improve the stability of siRNA molecules, thereby reducing the amount of siRNA molecules required for silencing. The addition of modified bases may produce siRNA molecules that are more or less stable than unmodified siRNAs.
[0233] "Modified nucleotide base" encompasses nucleotides with modified bases and / or modified sugars covalently linked. For example, modified nucleotides include nucleotides having sugars covalently linked to low molecular weight organic groups other than a 3' hydroxyl group and a 5' phosphate group. Therefore, modified nucleotides also include 2'-substituted sugars such as 2'-O-methylribose, 2'-O-alkylribose, 2'-O-allylribose, 2'-S-alkylribose, 2'-S-allylribose, 2'-fluororibose, 2'-halolibose, and 2'-azidoribose; carbocyclic sugar analogs; α-anomeric sugars; epimeric sugars such as arabinose, xylose, and lyxose; pyranose sugars, furanose sugars, and sedoheptulose.
[0234] Modified nucleotides are known in the art and include, for example, alkylated purines, alkylated pyrimidines, acylated purines, acylated pyrimidines, and other heterocycles. Such classes of pyrimidines and purines are known in the art and include, for example, pseudoisocytosine, N- 4 ,N 4 -Ethanocytosine, 8-hydroxy-N 6 -methyladenine, 4-acetylcytosine, 5-(carboxyhydroxymethyl)uracil, 5-fluorouracil, 5-bromouracil, 5-carboxymethylaminomethyl-2-thiouracil, 5-carboxymethylaminomethyluracil, dihydrouracil, inosine, N 6 -Isopentyladenine, 1-methyladenine, 1-methylpseudouracil, 1-methylguanine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N 6 -methyladenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, -D-mannosylkeuosine, 5-methoxycarbonylmethyluracil, 5-methoxyuracil, 2-methylthio-N 6 -isopentenyladenine, uracil-5-oxyacetic acid methyl ester, pseudouracil, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, N-uracil-5-oxyacetic acid methyl ester, uracil-5-oxyacetic acid, queuosine, 2-thiocytosine, 5-propyluracil, 5-propylcytosine, 5-ethyluracil, 5-ethylcytosine, 5-butyluracil, 5-pentyluracil, 5-pentylcytosine, 2,6-diaminopurine, methylpseudouracil, 1-methylguanine, and 1-methylcytosine.
[0235] Methods for silencing genes in C. elegans, Drosophila, plants, and mammals using RNAi are known in the art (Fire A, et al., 1998 Nature 391:806-811; Fire, A. Trends Genet. 15, 358-363 (1999); Sharp, PA RNA interference 2001. Genes Dev. 15, 485-490 (2001); Hammond, SM, et al., Nature Rev. Genet. 2, 110-1119 (2001); Tuschl, T. Chem. Biochem. 2, 239-245 (2001); Hamilton, A. et al., Science 286, 950-952 (1999); Hammond, SM, et al., Nature 404, 293-296 (2000); Zamore, PD, et al., Cell 101, 25-33 (2000); Bernstein, E., et al., Nature 409, 363-366 (2001); Elbashir, SM, et al., Genes Dev. 15, 188-200 (2001); WO0129058; WO9932619 and Elbashir SM, et al., 2001 Nature 411:494-498).
[0236] Thus, the present invention provides nucleic acids that, when appropriately introduced into or expressed in mammalian cells (e.g., human cells) that express IL-11, IL-11Rα, or gp130, can suppress the expression of IL-11, IL-11Rα, or gp130 by RNAi techniques.
[0237] IL-11, IL-11Rα or gp130 (e.g., accession numbers: BC012506.1 GI:15341754 (human IL-11), BC134354.1 GI:126632002 (mouse IL-11), AF347935.1 GI:13549072 (rat IL-11), NM_001142784.2 GI:391353394 (human IL-11Rα), NM_001163401.1 GI:254281268 (mouse IL-11Rα), NM_139116.1 GI:20806172 (rat IL-11Rα), NM_001190981.1 Nucleic acid sequences of oligonucleotides against known mRNA sequences available from GenBank (GI:300244534 (human gp130), NM_010560.3 GI:225007624 (mouse gp130), NM_001008725.3 GI:300244570 (rat gp130)) may be designed to inhibit or silence expression of IL-11, IL-11Rα or gp130.
[0238] The nucleic acid may have substantial sequence identity to a portion of the mRNA of IL-11, IL-11Rα, or gp130, for example, a portion of the sequence set forth in GenBank Accession No. NM_000641.3 GI:391353405 (IL-11), NM_001142784.2 GI:391353394 (IL-11Rα), or NM_001190981.1 GI:300244534 (gp130), or a sequence complementary to these mRNAs.
[0239] The nucleic acid may be a double-stranded siRNA (as will be appreciated by those skilled in the art, siRNA molecules may also contain a short DNA sequence at the 3' end, as will be described in more detail below).
[0240] Alternatively, the nucleic acid may be DNA (usually double-stranded DNA), which, when transcribed in a mammalian cell, results in RNA having two complementary portions linked via a spacer, and this RNA forms a hairpin structure when the two complementary portions hybridize with each other. In mammalian cells, this hairpin structure portion is cleaved from the RNA molecule by an enzyme called DICER, resulting in double-stranded RNA in which two different RNA molecules are hybridized.
[0241] In some preferred embodiments, the nucleic acid typically targets a sequence set forth in any of SEQ ID NOs: 4-7 (IL-11) or any of SEQ ID NOs: 8-11 (IL-11Rα).
[0242] Only single-stranded regions of mRNA transcripts (i.e., regions that are not self-hybridized) are expected to be suitable targets for RNAi. Therefore, other sequences of IL-11 or IL-11Rα mRNA transcripts that are highly similar to the sequences set forth in any of SEQ ID NOS: 4-7 and 8-11 are also expected to be suitable targets for RNAi. The length of such target sequences is preferably 17-23 nucleotides, and preferably overlaps (at one end) any of SEQ ID NOS: 4-7 and 8-11 by at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, or 18 nucleotides, or all 19 nucleotides.
[0243] Thus, the present invention provides nucleic acids that can suppress the expression of IL-11 or IL-11Rα by RNAi methods when appropriately introduced into or expressed in mammalian cells that express IL-11 or IL-11Rα, and these nucleic acids typically target any of the sequences shown in SEQ ID NOs: 4 to 7 and 8 to 11.
[0244] The term "normal target" means that the nucleic acid may target a sequence that overlaps with any of SEQ ID NOS: 4 to 7 and 8 to 11. Specifically, the nucleic acid may target a human IL-11 mRNA sequence or a human IL-11Rα mRNA sequence (preferably 17 to 23 nucleotides in length) that is identical to any of SEQ ID NOS: 4 to 7 and 8 to 11, except that the sequence is slightly longer or slightly shorter than these sequences.
[0245] Although it is preferable that there is complete identity / complementarity between the nucleic acid of the present invention and the target sequence, this is not expected to be essential. Thus, the nucleic acid of the present invention may contain a single base mismatch compared to IL-11 mRNA or IL-11Rα mRNA. However, even a single base mismatch is expected to reduce the efficiency, so it is preferable that there is no mismatch. If a 3'-end overhang is present, the 3'-end overhang does not need to be taken into account when determining the number of mismatches.
[0246] "Complementarity" is not limited to base pairing between nucleic acids composed of natural ribonucleotides and / or deoxyribonucleotides, as is commonly seen, but also includes base pairing between the nucleic acids of the present invention containing non-natural nucleotides and mRNA.
[0247] In one embodiment, the nucleic acid (herein referred to as double-stranded siRNA) comprises the double-stranded RNA sequences shown in SEQ ID NOs: 12 to 15. In another embodiment, the nucleic acid (herein referred to as double-stranded siRNA) comprises the double-stranded RNA sequences shown in SEQ ID NOs: 16 to 19.
[0248] However, slightly shorter or longer sequences targeting the same IL-11 or IL-11Rα mRNA regions are also expected to be effective, particularly double-stranded sequences of 17-23 bp in length.
[0249] Each strand of the double-stranded RNA may have a short 2-base 3'-end overhang, which may be DNA or RNA. Although 3'-end DNA overhangs have no effect on siRNA activity compared to 3'-end RNA overhangs, they reduce the cost of chemically synthesizing nucleic acid strands (Elbashir et al., 2001c). For this reason, 2-base DNA may be preferred.
[0250] If two-base overhangs are present at both 3' ends, these overhangs may be symmetrical to each other, but symmetry is not required. In fact, the 3' overhang on the sense strand (top strand) is not involved in mRNA recognition and degradation and is therefore not relevant for RNAi activity (Elbashir et al., 2001a, 2001b, 2001c).
[0251] Although RNAi experiments in Drosophila have suggested that the 3' overhang of the antisense strand may be involved in mRNA recognition and targeting (Elbashir et al., 2001c), in mammalian cells, the 3' overhang is not thought to be required for the RNAi activity of siRNAs, and therefore, misannealing of the 3' overhang is thought to have little effect in mammalian cells (Elbashir et al., 2001c; Czauderna et al., 2003).
[0252] Therefore, any two-base overhang may be used in the antisense strand of siRNA. However, the two-base overhang is preferably -UU or -UG (-TT or -TG if the overhang is DNA), and more preferably -UU (or -TT). The two-base overhang consisting of -UU (or -TT) is the most effective and coincides with (i.e., can form part of) the transcription termination signal of RNA polymerase III (the transcription termination signal is TTTTT). Therefore, these two bases are most preferred. The two bases AA, CC, and GG may also be used, but are less effective and therefore less preferred.
[0253] Additionally, the siRNA may not contain any 3' overhangs.
[0254] Furthermore, the present invention provides a single-stranded nucleic acid (referred to herein as single-stranded siRNA) that is one of the constituent strands of the double-stranded nucleic acid, and this single-stranded siRNA preferably has a 3'-end overhang, but may not have a 3'-end overhang. Furthermore, the present invention provides a kit containing a pair of such single-stranded nucleic acids, and these single-stranded nucleic acids can hybridize with each other in vitro to form the double-stranded siRNA, and this double-stranded siRNA can then be introduced into a cell.
[0255] Furthermore, the present invention provides DNA that is transcribed in mammalian cells into RNA (also referred to herein as shRNA) in which two complementary portions can self-hybridize to form a double-stranded motif, and the double-stranded motif formed includes, for example, a sequence selected from the group consisting of SEQ ID NOs: 12 to 15 and 16 to 19, or a sequence in which a single base pair is substituted in any of these sequences.
[0256] The complementary portions are usually linked by a spacer, which has an appropriate length and sequence to allow the two complementary portions to hybridize with each other. The two complementary portions (i.e., the sense strand and the antisense strand) may be linked at the 5' end and the 3' end, or either may be at the 5' end. The spacer may be a short sequence, usually about 4 to 12 nucleotides long, preferably 4 to 9 nucleotides long, more preferably 6 to 9 nucleotides long.
[0257] The 5'-end of the spacer (immediately following the 3'-end of the upstream complementary portion) preferably consists of the two bases -UU- or -UG-, with -UU- being more preferred (although, again, the use of these two specific bases is not essential). A suitable spacer recommended for use with the pSuper system from OligoEngine, Inc. (Seattle, Washington, USA) is UUCAAGAGA. When this or other spacers are used, both ends of the spacer hybridize to each other, resulting in a double-stranded motif that is a few base pairs (e.g., one or two base pairs) longer than the sequence shown in SEQ ID NOs: 12-15 or 16-19.
[0258] Similarly, the transcribed RNA preferably comprises a 3' overhang from the downstream complementary portion, again preferably -UU or -UG, more preferably -UU.
[0259] As described above, such shRNA molecules may be cleaved by the DICER enzyme in mammalian cells to form double-stranded siRNAs in which one or both of the single strands constituting the hybridized dsRNA contain a 3'-end overhang.
[0260] It goes without saying that techniques for synthesizing the nucleic acids of the present invention are well known in the art.
[0261] Those skilled in the art can easily construct a transcription vector suitable for the DNA of the present invention using well-known techniques and commercially available materials. Specifically, the DNA of the present invention is ligated to a control sequence such as a promoter and a transcription termination sequence.
[0262] The pSuper and pSuperior systems, commercially available from OligoEngine (Seattle, Washington, USA), are particularly suitable. These systems use a polymerase III promoter (H1) and a T5 transcription termination sequence, which adds two U residues to the 3' end of the transcript (which is then processed by DICER to produce siRNA with a 3'-terminal UU overhang on one RNA strand).
[0263] Another suitable system is described by Shin et al. (RNA, 2009 May; 15(5): 898-910), which uses another polymerase III promoter (U6).
[0264] The double-stranded siRNA of the present invention may be introduced into mammalian cells in vitro or in vivo using known techniques such as those described below to suppress the expression of IL-11 or IL-11 receptor.
[0265] Similarly, a transcription vector containing the DNA of the present invention may be introduced into tumor cells in vitro or in vivo using known techniques such as those described below, and the expression of IL-11 or IL-11 receptor may be suppressed by transiently or stably expressing the RNA.
[0266] Therefore, the present invention further provides a method for suppressing the expression of IL-11 or IL-11 receptor in mammalian (e.g., human) cells, the method comprising administering to the cells a double-stranded siRNA of the present invention or a transcription vector of the present invention.
[0267] Similarly, the present invention further provides a method for treating a metabolic disease, the method comprising administering the double-stranded siRNA of the present invention or the transcription vector of the present invention to a subject.
[0268] Furthermore, the present invention provides the double-stranded siRNA of the present invention and the transcription vector of the present invention for use in a method of treatment, preferably a method of treating a metabolic disease.
[0269] Furthermore, the present invention provides use of the double-stranded siRNA of the present invention and the transcription vector of the present invention in the preparation of a medicament for treating a metabolic disease.
[0270] Furthermore, the present invention provides a composition comprising the double-stranded siRNA of the present invention or the transcription vector of the present invention and one or more pharmaceutically acceptable carriers.Suitable carriers include lipophilic carriers or vesicles that can improve cell membrane permeability.
[0271] Materials and methods suitable for administering the double-stranded siRNA and DNA vectors of the present invention are well known in the art, and given the potential of RNAi technology, improved methods are under development.
[0272] A variety of techniques are generally available for introducing nucleic acids into mammalian cells. The technique to be used depends on whether the nucleic acid is to be introduced into cultured cells in vitro or into the patient's cells in vivo. Techniques suitable for introducing nucleic acids into mammalian cells in vitro include the use of liposomes, electroporation, microinjection, cell fusion, DEAE-dextran, and calcium phosphate precipitation. In vivo gene transfer techniques include transfection using viral vectors (usually retroviral vectors) and transfection using viral coat protein-liposome complexes (Dzau et al. (2003) Trends in Biotechnology 11, 205-210).
[0273] Specifically, suitable techniques for administering the nucleic acids of the present invention to cells in vitro or in vivo are described in the following documents:
[0274] Review: Borkhardt, A. 2002. Blocking oncogenes in malignant cells by RNA interference--new hope for a highly specific cancer treatment? Cancer Cell. 2:167-8. Hannon, GJ 2002. RNA interference. Nature. 418:244-51. McManus, MT, and PA Sharp. 2002. Gene silencing in mammals by small interfering RNAs. Nat Rev Genet. 3:737-47. Scherr, M., MA Morgan, and M. Eder. 2003b. Gene silencing mediated by small interfering RNAs in mammalian cells. Curr Med Chem. 10:245-56. Shuey, DJ, DE McCallus, and T. Giordano. 2002. RNAi: gene-silencing in therapeutic intervention. Drug Discov Today. 7:1040-6.
[0275] Editor-in-Chief: Lewis, DL, JE Hagstrom, AG Loomis, JA Wolff, and H. Herweijer. 2002. Efficient delivery of siRNA for inhibition of gene expression in postnatal mice. Night Genet. 32:107-8 Paul, CP, Good PD, Winer I, and English DR. 2002. Effective expression of small interfering RNA in human cells. Nat Biotechnol. 20:505-8 Song , E. , SK Lee , J. Wang , N. Ince , N. Ouyang , J. Min , J. Chen , P. Shankar , and J. Lieberman . 2003. RNA interference targeting Fas protects mice from fulminant hepatitis. Nat Med. 9:347-5 Sorensen , DR , Leirdal M , and M Sioud . 2003. Gene silencing by systemic delivery of synthetic siRNAs in adult mice. J Mol Biol. 327:761-6
[0276] Abbas-Terki, T., W. Blanco-Bose, N. Deglon, W. Pralong, and P. Aebischer. 2002. Lentiviral-mediated RNA interference. Hum Gene Ther. 13:2197–2 Barton , GM , and R. Medzhitov . 2002. Retroviral delivery of small interfering RNA into primary cells. Proc Natl Acad Sci US A. 99:14943–5. Devroe , E. , and PA Silver . 2002. Retrovirus-delivered siRNA. BMC Biotechnol. 2:1 Lori , F. , P. Guallini , L. Galluzzi , and J. Lisziewicz . 2002. Gene therapy approaches to HIV infection. Am J Pharmacogenomics. 2:245-5 Matta , H. , B. Hozayev , R. Tomar , P. Chugh , and PM Chaudhary . 2003. Use of lentiviral vectors for delivery of small interfering RNA. Cancer Biol Ther. 2:206-1 Qin , XF , DS An , IS Chen , and D. Baltimore . 2003. Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5. Proc Natl Acad Sci US A. 100:183–8. Scherr , M. , K. Battmer , A. Ganser , and M. Eder . 2003a.Modulation of gene expression by lentiviral-mediated delivery of small interfering RNA. Cell Cycle. 2:251-7. Shen, C., AK Buck, X. Liu, M. Winkler, and SN Reske. 2003. Gene silencing by adenovirus-delivered siRNA. FEBS Lett. 539:111-4.
[0277] Peptide delivery: Morris, MC, L. Chaloin, F. Heitz, and G. Divita. 2000. Translocating peptides and proteins and their use for gene delivery. Curr Opin Biotechnol. 11:461-6. Simeoni, F., MC Morris, F. Heitz, and G. Divita. 2003. Insight into the mechanism of the peptide-based gene delivery system MPG: implications for delivery of siRNA into mammalian cells. Nucleic Acids Res. 31:2717-24. Other techniques that may be suitable for delivering siRNA to target cells include the use of nanoparticles or nanocapsules, such as those described in U.S. Pat. No. 6,649,192(B) and U.S. Pat. No. 5,843,509(B).
[0278] Inhibition of IL-11-mediated signaling In embodiments of the present invention, an agent capable of suppressing the action of IL-11 may have one or more of the following functional properties: Inhibition of IL-11-mediated signaling Inhibition of signal transduction via binding of IL-11 to the IL-11Rα:gp130 receptor complex Inhibition of signal transduction (i.e., IL-11 trans-signaling) via binding of the IL-11:IL-11Rα complex to gp130 Inhibition of IL-11-mediated processes Inhibition of IL-11 and / or IL-11Rα gene / protein expression
[0279] These properties can be measured by analyzing the relevant factors in a suitable assay, which may involve comparing the performance of the agent to that of an appropriate control. Those skilled in the art can determine appropriate control conditions for a given assay.
[0280] IL-11-mediated signal transduction and / or IL-11-mediated processes include signal transduction via IL-11 fragments and signal transduction via polypeptide complexes containing IL-11 or fragments thereof. IL-11-mediated signal transduction may be signal transduction via human IL-11 and / or mouse IL-11. IL-11-mediated signal transduction may be signal transduction caused by the binding of IL-11 or an IL-11-containing complex to a receptor to which IL-11 or an IL-11-containing complex binds.
[0281] In some embodiments, the agents of the invention may be capable of inhibiting the biological activity of IL-11 or an IL-11-containing complex.
[0282] In some embodiments, agents of the present invention are antagonists of one or more signaling pathways activated by signaling through receptors comprising IL-11Rα and / or gp130 (e.g., IL-11Rα:gp130). In some embodiments, agents of the present invention can inhibit signaling through one or more immune receptor complexes comprising IL-11Rα and / or gp130 (e.g., IL-11Rα:gp130). In various aspects of the present invention, agents provided herein can inhibit IL-11-mediated cis-signaling and / or trans-signaling. In some embodiments according to various aspects of the present invention, agents provided herein can inhibit IL-11-mediated cis-signaling.
[0283] In some embodiments, an agent of the invention may be capable of inhibiting IL-11-mediated signaling to less than 100%, for example, 99% or less, 95% or less, 90% or less, 85% or less, 80% or less, 75% or less, 70% or less, 65% or less, 60% or less, 55% or less, 50% or less, 45% or less, 40% or less, 35% or less, 30% or less, 25% or less, 20% or less, 15% or less, 10% or less, 5% or less, or 1% or less, compared to the amount of IL-11-mediated signaling in the absence of the agent (or in the presence of a suitable control agent). In some embodiments, an agent of the invention can reduce IL-11-mediated signaling by less than 1-fold, e.g., 0.99-fold or less, 0.95-fold or less, 0.9-fold or less, 0.85-fold or less, 0.8-fold or less, 0.75-fold or less, 0.7-fold or less, 0.65-fold or less, 0.6-fold or less, 0.55-fold or less, 0.5-fold or less, 0.45-fold or less, 0.4-fold or less, 0.35-fold or less, 0.3-fold or less, 0.25-fold or less, 0.2-fold or less, 0.15-fold or less, or 0.1-fold or less, compared to the amount of IL-11-mediated signaling in the absence of the agent (or in the presence of a suitable control agent).
[0284] In some embodiments, IL-11-mediated signaling may be signaling via binding of IL-11 to the IL-11Rα:gp130 receptor. Such signaling can be analyzed, for example, by treating cells expressing IL-11Rα and gp130 with IL-11 or stimulating IL-11 production in cells expressing IL-11Rα and gp130.
[0285] IC of inhibition of IL-11-mediated signaling by agents of the invention 50 For example, Ba / F3 cells expressing IL-11Rα and gp130 are cultured in the presence of human IL-11 and the agent of the present invention, and the binding to DNA is detected. 3 In some embodiments, the IC of an agent of the invention in such an assay may be measured by measuring the incorporation of H-thymidine. 50 The value may be 10 μg / ml or less, preferably 5 μg / ml or less, 4 μg / ml or less, 3.5 μg / ml or less, 3 μg / ml or less, 2 μg / ml or less, 1 μg / ml or less, 0.9 μg / ml or less, 0.8 μg / ml or less, 0.7 μg / ml or less, 0.6 μg / ml or less or 0.5 μg / ml or less.
[0286] In some embodiments, IL-11-mediated signaling may be signaling via binding of the IL-11:IL-11Rα complex to gp130. In some embodiments, the IL-11:IL-11Rα complex may be soluble, e.g., a complex of the extracellular domain of IL-11Rα and IL-11, or a complex of a soluble IL-11Rα isoform / fragment and IL-11. In some embodiments, the soluble IL-11Rα is a soluble (secreted) isoform of IL-11Rα or a product liberated by proteolysis of the extracellular domain of membrane-bound IL-11Rα.
[0287] In some embodiments, the IL-11:IL-11Rα complex may be membrane-bound, e.g., a complex consisting of membrane-bound IL-11Rα and IL-11. Signal transduction mediated by the binding of the IL-11:IL-11Rα complex to gp130 can be analyzed by treating gp130-expressing cells with the IL-11:IL-11Rα complex, e.g., by treating gp130-expressing cells with a recombinant fusion protein (e.g., hyper IL-11) containing IL-11 linked to the extracellular domain of IL-11Rα via a peptide linker. Hyper IL-11 was constructed using a fragment of IL-11Rα (amino acid residues 1-317 comprising domains 1-3; UniProtKB: Q14626), IL-11 (amino acid residues 22-199 of UniProtKB: P20809), and a 20-amino acid linker (SEQ ID NO: 20). The amino acid sequence of hyper IL-11 is shown in SEQ ID NO:21.
[0288] In some embodiments, the agents of the invention may be capable of inhibiting signaling mediated by binding of the IL-11:IL-11Rα complex to gp130, and may also inhibit signaling mediated by binding of IL-11 to the IL-11Rα:gp130 receptor.
[0289] In some embodiments, agents of the invention may be capable of suppressing IL-11 mediated processes.
[0290] In some embodiments, the agent may be capable of suppressing IL-11 and / or IL-11Rα gene / protein expression. Gene and / or protein expression can be measured by methods described herein or methods well known to those skilled in the art.
[0291] In some embodiments, the agent may be capable of suppressing expression of the IL-11 and / or IL-11Rα gene / protein to less than 100%, for example, 99% or less, 95% or less, 90% or less, 85% or less, 80% or less, 75% or less, 70% or less, 65% or less, 60% or less, 55% or less, 50% or less, 45% or less, 40% or less, 35% or less, 30% or less, 25% or less, 20% or less, 15% or less, 10% or less, 5% or less, or 1% or less, compared to the expression level of the IL-11 and / or IL-11Rα gene / protein in the absence of the agent (or in the presence of an appropriate control agent). In some embodiments, the agent is capable of suppressing expression of the IL-11 and / or IL-11Rα gene / protein to less than 1-fold, for example, 0.99-fold or less, 0.95-fold or less, 0.9-fold or less, 0.85-fold or less, 0.8-fold or less, 0.75-fold or less, 0.7-fold or less, 0.65-fold or less, 0.6-fold or less, 0.55-fold or less, 0.5-fold or less, 0.45-fold or less, 0.4-fold or less, 0.35-fold or less, 0.3-fold or less, 0.25-fold or less, 0.2-fold or less, 0.15-fold or less, or 0.1-fold or less, compared to the expression level of the IL-11 and / or IL-11Rα gene / protein in the absence of the agent (or in the presence of an appropriate control agent).
[0292] Treatment / prevention of metabolic diseases The present invention provides methods and inventions (medicaments and compositions) for the treatment and / or prevention of metabolic disorders, eg, those described herein.
[0293] Treatment is achieved by suppressing IL-11-mediated signaling (i.e., antagonizing IL-11-mediated signaling). That is, the present invention treats / prevents metabolic diseases through the suppression of IL-11-mediated signaling in, for example, cells, tissues / organs / organ systems, subjects, etc. In some embodiments, the suppression of IL-11-mediated signaling according to the present disclosure includes suppressing IL-11-mediated signaling in liver cells (e.g., hepatocytes).
[0294] Accordingly, the present invention provides agents capable of inhibiting interleukin-11 (IL-11) mediated signaling for use in methods for the treatment or prevention of metabolic diseases.
[0295] Also provided is the use of an agent capable of inhibiting interleukin-11 (IL-11)-mediated signaling in the manufacture of a medicament for use in a method for treating or preventing metabolic disease.
[0296] Further provided is a method for treating or preventing a metabolic disease, comprising administering to a subject in need thereof a therapeutically effective amount of an agent capable of inhibiting interleukin-11 (IL-11)-mediated signal transduction.
[0297] The utility of the present invention extends to the treatment / prevention of any metabolic disease. The present invention treats / prevents diseases / conditions caused by or exacerbated by metabolic diseases. In some embodiments, the present invention treats / prevents diseases / conditions in subjects with metabolic diseases with poor prognosis.
[0298] In some embodiments, the metabolic disease to be treated / prevented may be characterized by increased expression of IL-11 and / or IL-11Rα (i.e., expression of their genes and / or proteins) in an organ / tissue / subject affected by the metabolic disease, for example, compared to a normal organ / tissue / subject (i.e., compared to an organ / tissue / subject in the absence of the metabolic disease).
[0299] The treatment / prevention of metabolic diseases according to the present invention may be treatment / prevention of metabolic diseases associated with upregulation of IL-11, for example, treatment / prevention of metabolic diseases associated with upregulation of IL-11 in cells or tissues that show or may develop symptoms of metabolic diseases, or treatment / prevention of metabolic diseases associated with upregulation of extracellular IL-11 or IL-11Rα.
[0300] A metabolic disorder can affect any tissue, organ, or organ system, hi some embodiments, a metabolic disorder can affect several tissues / organs / organ systems.
[0301] In some embodiments, the metabolic disorder affects one or more of the liver, pancreas, circulatory system, digestive system, excretory system, respiratory system, renal system, reproductive system, circulatory system, muscular system, endocrine system, exocrine system, lymphatic system, immune system, nervous system, and / or skeletal system.
[0302] According to various aspects disclosed herein, in some embodiments, the metabolic disease is characterized by decreased liver function or decreased liver cell (e.g., hepatocyte) function compared to the absence of the metabolic disease. In some embodiments, the metabolic disease is characterized by elevated (e.g., serum) ALT and / or AST levels and / or decreased GSH levels compared to the absence of the metabolic disease.
[0303] In some embodiments, the metabolic disease is characterized by liver inflammation and / or fibrosis. In some embodiments, the metabolic disease is characterized by increased gene / protein expression of pro-inflammatory and / or pro-fibrotic factors (e.g., IL-11, IL-6, CCL2 and / or CCL5) by liver cells (e.g., hepatocytes) compared to the absence of the metabolic disease. In some embodiments, the metabolic disease is characterized by increased collagen gene / protein expression by liver cells and / or increased collagen content in the liver compared to the absence of the metabolic disease.
[0304] In some embodiments, the metabolic disorder is characterized by an increased number / proportion of myofibroblasts in the liver compared to the absence of the metabolic disorder.
[0305] In some embodiments, the metabolic disease is characterized by increased apoptosis and / or necrosis of liver cells (e.g., hepatocytes) compared to the absence of the metabolic disease, hi some embodiments, the metabolic disease is characterized by an increased number / proportion of apoptotic and / or necrotic hepatocytes compared to the absence of the metabolic disease.
[0306] In some embodiments, the metabolic disease is characterized by increased fatty acid synthase (FASN) gene / protein expression by liver cells (e.g., hepatocytes) compared to the absence of the metabolic disease. In some embodiments, the metabolic disease is characterized by increased amounts of reactive oxygen species (ROS) in liver cells (e.g., hepatocytes) compared to the absence of the metabolic disease. In some embodiments, the metabolic disease is characterized by increased NOX4 gene / protein expression by liver cells (e.g., hepatocytes) compared to the absence of the metabolic disease. In some embodiments, the metabolic disease is characterized by increased levels of ERK and / or JNK activation in liver cells (e.g., hepatocytes) compared to the absence of the metabolic disease.
[0307] In some embodiments, the metabolic disease is characterized by increased triglyceride levels in liver cells (e.g., hepatocytes) or the liver compared to the absence of the metabolic disease. In some embodiments, the metabolic disease is characterized by hyperglycemia. In some embodiments, the metabolic disease is characterized by hypertriglyceridemia. In some embodiments, the metabolic disease is characterized by hypercholesterolemia. In some embodiments, the metabolic disease is characterized by increased body weight compared to the absence of the metabolic disease. In some embodiments, the metabolic disease is characterized by increased liver weight compared to the absence of the metabolic disease.
[0308] The treatment may be effective in inhibiting / slowing / preventing the onset or progression of a metabolic disease. The treatment may be effective in inhibiting / slowing / preventing the worsening of one or more symptoms of a metabolic disease. The treatment may be effective in ameliorating one or more symptoms of a metabolic disease. The treatment may be effective in reducing the severity of a metabolic disease and / or reversing one or more symptoms of a metabolic disease. The treatment may be effective in reversing the effects of a metabolic disease.
[0309] "Prevention" may be prevention of the onset of a metabolic disease and / or prevention of the worsening of a metabolic disease, for example prevention of the progression of a metabolic disease to a late or chronic stage.
[0310] According to various aspects of the present invention, the inventive method for treating and / or preventing a metabolic disease comprises: Reducing blood lipid levels; Reducing blood sugar levels; enhancing glucose tolerance (e.g., in glucose intolerant subjects); enhancing insulin resistance (e.g., in insulin-resistant subjects); Enhancement of pancreatic function; reducing weight (e.g., in overweight / obese subjects); Reducing body fat mass; Increasing lean body mass; Reducing fasting blood sugar levels; reducing serum triglyceride levels; Reducing serum cholesterol levels; enhancing glucose tolerance; enhancing pancreatic function (e.g., exocrine and / or endocrine function); Enhancement of pancreatic tissue growth; regenerating pancreatic tissue; Increasing pancreatic weight; Inhibition of pancreatic stellate cell (PSC)-mediated transformation of pancreatic stellate cells into myofibroblasts; Reducing the number / proportion of myofibroblasts within the pancreas; Reducing the amount of hydroxyproline in the pancreas; Reducing the amount of collagen in the pancreas; reducing pancreatic injury; reducing islet cell hyperplasia; reducing glucagon expression; enhancing insulin expression; To increase weight (e.g., in a subject with a wasting disease (e.g., cachexia)); reducing IL-11 protein expression in the liver; reducing Erk activation in the liver; reducing JNK activation in the liver; reducing caspase 3 cleavage in the liver; Reducing the amount of ROS in the liver; Reducing NOX4 expression in the liver; inhibiting fatty degeneration, for example in the liver; Reducing triglyceride levels in the liver; reducing the expression of fatty acid synthase; reducing serum ALT and / or serum AST levels; reducing the expression of pro-inflammatory factors (e.g., TNFα, CCL2, CCL5, IL-6, CXCL5 and / or CXCL1); reducing the expression of profibrotic factors (e.g., IL-11, TIMP1, ACTA2, TGFβ1, MMP2, TIMP2, MMP9, COL1A2, COL1A1, and / or COL3A1); Reducing serum TGFβ1 levels; reducing the expression / production of IL-11, ACTA2, MMP2, TGFβ1, PDGF, ANGII, bFGF, CCL2 and / or H2O2 by hepatic stellate cells; Inhibition of hepatic stellate cell-to-myofibroblast transformation by hepatic stellate cells; Reducing the number / proportion of myofibroblasts in the liver; Reducing hydroxyproline levels in the liver; Reducing collagen levels in the liver; Enhance liver function; Increasing serum GSH levels; enhancing the function of organs / tissues affected by metabolic diseases; reducing liver damage; reducing liver cell death; reducing cell death caused by lipotoxicity; Reducing IL-11-mediated signaling in hepatocytes; and Reducing the number / percentage of CD45+ cells in the liver It may include one or more of:
[0311] According to various aspects and embodiments described herein, the treatment / prevention of metabolic disease more specifically includes, for example, the suppression, reduction, or prevention of lipotoxicity in a given organ system / organ / tissue / cell type. In some embodiments, the treatment / prevention of metabolic disease includes the suppression / reduction / prevention of lipotoxicity in the liver (e.g., hepatocytes).
[0312] Administration Preferably, the agent capable of inhibiting IL-11-mediated signaling is administered in a "therapeutically effective" or "prophylactically effective" amount sufficient to provide benefit to the subject.
[0313] The actual dosage, administration rate and time course after administration depend on the characteristics and severity of the disease and the characteristics of the drug.The prescription of treatment (for example, determining dosage) is under the responsibility of general practitioners and other medical practitioners, and usually takes into account the disease / condition to be treated, the condition of each individual patient, delivery site, administration method and other factors that are well known to medical practitioners.Examples of such methods and protocols are described in Remington's Pharmaceutical Sciences, 20th Edition, 2000, pub. Lippincott, Williams & Wilkins.
[0314] The agents of the invention may be administered multiple times, and may be administered in one or more doses, or each dose may be administered simultaneously or sequentially with another therapeutic agent.
[0315] The multiple administrations may be spaced apart by a predetermined time interval, which may be 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, or 31 days, or 1, 2, 3, 4, 5, or 6 months. For example, the administration may be once every 7 days, once every 14 days, once every 21 days, or once every 28 days (±3, ±2, or ±1 day).
[0316] For therapeutic use, agents capable of inhibiting IL-11-mediated signal transduction are preferably formulated as a medicament or pharmaceutical preparation together with one or more other pharmaceutically acceptable ingredients well known to those skilled in the art, including, but not limited to, pharmaceutically acceptable carriers, adjuvants, excipients, diluents, fillers, buffers, preservatives, antioxidants, lubricants, stabilizers, solubilizers, surfactants (e.g., wetting agents), masking agents, colorants, flavoring agents, and sweetening agents.
[0317] As used herein, "pharmaceutically acceptable" refers to a compound, ingredient, material, composition, dosage form, etc. that is suitable, within the scope of sound medical judgment, for use in contact with the tissues of a recipient (e.g., a human) without causing excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit-risk ratio. Moreover, each carrier, adjuvant, excipient, etc. must be "acceptable" in terms of compatibility with the other ingredients in the formulation.
[0318] Suitable carriers, adjuvants, excipients, etc. can be found in standard pharmaceutical textbooks, such as, for example, Remington's Pharmaceutical Sciences, 18th edition, Mack Publishing Company, Easton, Pa., 1990; and Handbook of Pharmaceutical Excipients, 2nd edition, 1994.
[0319] The formulations may be prepared by any method well known in the art of pharmacy. Such methods include the step of mixing the active compound with a carrier, which constitutes one or more accessory ingredients. In general, formulations are prepared by uniformly and intimately mixing the active compound with a carrier (e.g., a liquid carrier, a finely divided solid carrier, etc.), and then shaping the resulting mixture, if necessary.
[0320] The formulations may be prepared for administration via local, parenteral, systemic, intravenous, intraarterial, intramuscular, intrathecal, intraocular, intraconjunctival, subcutaneous, oral, or transdermal routes, which may include injection. Injectable formulations may contain the selected agent in a sterile or isotonic solvent. The formulation and administration method may be selected depending on the agent of the present invention and the disease to be treated.
[0321] Detection of IL-11 and IL-11 receptor Some aspects and embodiments of the present invention relate to detecting the expression of IL-11 or an IL-11 receptor (e.g., IL-11Rα, gp130, or a complex comprising IL-11Rα and / or gp130) in a sample obtained from a subject.
[0322] In some aspects and embodiments, the present invention relates to the upregulation (overexpression) of expression of IL-11 or IL-11 receptor (either as protein or as oligonucleotides encoding IL-11 or IL-11 receptor) and the detection of upregulation of expression of IL-11 or IL-11 receptor as an indicator of suitability for treatment with agents capable of suppressing the action of IL-11 or inhibiting or reducing expression of IL-11 or IL-11 receptor.
[0323] Upregulation of expression includes expression that exceeds the expression level normally expected in a given type of cell or tissue. Upregulation may be measured by measuring the expression level of the associated factor in the cell or tissue. The expression level of the associated factor in a cell or tissue sample obtained from a subject may be compared to a reference level of the associated factor (e.g., a value or range of values representing the normal expression level of the associated factor in the same type of cell or tissue or a corresponding cell or tissue). In some embodiments, the reference level may be determined by detecting the expression of IL-11 or IL-11 receptor in a control sample (e.g., a corresponding cell or tissue obtained from a healthy subject or a corresponding cell or tissue obtained from a healthy tissue of the same subject). In some embodiments, the reference level may be obtained from a standard curve or a standard dataset.
[0324] The expression level may be quantified by absolute comparison or by relative comparison.
[0325] In some embodiments, IL-11 or an IL-11 receptor (e.g., IL-11Rα, gp130, or a complex containing IL-11Rα and / or gp130) may be considered upregulated if the expression level in the test sample is at least 1.1 times the reference level. More preferably, the expression level when upregulated may be selected from at least 1.2 times, at least 1.3 times, at least 1.4 times, at least 1.5 times, at least 1.6 times, at least 1.7 times, at least 1.8 times, at least 1.9 times, at least 2.0 times, at least 2.1 times, at least 2.2 times, at least 2.3 times, at least 2.4 times, at least 2.5 times, at least 2.6 times, at least 2.7 times, at least 2.8 times, at least 2.9 times, at least 3.0 times, at least 3.5 times, at least 4.0 times, at least 5.0 times, at least 6.0 times, at least 7.0 times, at least 8.0 times, at least 9.0 times and at least 10.0 times the baseline level.
[0326] The expression level may be measured by any of a variety of known in vitro analytical techniques, such as PCR-based assays, in situ hybridization assays, flow cytometry assays, immunological assays, and immunohistochemical assays.
[0327] As an example, a suitable technique includes detecting the amount of IL-11 or IL-11 receptor in a sample by contacting the sample with an agent capable of binding to IL-11 or IL-11 receptor and detecting the formation of a complex consisting of IL-11 or IL-11 receptor and the agent. The agent may be any suitable binding molecule, such as an antibody, polypeptide, peptide, oligonucleotide, aptamer, small molecule, etc., and may be labeled so that the complex formed can be detected (e.g., visualized). Suitable labels and methods for detecting such complexes are well known in the art and include, for example, fluorescent labels (e.g., fluorescein, rhodamine, eosin, NDB, green fluorescent protein (GFP); rare earth element chelates such as europium (Eu), terbium (Tb), samarium (Sm); tetramethylrhodamine, Texas Red, 4-methylumbelliferone, 7-amino-4-methylcoumarin, Cy3, Cy5), isotopic markers, radioisotopes (e.g., 32 P, 33 P, 35 Examples of suitable labels include chemiluminescent labels (e.g., acridinium esters, luminol, isoluminol), enzymes (e.g., peroxidase, alkaline phosphatase, glucose oxidase, β-galactosidase, luciferase), antibodies, ligands, and receptors. Detection techniques are well known to those skilled in the art and can be selected depending on the labeling agent. Suitable techniques include PCR amplification of oligonucleotide tags, mass spectrometry, detection of fluorescence or color (e.g., produced by enzymatic conversion of a substrate by a reporter protein), or detection of radioactivity.
[0328] The assay may be configured to quantify the amount of IL-11 or IL-11 receptor in a sample. The amount of IL-11 or IL-11 receptor quantified from a test sample may be compared to a reference amount, and such comparison may determine whether the amount of IL-11 or IL-11 receptor contained in the test sample is higher or lower than the reference amount at a selected level of statistical significance.
[0329] The detected IL-11 or IL-11 receptor may be quantified to measure up-regulation, down-regulation, or amplification of the gene encoding IL-11 or IL-11 receptor. When the test sample contains fibrotic cells, such up-regulation, down-regulation, or amplification may be compared with a reference amount to determine whether there is a statistically significant difference.
[0330] The sample obtained from the subject may be of any type. The biological sample may be obtained from any tissue or bodily fluid, such as a blood sample, a blood-derived sample, a serum sample, a lymph sample, a semen sample, a saliva sample, or a synovial fluid sample. The blood-derived sample may be a selected fraction derived from the patient's blood, such as a selected cell-containing fraction, a plasma fraction, or a serum fraction. The sample may include a tissue sample or a biopsy sample, or cells isolated from the subject. The sample may also be obtained by known techniques, such as biopsy or fine needle aspiration. Furthermore, the sample may be stored until the level of IL-11 expression is measured and / or may be processed before measuring the level of IL-11 expression.
[0331] A sample obtained from a subject may be used to measure upregulation of IL-11 or IL-11 receptor in the subject.
[0332] In some preferred embodiments, the sample may be a tissue sample (e.g., a biopsy sample) obtained from a tissue / organ affected by a metabolic disease. The sample may comprise cells.
[0333] Subjects for treatment / prevention according to the present invention may be selected based on the confirmed upregulation of IL-11 or IL-11 receptor (e.g., IL-11Rα, gp130, or a complex containing IL-11Rα and / or gp130) expression in the subject. Also, upregulation of IL-11 or IL-11 receptor expression may be used as a marker of metabolic disease suitable for treatment with an agent capable of suppressing IL-11-mediated signaling.
[0334] The upregulation may be in a specific tissue or in selected cells derived from the specific tissue. Preferred tissues may be liver tissue or pancreatic tissue. The upregulation of IL-11 or IL-11 receptor expression may be measured in circulating body fluids (e.g., blood) or in blood-derived samples. The upregulation may be the upregulation of extracellular IL-11 or IL-11Rα. In some embodiments, the expression may be upregulated locally or systemically.
[0335] As described in the following sections, an agent capable of inhibiting IL-11-mediated signaling may be administered to a subject.
[0336] Diagnosis and Prognosis Detection of upregulated expression of IL-11 or an IL-11 receptor (e.g., IL-11Rα, gp130, or a complex comprising IL-11Rα and / or gp130) may be used in methods of diagnosing metabolic disease and identifying subjects at risk for developing metabolic disease, and may be used in methods of prognosticating or predicting a subject's responsiveness to treatment with an agent capable of inhibiting IL-11-mediated signaling.
[0337] The terms "develop" and "development", as well as other forms of the term "develop", may refer to the onset of a disorder / disease or the continuation or progression of a disorder / disease.
[0338] In some embodiments, a subject may be determined to have or be suspected of having a metabolic disease based on, for example, the presence or absence of other symptoms indicative of the presence of a metabolic disease in the subject's organism or selected cells / tissues derived therefrom, or may be considered to be at risk for developing a metabolic disease due to, for example, a genetic predisposition or exposure to environmental conditions known to be risk factors for metabolic disease. Measuring upregulated expression of IL-11 or the IL-11 receptor may also confirm a diagnosis or a suspected diagnosis, or confirm that a subject is at risk for developing a metabolic disease. Measuring upregulated expression of IL-11 or the IL-11 receptor may also diagnose whether a metabolic disease or predisposition is amenable to treatment with an agent capable of suppressing IL-11-mediated signaling.
[0339] Thus, there may be provided a method of providing a prognosis for a subject suffering from or suspected of suffering from a metabolic disease, the method comprising determining whether expression of IL-11 or an IL-11 receptor is upregulated in a sample obtained from the subject, and providing a prognosis for treatment of the subject with an agent capable of inhibiting IL-11-mediated signaling based on said determination.
[0340] In some embodiments, methods for prognosing or predicting a subject's responsiveness to treatment with an agent capable of suppressing IL-11-mediated signaling or diagnostic methods may not require measuring the expression level of IL-11 or IL-11 receptor, but may be based on measuring genetic factors in the subject that predict upregulation of IL-11 or IL-11 receptor expression or activity. Such genetic factors include measuring genetic mutations, single nucleotide polymorphisms (SNPs), or gene amplifications in IL-11, IL-11Rα, and / or gp130 that correlate with and / or can predict upregulation of IL-11 or IL-11 receptor expression or activity or upregulation of IL-11-mediated signaling. The use of genetic factors to predict predisposition to a disease state or responsiveness to treatment is known in the art; see, e.g., Peter Starkel Gut 2008;57:440-442; Wright et al., Mol. Cell. Biol. March 2010 vol. 30 no. 6 1411-1420.
[0341] Genetic factors may be analyzed by methods known to those skilled in the art, such as PCR-based assays, e.g., quantitative PCR, competitive PCR, etc. For example, determining the presence or absence of a genetic factor, e.g., in a sample obtained from a subject, may confirm a diagnosis, classify a subject as at risk for developing a metabolic disease, and / or identify a subject as suitable for treatment with an agent capable of suppressing IL-11-mediated signaling.
[0342] Some methods may involve identifying the presence or absence of one or more SNPs associated with susceptibility to developing metabolic diseases or secretion of IL-11. SNPs are usually biallelic and therefore can be easily identified using any of a variety of conventional assays known to those skilled in the art (see, for example, Anthony J. Brookes. The essence of SNPs. Gene Volume 234, Issue 2, 8 July 1999, 177-186; Fan et al., Highly Parallel SNP Genotyping. Cold Spring Harb Symp Quant Biol 2003. 68: 69-78; Matsuzaki et al., Parallel Genotyping of Over 10,000 SNPs using a one-primer assay on a high-density oligonucleotide array. Genome Res. 2004. 14: 414-425).
[0343] The method may include identifying which SNP alleles are present in a sample obtained from the subject. In some embodiments, identifying the presence or absence of a minor allele may identify a susceptibility to developing a metabolic disease or increased secretion of IL-11.
[0344] Thus, in one aspect of the invention there is provided a method of screening a subject, comprising the steps of: obtaining a nucleic acid sample from a subject; and In the sample, determine which alleles are present at the polymorphic nucleotide positions of one or more SNPs listed in Figure 33, Figure 34 or Figure 35 of WO 2017 / 103108(A1) (which document is incorporated herein by reference), or identify alleles that are present at any one of the SNPs listed in these figures. 2 Identifying SNPs that exhibit linkage disequilibrium of ≧0.8 The present invention provides a method comprising:
[0345] The step of identifying alleles or SNPs may include identifying the presence or absence of minor alleles at selected polymorphic nucleotide positions in the sample, and may include identifying the presence or absence of zero, one, or two minor alleles.
[0346] Said screening method may be or form part of a method for identifying a subject's susceptibility to developing a metabolic disease, or a diagnostic or prognostic method as described above.
[0347] The method may further comprise identifying the subject as having a susceptibility to or at high risk of developing a metabolic disease, for example, if the subject is identified as having a minor allele at the polymorphic nucleotide position. The method may further comprise selecting the subject for treatment with an agent capable of suppressing IL-11-mediated signaling, and / or administering to the subject an agent capable of suppressing IL-11-mediated signaling to treat the metabolic disease in the subject or prevent the onset or progression of a metabolic disease in the subject.
[0348] In some embodiments, methods for diagnosing metabolic diseases, identifying subjects at risk for developing metabolic diseases, or prognosing or predicting a subject's responsiveness to treatment with an agent capable of inhibiting IL-11-mediated signaling use indicators that are not for detecting upregulation of IL-11 or IL-11 receptor expression, and that are not genetic factors.
[0349] In some embodiments, methods for diagnosing metabolic disease, identifying subjects at risk for developing metabolic disease, or prognosing or predicting a subject's responsiveness to treatment with an agent capable of inhibiting IL-11-mediated signaling are based on the detection, measurement, and / or identification of one or more indicators of metabolic disease.
[0350] The diagnostic or prognostic method may be performed in vitro using a sample obtained from a subject, or may be performed in vitro after processing a sample obtained from a subject. The patient from whom the sample was taken does not need to be present before the in vitro diagnostic or prognostic method is performed, and therefore the method does not need to be performed on a living human or animal. The sample obtained from the subject may be of any type, as described above.
[0351] The methods described herein may be used in conjunction with other diagnostic or prognostic tests to enhance the accuracy of the diagnosis or prognosis or to confirm the results obtained using the test methods described herein.
[0352] subject The subject may be an animal or a human. Preferably, the subject is a mammal, more preferably a human. The subject may be a non-human mammal, more preferably a human. The subject may be male or female. The subject may be a patient.
[0353] The patient may have a metabolic disease as described herein. The subject may be a subject who has been diagnosed with a metabolic disease in need of treatment, a subject who is suspected of having such a metabolic disease, or a subject who is at risk of developing a metabolic disease.
[0354] In embodiments according to the present invention, the subject is preferably a human subject. In embodiments according to the present invention, subjects may be selected for treatment with the methods of the present invention based on the characterization of particular markers for metabolic disease.
[0355] Further methods and uses provided herein The present invention further provides methods for reducing blood lipid levels, methods for reducing blood glucose levels, methods for enhancing glucose tolerance (e.g., in a glucose intolerant subject), methods for enhancing insulin resistance (e.g., in an insulin resistant subject), methods for enhancing pancreatic function, methods for reducing weight (e.g., in an overweight / obese subject), methods for reducing body fat mass, methods for increasing lean body mass, methods for reducing fasting blood glucose levels, methods for reducing serum triglyceride levels, methods for reducing serum cholesterol levels, methods for enhancing glucose tolerance, methods for enhancing pancreatic function (e.g., exocrine function and / or endocrine function), methods for enhancing proliferation of pancreatic tissue, methods for regenerating pancreatic tissue, methods for increasing pancreatic mass, methods for inhibiting pancreatic stellate cell (PSC) conversion to myofibroblasts, methods for reducing the number / proportion of myofibroblasts in the pancreas, methods for reducing the amount of hydroxyproline in the pancreas, methods for reducing the amount of collagen in the pancreas, methods for reducing pancreatic injury, methods for reducing islet cell hyperplasia, methods for reducing glucagon expression, methods for enhancing insulin expression, methods for increasing weight (e.g., in a subject with a wasting disease (e.g., cachexia)). a method for reducing the expression of IL-11 protein in the liver, a method for reducing Erk activation in the liver, a method for reducing JNK activation in the liver, a method for reducing caspase 3 cleavage in the liver, a method for reducing the amount of ROS in the liver, a method for reducing NOX4 expression in the liver, a method for suppressing fatty degeneration of, for example, the liver, a method for reducing triglyceride levels in the liver, a method for reducing fatty acid synthase expression, a method for reducing serum ALT levels and / or serum AST levels, a method for suppressing the expression of pro-inflammatory factors (e.g., TNFα, CCL2, CCL5, I a method for reducing the expression of pro-fibrotic factors (e.g., IL-11, TIMP1, ACTA2, TGFβ1, MMP2, TIMP2, MMP9, COL1A2, COL1A1 and / or COL3A1); a method for reducing serum TGFβ1 levels; a method for reducing the expression / production of IL-11, ACTA2, MMP2, TGFβ1, PDGF, ANGII, bFGF, CCL2 and / or H2O2 by hepatic stellate cells; a method for inhibiting the conversion of hepatic stellate cells to myofibroblasts by hepatic stellate cells;Provided is an agent capable of suppressing IL-11-mediated signaling for use in a method for reducing the number / proportion of myofibroblasts in the liver, a method for reducing the amount of hydroxyproline in the liver, a method for reducing the amount of collagen in the liver, a method for enhancing liver function, a method for increasing serum GSH levels, a method for enhancing the function of an organ / tissue affected by a metabolic disease, a method for reducing liver damage, a method for reducing liver cell death, a method for reducing cell death (e.g., death of liver cells) caused by lipotoxicity, a method for reducing IL-11-mediated signaling in hepatocytes, or a method for reducing the number / proportion of CD45+ cells in the liver, or the use of an agent capable of suppressing IL-11-mediated signaling in these methods.
[0356] The present invention also provides methods for reducing blood lipid levels, methods for reducing blood glucose levels, methods for enhancing glucose tolerance (e.g., in a glucose intolerant subject), methods for enhancing insulin resistance (e.g., in an insulin resistant subject), methods for enhancing pancreatic function, methods for reducing weight (e.g., in an overweight / obese subject), methods for reducing body fat mass, methods for increasing lean body mass, methods for reducing fasting blood glucose levels, methods for reducing serum triglyceride levels, methods for reducing serum cholesterol levels, methods for enhancing glucose tolerance, methods for enhancing pancreatic function (e.g., exocrine function and / or endocrine function), methods for enhancing proliferation of pancreatic tissue, methods for regenerating pancreatic tissue, methods for increasing pancreatic weight, methods for reducing islet cell hyperplasia, methods for reducing glucagon expression, methods for enhancing insulin expression, methods for increasing weight (e.g., in a subject with a wasting disease (e.g., cachexia)), methods for reducing IL-11 protein expression in the liver, methods for reducing Erk activation in the liver, methods for reducing JNK activation in the liver, methods for reducing caspase 3 cleavage in the liver, methods for reducing ROS levels in the liver, methods for enhancing the proliferation of pancreatic tissue ... methods for reducing NOX4 expression in, for example, a method for suppressing fatty degeneration of the liver or the like, a method for reducing triglyceride levels in the liver, a method for reducing fatty acid synthase expression, a method for reducing serum ALT levels and / or serum AST levels, a method for reducing the expression of pro-inflammatory factors (e.g., TNFα, CCL2, CCL5, IL-6, CXCL5 and / or CXCL1), a method for reducing the expression of pro-fibrotic factors (e.g., IL-11, TIMP1, ACTA2, TGFβ1, MMP2, TIMP2, MMP9, COL1A2, COL1A1 and / or COL3A1), methods for reducing the expression / production of IL-11, ACTA2, MMP2, TGFβ1, PDGF, ANGII, bFGF, CCL2 and / or H2O2 by hepatic stellate cells; methods for inhibiting the conversion of hepatic stellate cells to myofibroblasts by hepatic stellate cells; methods for reducing the number / proportion of myofibroblasts in the liver; methods for reducing the amount of hydroxyproline in the liver; methods for reducing the amount of collagen in the liver; methods for enhancing liver function; methods for increasing serum GSH levels; methods for enhancing the function of organs / tissues affected by metabolic diseases;The present invention provides use of an agent capable of suppressing IL-11-mediated signaling in the manufacture of a composition used in a method for reducing liver damage, a method for reducing liver cell death, a method for reducing cell death (e.g., hepatocyte death) caused by lipotoxicity, a method for reducing IL-11-mediated signaling in liver cells, or a method for reducing the number / proportion of CD45+ cells in the liver.
[0357] Further, the present invention provides methods for reducing blood lipid levels, methods for reducing blood glucose levels, methods for enhancing glucose tolerance (e.g., in a glucose intolerant subject), methods for enhancing insulin resistance (e.g., in an insulin resistant subject), methods for enhancing pancreatic function, methods for reducing weight (e.g., in an overweight / obese subject), methods for reducing body fat mass, methods for increasing lean body mass, methods for reducing fasting blood glucose levels, methods for reducing serum triglyceride levels, methods for reducing serum cholesterol levels, methods for enhancing glucose tolerance, methods for enhancing pancreatic function (e.g., exocrine function and / or endocrine function), methods for enhancing proliferation of pancreatic tissue, methods for regenerating pancreatic tissue, methods for increasing pancreatic weight, methods for reducing islet cell hyperplasia, methods for reducing glucagon expression, methods for enhancing insulin expression, methods for increasing weight (e.g., in a subject with a wasting disease (e.g., cachexia)), methods for reducing expression of IL-11 protein in the liver, methods for reducing activation of Erk in the liver, methods for reducing activation of JNK in the liver, methods for reducing cleavage of caspase 3 in the liver, methods for reducing the amount of ROS in the liver, methods for enhancing the proliferation of pancreatic tissue ... methods for reducing NOX4 expression in, for example, a method for suppressing fatty degeneration of the liver or the like, a method for reducing triglyceride levels in the liver, a method for reducing fatty acid synthase expression, a method for reducing serum ALT levels and / or serum AST levels, a method for reducing the expression of pro-inflammatory factors (e.g., TNFα, CCL2, CCL5, IL-6, CXCL5 and / or CXCL1), a method for reducing the expression of pro-fibrotic factors (e.g., IL-11, TIMP1, ACTA2, TGFβ1, MMP2, TIMP2, MMP9, COL1A2, COL1A1 and / or COL3A1), methods for reducing the expression / production of IL-11, ACTA2, MMP2, TGFβ1, PDGF, ANGII, bFGF, CCL2 and / or H2O2 by hepatic stellate cells; methods for inhibiting the conversion of hepatic stellate cells to myofibroblasts by hepatic stellate cells; methods for reducing the number / proportion of myofibroblasts in the liver; methods for reducing the amount of hydroxyproline in the liver; methods for reducing the amount of collagen in the liver; methods for enhancing liver function; methods for increasing serum GSH levels; methods for enhancing the function of organs / tissues affected by metabolic diseases;The present invention provides a method for reducing liver damage, reducing liver cell death, reducing cell death (e.g., hepatocyte death) caused by lipotoxicity, reducing IL-11-mediated signaling in liver cells, or reducing the number / proportion of CD45+ cells in the liver.
[0358] Sequence identity Pairwise sequence alignment and multiple sequence alignment to determine the percent identity between two or more amino acid or nucleic acid sequences can be performed using various methods known to those skilled in the art, such as publicly available computer software such as ClustalOmega software (Soding, J. 2005, Bioinformatics 21, 951-960), T-coffee software (Notredame et al. 2000, J. Mol. Biol. (2000) 302, 205-217), Kalign software (Lassmann and Sonnhammer 2005, BMC Bioinformatics, 6(298)), and MAFFT software (Katoh and Standley 2013, Molecular Biology and Evolution, 30(4) 772-780). When using such software, it is preferable to use default parameters, such as gap penalties and extension penalties.
[0359] [Table 2] TIFF0007595028000003.tif224170TIFF0007595028000004.tif189170TIFF0007595028000005.tif100170
[0360] The present invention includes combinations of the aspects and preferred features described herein except where such combinations are clearly unacceptable or clearly to be avoided.
[0361] The features of the disclosure expressed in the foregoing detailed description, the following claims, or the accompanying drawings as particular forms or means for performing a disclosed function, or methods or processes for suitably obtaining the results of the disclosure, may be used separately or in any combination to realize the invention in various forms.
[0362] For the avoidance of doubt, the logical explanations provided herein are provided for the purpose of enhancing the reader's understanding, and the inventors do not wish to constrain the present invention by these logical explanations.
[0363] All section headings used herein are for organizational purposes only and should not be construed as limiting the subject matter described herein.
[0364] Throughout this specification, including the claims which follow, unless otherwise indicated, the terms "comprise" and "include", and their variations "comprises", "comprising" and "including", are to be understood to include a stated element or step or elements or steps, but not to exclude elements or steps or elements or steps other than those stated.
[0365] As used in this specification and the appended claims, it should be noted that the singular forms "a," "an," and "the" include plural references unless the context clearly dictates otherwise. Numerical ranges are expressed herein as "about" a particular value and / or as a range from "about" a particular value to "about" another particular value. When such a range is expressed, another embodiment includes the non-approximately specified particular value and / or a range from the non-approximately specified particular value to the other particular value. Similarly, when a particular value is expressed as an approximation by use of the antecedent "about," it is understood that the non-approximately specified particular value also constitutes another embodiment. The term "about" in connection with a numerical value indicates discretion and refers to the mean value (e.g., ±10%).
[0366] The methods disclosed herein may be performed in vitro, ex vivo, or in vivo, and the products of the invention may be in vitro, ex vivo, or in vivo products. "In vitro" encompasses experiments using materials, biological substances, cells, and / or tissues in laboratory conditions or culture. In contrast, "in vivo" encompasses experiments and manipulations using living multicellular organisms. In some embodiments, methods performed in vivo may be performed in a non-human animal. "Ex vivo" refers to something existing or performed outside of a living organism, e.g., outside the human or animal body, and may be present in or performed on tissues (e.g., whole organs) or cells removed from an organism.
[0367] When a nucleic acid sequence is disclosed herein, the reverse complement thereof is also specifically contemplated.
[0368] For standard molecular biology techniques, see Sambrook, J., Russell, DW Molecular Cloning, A Laboratory Manual. 3 ed. 2001, Cold Spring Harbor, New York: Cold Spring Harbor Laboratory Press.
[0369] Aspects and embodiments of the present invention are described below with reference to the accompanying drawings. Further aspects and embodiments will be readily apparent to those skilled in the art. All documents cited herein are incorporated by reference in their entirety as part of this specification. The present invention will be described in conjunction with the following exemplary embodiments, but those skilled in the art will readily recognize various equivalent modifications and variations upon reading this disclosure. Accordingly, the exemplary embodiments of the present invention set forth above are considered to be illustrative and not limiting of the present invention. Various modifications may be made to the embodiments described herein without departing from the spirit and scope of the present invention.
[0370] Hereinafter, embodiments and experiments illustrating the principles of the present invention will be described with reference to the accompanying drawings. [Brief explanation of the drawings]
[0371] [Figure 1A-1B] Figure 1A shows the percentage change in body weight over time in IL-11RA knockout mice (Il11ra1- / -) or wild-type mice expressing IL-11RA (Il11ra1+ / +) fed either (Figure 1A) a normal chow diet (NCD) or (Figure 1B) a fructose-supplemented Western diet (WDF).
[0372] [Figure 2A-2B]Bar graphs showing the percent change in total body fat mass in IL-11RA knockout mice (Il11ra1KO) or IL-11RA-expressing wild-type mice (Il11raWT) fed (Figure 2A) a normal chow diet (NCD) or (Figure 2B) a fructose-supplemented Western diet (WDF).
[0373] [Figure 3] FIG. 1 is a graph showing fasting blood glucose levels (mM) in IL-11RA knockout mice (KO) or wild-type mice expressing IL-11RA (WT) fed normal chow (NC) or a fructose-supplemented Western diet (WDF).
[0374] [Figure 4] 1 is a graph showing serum triglyceride levels (mg / g) in IL-11RA knockout mice (KO) or wild-type mice expressing IL-11RA (WT) fed normal chow (NC) or a fructose-supplemented Western diet (WDF).
[0375] [Figure 5A-5B] Graphs showing serum cholesterol levels (mg / dl) in IL-11RA knockout mice (KO) or wild-type mice expressing IL-11RA (WT) fed (Figure 5A) normal chow (NC) or (Figure 5B) fructose-supplemented Western diet (WDF).
[0376] [Figures 6A-6B] Graphs and boxplots showing changes in body weight in mice fed normal chow (NC) or a fructose-supplemented Western diet (WDF) and treated with anti-IL-11RA antibody or IgG control. (Figure 6A) Percent change in body weight over time (weekly) is shown. (Figure 6B) Percent difference between total fat mass and lean body mass is shown. *P<0.05.
[0377] [Figures 7A-7B]7A and 7B show graphs, a schematic diagram, and a bar graph showing the results of an intraperitoneal glucose tolerance test (ipGTT) performed on mice fed a fructose-supplemented Western diet (WDF) and treated with anti-IL-11RA antibody or an IgG control. (FIG. 7A) Change in blood glucose (mM) from 1 minute is shown. (FIG. 7B) Area under the curve is shown. *P<0.05, **P<0.01.
[0378] [Figure 8] Boxplot showing pancreatic weights from mice fed normal chow (NCD) or a fructose-supplemented Western diet (WDF) and treated with anti-IL-11RA antibody or IgG control at various time points. ****P<0.0001.
[0379] [Figures 9A-9C] Box plots showing (FIG. 9A) serum cholesterol levels (mg / dl), (FIG. 9B) serum triglyceride levels (mg / g), and (FIG. 9C) fasting blood glucose levels (mM) for mice fed a normal chow diet (NCD) or a fructose-supplemented Western diet (WDF) and treated with anti-IL-11RA antibody or IgG control at the indicated time points.
[0380] [Figures 10A-10B] 10A and 10B show the results of immunohistochemical analysis of (FIG. 10A) glucagon content and (FIG. 10B) insulin content in sections of pancreatic tissue taken at week 24 from mice fed a normal chow diet (NCD) or a fructose-supplemented Western diet (WDF) and treated with anti-IL-11RA antibody or IgG control from week 16.
[0381] [Figures 11A-11B]These graphs and images show the effect of treatment with anti-IL-11 or anti-IL-11Rα antibodies on cachexia-associated weight loss. (Figure 11A) Mice fed a cachexia-inducing high-fat, methionine-choline-deficient (HFMCD) diet were treated twice weekly with anti-IL-11 or anti-IL-11Rα antibodies, resulting in a return to normal or near-normal body weight. Control mice were fed normal chow (NC) or HFMCD diet and treated with an IgG isotype control. (Figure 11B) An example of a comparison of body size between mice fed an HFMCD diet and treated with IgG or anti-IL-11 or anti-IL-11Rα antibodies is shown.
[0382] [Figures 12A-12C] 12A and 12B are graphs showing the effect of treatment with anti-IL-11 or anti-IL-11Rα antibodies on body weight in a cachexia-associated weight loss model. Mice fed an HFMCD diet were treated twice weekly with anti-IL-11Rα antibody (FIG. 12A) or one of two anti-IL-11 antibodies (FIGS. 12B and 12C) at doses of 0.5 mg / kg, 1 mg / kg, 5 mg / kg, or 10 mg / kg. Control mice were fed a normal chow diet (NC) or an HFMCD diet and treated with an IgG isotype control.
[0383] [Figures 13A-13C] 13A-C are graphs showing the effect of treatment with anti-IL-11 or anti-IL-11Rα antibodies on food intake in a model of cachexia-associated weight loss. Mice fed an HFMCD diet were treated twice weekly with anti-IL-11Rα antibody (FIG. 13A) or one of two anti-IL-11 antibodies (FIGS. 13B and 13C) at doses of 0.5 mg / kg, 1 mg / kg, 5 mg / kg, or 10 mg / kg. Control mice were fed normal chow (NC) or an HFMCD diet and treated with an IgG isotype control.
[0384] [Figures 14A-14B]These graphs show the effect of treatment with anti-IL-11 or anti-IL-11Rα antibodies on cachexia-associated weight loss after folic acid-induced acute kidney injury. (Figure 14A) Mice with folic acid-induced kidney injury were treated with anti-IL-11Rα, anti-IL-11, or IgG control starting 1 hour before and continuing for 28 days after kidney injury induction. "Control" mice received vehicle only. (Figure 14B) Mice with folic acid-induced kidney injury were treated with anti-IL-11 or IgG control starting 21 days after kidney injury induction. FA = folic acid.
[0385] [Figure 15] 1 is a graph showing the effect of treatment with anti-IL-11 antibody on weight loss associated with cachexia after induction of acute kidney injury by unilateral ureteral obstruction (UUO). Mice with unilateral ureteral obstruction-induced kidney injury were treated with anti-IL-11 antibody or IgG control for 10 days after induction of kidney injury.
[0386] [Figures 16A-16B] 16A-16B are graphs showing the effect of IL-11 overexpression on body weight gain. (FIG. 16A) Administration of recombinant mouse IL-11 (rmIL11) delayed the progression of weight gain in normal mice. (FIG. 16B) Induction of the IL-11 transgene (IL-11 Tg) in mice resulted in weight loss over time.
[0387] [Figures 17A-17N]IL-11 activates hepatic stellate cells (HSCs) and induces liver fibrosis. (A) IL-11 RNA is upregulated in hepatic stellate cells stimulated with TGFβ1. (B) IL-11 protein is secreted from hepatic stellate cells stimulated with TGFβ1. (C) Precision thin sections of human liver were stimulated with TGFβ1, and IL-11 protein was measured in the supernatant. (D) Immunofluorescence images showing the expression of IL6R and IL11RA in hepatic stellate cells and activated THP-1 cells (scale bar = 100 μm). (E) Immunofluorescence images (scale bar = 100 μm) and (F) Western blots of ACTA2 are shown for hepatic stellate cells incubated without stimulation (-) or stimulated with TGFβ1, PDGF, or IL-11. (G) Immunofluorescence images (scale bar = 100 μm) of type I collagen staining in hepatic stellate cells stimulated with TGFβ1, PDGF, or IL-11, and (H) collagen secretion into the supernatant of these cells. (I) Dose-dependent invasion of IL-11-induced hepatic stellate cells into Matrigel. (J) ELISA showing hyperIL-11-induced secretion of IL-11 protein from hepatic stellate cells. (A-C, E-H, J) TGFβ1 (5 ng / ml), hyperIL-11 (0.2 ng / ml), PDGF (20 ng / ml), IL-11 (5 ng / ml); 24 hours; (I) 48 hours. (K) Schematic diagram showing the experimental procedure in which mice were injected daily with saline (control) or rmIL-11 (100 μg / kg). (L-N) Data obtained by injection of rmIl-11 in the experiment shown in Figure 17K (n≧7 / group) are shown. (L) Relative hydroxyproline content in the liver, (M) mRNA expression of profibrotic and proinflammatory markers in the liver, and (N) serum ALT levels are shown. (A, B, H-J, L, N) Data are shown as mean ± SD. (C, M) Boxplots show the median (center line), 25th to 75th percentiles (boxes), and range from lowest to highest percentile (whiskers). (A-C, J, L-N) Two-tailed Student's t-test; (H-I) Two-tailed Dunnett's test. FC: fold change; I / A: intensity per unit area.
[0388] [Figures 18A-18N] Il11ra1-deficient mice are protected from NASH-induced liver lesions, hyperlipidemia, and hyperglycemia. (A) Western blots of Il-11, Gapdh, p-Erk, and Erk in the livers of mice fed an HFMCD diet for 1, 4, 6, or 10 weeks. (B) Representative Masson's Trichrome stained images of livers (scale bar = 100 μm) from Il11ra+ / + (WT) or Il11ra- / - (KO) mice fed an HFMCD diet for 10 weeks. (C) Liver triglyceride levels, (D) serum ALT levels, and (E) mRNA expression levels of pro-inflammatory markers in the liver are shown (n ≥ 5 / group). (F-N) Data from WT and KO mice fed a fructose-supplemented Western diet (WDF) for 16 weeks are shown. (F) Western blots of Il-11 and Gapdh in the liver. (G) Relative expression levels of pro-inflammatory marker mRNA in the liver, (H) serum ALT levels, and (I) relative hydroxyproline content in the liver (n ≥ 4 / group). (J) Representative images of Masson's trichrome stained livers (scale bar = 100 μm). (K) Western blots showing Erk activation status in the liver, (L) fasting blood glucose levels, (M) serum triglyceride levels, and (N) serum cholesterol levels (n ≥ 3 / group). (C-E, G-I) Data are shown as box-and-whisker plots showing the median (center line), 25th-75th percentiles (boxes), and range from lowest to highest percentile (whiskers). (L-N) Data are shown as mean ± SD. The dotted line indicates the mean value for WT mice fed a normal chow diet (NC). Student's t-test with Sidak's correction. FC: fold change; NC: normal chow; HFMCD: high-fat methionine-choline-deficient diet; WDF: Western diet plus 15% (w / v) fructose.
[0389] [Figures 19A-19J]We demonstrate that anti-IL-11 therapy inhibits hepatic stellate cell (HSC) myofibroblast transformation in an ERK-dependent manner and has a favorable metabolic safety profile. (A) Dose-response curves and IC50 values for X203 and X209 (61 pg / ml to 4 μg / ml; 4-fold dilutions) in inhibiting MMP2 secretion by TGFβ1-stimulated hepatic stellate cells are shown. (B) ELISA results measuring IL-11 secretion from hepatic stellate cells stimulated with various NASH factors (≥5 / group). (C) Representative fluorescence images and quantification of ACTA2-positive cells in hepatic stellate cells treated with TGFβ1 or other NASH factors in the presence of IgG, X203, or X209 (scale bar 100 μm, dotted line indicates median baseline). (D) The effect of X203 or X209 on PDGF- or CCL2-induced hepatic stellate cell invasion are shown. (E) Western blots of p-ERK and ERK in lysates of hepatic stellate cells stimulated with IL-11 (top panel) and various NASH factors in the presence of IgG or X209 (bottom panel). (F) Representative fluorescent images and quantification of ACTA2-positive cells in hepatic stellate cells treated with IL-11 or key NASH factors in the presence of ERK / MEK inhibitors U0126 or PD98059 (scale bar 100 μm, dotted line indicates median baseline). (A-F) TGFβ1 (5 ng / ml), IL-11 (5 ng / ml), PDGF (20 ng / ml), Ang II (100 nM), bFGF (10 ng / ml), CCL2 (5 ng / ml), HO (0.2 mM), IgG, X203 and X209 (2 μg / ml), U0126, or PD98059 (10 μM); (A, C, E-F) 24 h; (B, D) 48 h. (G) Peripheral blood platelet count, (H) serum ALT level, (I) serum triglyceride level, and (J) serum cholesterol level are shown in mice (≥5 / group) receiving twice-weekly injections of 10 mg / kg X203 or X209 for 5 months. (B, D) Data are shown as mean ± SD.(C, F, G-J) Data are shown as boxplots showing the median (center line), 25th-75th percentiles (boxes), and range from lowest to highest percentile (whiskers). (B, D, G-J) Two-tailed Dunnett's test; (C, F) Two-tailed Student's t test with Tukey's correction. FC: fold change.
[0390] [Figures 20A-20N]We demonstrate that therapeutic targeting of IL-11 suppresses and reverses NASH pathology in preclinical models. (A) Schematic diagram showing the treatment procedure for mice fed an HFMCD diet with X203 or X209 (10 mg / kg, twice weekly) for the experiments shown in (B-E). X203, X209, or an IgG isotype control were administered at weeks 6-10 of the HFMCD diet. (B) Representative liver histological images (Masson's trichrome staining; scale bar = 100 μm), (C) relative hydroxyproline content in the liver, (D) relative mRNA expression levels of pro-inflammatory markers in the liver (≥6 / group), and (E) serum ALT levels. (F) Western blot showing Erk activation status in the liver. (G) Schematic diagram showing the administration of X203 or IgG to db / db mice fed an MCD diet for the experiments shown in H-N. Western blots for (H) Il-11 and Gapdh and (I) p-Erk and Erk in liver are shown. (J) Representative Masson's trichrome staining images of livers from db / db mice fed an MCD diet and treated with X203 or IgG (scale bar = 100 μm). (K) Liver triglyceride levels, (L) relative liver hydroxyproline expression levels, (M) serum ALT levels, and (N) liver mRNA expression levels of pro-inflammatory markers (≥5 / group). (C-E, K-N) Data are shown as boxplots showing the median (midline), 25th-75th percentiles (boxes), and ranges from lowest to highest percentiles (whiskers); two-tailed Student's t-test with Tukey's correction. FC: fold change; NC: normal chow; HFMCD: high-fat, methionine-choline-deficient diet; MCD: methionine-choline-deficient diet.
[0391] [Figures 21A-21L]We demonstrate that inhibition of IL-11 signaling ameliorates NASH pathology in a preclinical model and reverses the transformation of hepatic stellate cells into myofibroblasts. (A) Schematic diagram showing the treatment regimen used in the NASH reversal experiment to obtain the data shown in (B-G). Mice were fed a WDF diet for 16 weeks to induce NASH, and then treated with X209 (10 mg / kg) or IgG for 8 weeks while continuing to feed on the WDF diet. (B) Total hydroxyproline content in liver, (C) liver triglyceride levels, (D) serum ALT levels, (E) fasting blood glucose levels, (F) serum triglyceride levels, and (G) serum cholesterol levels in mice fed a NC diet or mice fed a WDF diet and treated with IgG or X209 (≥5 / group) are shown. (H) Schematic diagram showing the recovery experiment procedure. Mice were fed an HFMCD diet for 10 weeks to establish fibrosis, then switched to a NC diet and treated with antibodies (X203 or X209). Mice were euthanized at the indicated time points. (I) Total hydroxyproline content in the liver (dotted line indicates the mean value for NC = 0.93) and (J) relative Mmp2 / Timp1 mRNA expression are shown for groups of ≥3 mice per group at weeks 1, 3, or 6 after metabolic intervention (diet switching) and treatment with X203, X209, or IgG. Quantification of immunostaining of ACTA2-positive cells is shown (n = 5 per group) after incubation with (K) TGFβ1 or (L) PDGF before or after the addition of X203, X209, or IgG (scale bar = 200 μm). (K-L) TGFβ1 (5 ng / ml), PDGF (20 ng / ml), IgG, X203, and X209 (2 μg / ml). (B-G, K-L) Data are shown as boxplots showing the median (center line), 25th-75th percentiles (boxes), and range from lowest to highest percentile (whiskers). (I) Data are shown as mean ± SD. (J) Data are shown as line graphs (mean values), with shaded areas indicating SD. (B) Two-tailed Student's t-test; (C-G, K-L) Two-tailed Student's t-test with Tukey's correction; (I-J) Two-way ANOVA.FC: fold change; NC: normal chow; WDF: Western diet + 15% (w / v) fructose; HFMCD: high-fat methionine-choline-deficient diet.
[0392] [Figures 22A-22K]Neutralization of IL-11 signaling reverses liver injury in early NASH. (A) The graph shows the relative mRNA expression levels of fibrotic and inflammatory markers in the livers of mice fed a NC or HFMCD diet until the indicated time points. (B) A schematic diagram showing the procedure for early anti-IL-11 therapy in the HFMCD diet-induced NASH model. Antibody treatment began 1 week after the start of NASH-inducing diet feeding, and X209, X203, or IgG (10 mg / kg, twice weekly) was administered intraperitoneally for 5 weeks. (C-G) Data from the experiment shown in Figure 21B are shown. (C) Representative macroscopic photographs of livers and (D) Masson's trichrome stained images of livers (scale bar = 100 μm) are shown after 5 weeks of treatment with IgG or X209. (E) Liver triglyceride levels (n ≥ 5 / group), (F) liver hydroxyproline content (n ≥ 5 / group), and (G) serum ALT levels (n ≥ 5 / group) are shown for mice treated with X209 or IgG. (H) Immunofluorescence images showing IL6R and IL11RA expression in hepatocytes (scale bar = 100 μm). (I) The dose-dependent effect of IL-11 on ALT in hepatocyte supernatants and (J) the dose-dependent effect of IL-11 on stress fiber formation in hepatocytes (rhodamine phalloidin staining) (scale bar = 200 μm) are shown. (K) IL-11 protein secretion from human primary hepatocytes stimulated with TGFβ1 (5 ng / ml) (24 h). (E) Data are shown as box-and-whisker plots showing the median (center line), 25th–75th percentiles (box), and range from lowest to highest percentile (whiskers). (F–G, I, K) Data are shown as mean ± SD. (E) Two-tailed Student's t-test with Tukey's correction; (F, G) Two-way ANOVA; (I, K) Two-tailed Dunnett's test. FC: fold change; NC: normal chow; HFMCD: high-fat, methionine-choline-deficient diet.
[0393] [Figures 23A-23G]Anti-IL11RA therapy reverses the NASH molecular signature to a normal liver profile while suppressing immune cell activation. (A-G) Data from the experiment shown in Figure 22B are shown. (A) Principal component analysis (PCA) plots of gene expression in the liver of mice fed either a NC or HFMCD diet and treated with IgG, X203, or X209 antibodies for the time periods shown in Figure 6B. Arrows indicate the transition from normal gene expression (NC diet) to the most perturbed gene expression in NASH (HFMCD diet + IgG); the transition from this most perturbed gene expression to the intermediate reverted gene expression (HFMCD diet + antibody (3 weeks)); and the transition from the intermediate reverted gene expression to normalized gene expression (HFMCD diet + antibody (6 weeks)). (B) Heatmaps of profibrotic and proinflammatory gene expression (assessed by transcripts per million (TPM)). (C) Expression levels of TNFα, Ccl2, and Ccl5 mRNA measured by qPCR (n ≥ 5 / group). (D) Representative pseudocolor plots showing the number of CD45+ immune cells in the liver, (E) Ly6C+TGFβ1+ cells in the overall CD45+ population, and (F) the gating method used to detect Ly6C+TGFβ1+ cells (n ≥ 4 / group). (G) Serum TGFβ levels (n ≥ 5 / group). (C-E, G) Data are shown as box-and-whisker plots showing the median (midline), 25th-75th percentiles (boxes), and range from lowest to highest percentile (whiskers). (C, G) Two-tailed Student's t-test with Tukey's correction; (D, E) Two-tailed Student's t-test. FC: fold change; NC: normal chow; HFMCD: high-fat, methionine-choline-deficient diet.
[0394] [Figures 24A-24K]Hepatic stellate cells secrete IL-11 and respond to IL-11, demonstrating that IL-11 injection in mice leads to liver fibrosis. (A) Genome-wide changes in RNA expression in hepatic stellate cells after stimulation with TGFβ1 (n=3, RNA-seq). (B) Stiffness-induced RNA upregulation in human hepatic stellate cells (RNA-seq14). Genes were ranked according to FPKM (fragments per kilobase million). Of the genome-wide upregulated genes, IL-11 upregulation was the most significant. (C) IL11RA transcripts in human cardiac fibroblasts (HCF), human lung fibroblasts (HLF), and human hepatic stellate cells (HSC) are shown. (D) Western blot and (E) densitometric measurements of IL-11 and GAPDH in human liver samples from healthy controls, patients with alcoholic liver disease (ALD), patients with primary sclerosing cholangitis (PSC), patients with primary biliary cirrhosis (PBC), or patients with nonalcoholic steatohepatitis (NASH). (F) Autofluorescence quantification of ACTA2-positive cells and (G) immunostaining for type I collagen in liver samples incubated without stimulation (-) or with stimulation with TGFβ1, PDGF, or IL-11. (H) ELISA measurement of MMP-2 concentration in the supernatant of hepatic stellate cells without stimulation (-) or with stimulation with TGFβ1 or IL-11. (A, F-H) TGFβ1 and IL-11 (5 ng / ml), PDGF (20 ng / ml); 24-hour stimulation. (I) Representative images of Masson's trichrome staining of liver sections from mice injected with saline or rmIl-11 (scale bar = 100 μm) and (J) the quantification. (K) Schematic diagram showing the experimental procedure for obtaining GFP-positive cells by daily injection of rmIl-11 or saline into Col1a1-GFP mice, along with representative fluorescent images of the resulting GFP-positive cells. Each section was immunostained for Acta2 and counterstained with DAPI (scale bar = 200 μm).(C, F-G) Data are shown as boxplots showing the median (midline), 25th-75th percentiles (boxes), and range from lowest to highest percentile (whiskers). (E, H, J) Data are shown as mean ± sd. (F-H) Two-tailed Dunnett's test; (J) Two-tailed Student's t-test. FC: fold change; TPM: transcripts per millions.
[0395] [Figures 25A-25I]We demonstrate that genetic suppression of Il-11 signaling protects mice from the pathology of NASH induced by an HFMCD diet. The effects of 16 weeks of HFMCD diet feeding on (A) Il-11 mRNA and (B) Il-11 protein levels in the liver were compared with those on an NC diet. (A-B) RNA and protein were extracted from the same mice (n = 5 / group). (C) Relative hydroxyproline content in the liver and (D) serum ALT levels are shown for mice (n ≥ 5 / group) fed an NC or HFMCD diet for 1, 4, 6, or 10 weeks. (E-I) Data from Il11ra+ / + (WT) or Il11ra- / - (KO) mice fed an HFMCD diet for 10 weeks are shown. (E) Relative hydroxyproline content in the liver, as well as (F) representative images of Masson's trichrome staining of the liver (scale bar = 100 μm) and (G) its quantification are shown. (H) Relative expression levels of Acta2, Col1a1, Col1a2, and Col3a1 mRNA in the liver (n ≥ 5 / group). (I) Western blot analysis of phosphorylated and total Erk levels after 10 weeks of NC or HFMCD diet feeding. (A, E, H) Data are shown as box-and-whisker plots, showing the median (center line), 25th–75th percentiles (boxes), and range from lowest to highest percentile (whiskers). (C–D, G) Data are shown as mean ± SD. (A, G) Two-tailed Student's t-test; (C–D) Two-way ANOVA; (E, H) Student's t-test with Sidak's correction. (C) Values for mice fed NC or HFMCD diets for 6 weeks are the same as those used in Figure 20C. Values for mice fed NC or HFMCD diets for 1 week are the same as those used in Figure 22F. (D) The values for mice fed the HFMCD diet for 6 weeks are the same as those used in Figure 20D, and the values for mice fed the NC or HFMCD diet for 1 week are the same as those used in Figure 22G. FC: fold change; NC: normal chow; HFMCD: high-fat, methionine-choline-deficient diet.
[0396] [Figures 26A-26E]We demonstrate that genetic suppression of Il-11 signaling protects mice from the pathology of NASH induced by a WDF diet. (A) The effect of feeding a WDF diet for 16 weeks on body weight in Il11ra+ / + (WT) and Il11ra- / - (KO) mice (n ≥ 6 / group) is shown. (B) Liver triglyceride levels, (C) Representative images of Masson's trichrome staining of liver (scale bar = 100 μm) and (D) quantification, and (E) relative mRNA expression levels of pro-fibrotic genes in livers are shown in WT or KO mice (n ≥ 5 / group) fed a NC or WDF diet for 16 weeks. (A, D) Data are shown as mean ± SD; two-tailed Student's t-test; (B, E) Data are shown as boxplots showing the median (midline), 25th–75th percentiles (boxes), and range from lowest to highest percentile (whiskers); Student's t-test with Sidak's correction. FC: fold change; NC: normal chow; WDF: Western diet + 15% (w / v) fructose.
[0397] [Figures 27A-27F]Construction of anti-IL-11RA monoclonal neutralizing antibodies. (A) Purified mouse monoclonal anti-IL11RA antibody candidates (6 μg / ml) inhibited the transformation of TGFβ1-stimulated human atrial fibroblasts (top panel), hyperIL-11-stimulated human atrial fibroblasts (middle panel), or TGFβ1-stimulated mouse atrial fibroblasts (bottom panel) into ACTA2-positive cells. (B) Interaction of X209 with IL11RA measured by surface plasmon resonance (SPR) (Langmuir-type 1:1 binding model). (C) Pharmacokinetics of 125I-X209 in the blood of mice (n = 5). Results were fit to a two-component exponential decay model (R2 = 0.92). (D) Percent liver uptake of 125I-X209 measured at the indicated time points after retroorbital injection (n = 5). (E–F) Representative immunofluorescence images (scale bar = 100 μm) and their quantification of type I collagen in hepatic stellate cells treated with various NASH factors in the presence of (E) IgG control, X203, or X209, or (F) MEK / ERK inhibitors (U0126 or PD98059). (A, E–F) TGFβ1 (5 ng / ml), IL-11 (5 ng / ml), PDGF (20 ng / ml), Ang II (100 nM), bFGF (10 ng / ml), CCL2 (5 ng / ml), HO (0.2 mM), IgG, X203, and X209 (2 μg / ml), U0126, or PD98059 (10 μM); 24 h of stimulation. (C-D) Data are shown as mean ± SD; (E-F) Data are shown as boxplots showing the median (center line), 25th-75th percentiles (boxes), and range from lowest to highest percentile (whiskers); dotted lines indicate mean baseline values; Student's t-test with Tukey's correction. FC: fold change; I / A: intensity per unit area.
[0398] [Figures 28A-28F]This shows that NASH pathology induced by an HFMCD or WDF diet is suppressed by anti-IL-11 and anti-IL11RA neutralizing antibodies. (A-D) Data from HFMCD-fed mice treated with X203 or X209 according to the experimental procedure described in Figure 20A are shown. (A) Quantitative analysis of Masson's trichrome staining of liver sections is shown (the dotted line indicates the mean value for mice fed an NC diet). (B) Relative expression levels of fibrosis gene mRNA in the liver and (C) triglyceride content in the liver are shown (n≧5 / group). (D) Western blot analysis showing ERK activation in the liver of mice fed an NC diet or mice fed an HFMCD diet and treated with IgG or X203 (10 mg / kg, twice a week). (E) Quantitative analysis of Masson's trichrome staining of liver sections is shown. The dotted line indicates the mean value for fatty liver in 12-week-old db / db mice (see Figure 20G). (F) Schematic diagram of the experimental procedure (Figure 20G) shows the relative expression levels of profibrotic gene mRNA in the liver of db / db steatotic mice fed an MCD diet after injection of IgG or X203 (n ≥ 5 / group). (A, E) Data are shown as mean ± SD; (B-C, F) Data are shown as box-and-whisker plots showing the median (center line), 25th-75th percentiles (boxes), and range from lowest to highest percentile (whiskers). (A-C, E-F) Two-tailed Student's t-test with Tukey's correction. FC: fold change; NC: normal chow; HFMCD: high-fat methionine-choline-deficient diet; MCD: methionine-choline-deficient diet.
[0399] [Figures 29A-29E]These results demonstrate that anti-IL11RA neutralizing antibody therapy reverses NASH pathology induced by a WDF diet. (A-E) Experimental data from WDF-fed mice were treated with an anti-IL-11RA antibody, according to a schematic diagram illustrating the experimental procedure (Figure 21A). WDF-fed mice were treated with IgG or X209 (10 mg / kg) twice weekly starting at week 16 and continuing for 8 weeks until sacrifice (week 24). (A) Western blot analysis of p-Erk and Erk in the liver of mice fed a NC or WDF diet for 24 weeks. (B) Body weights measured every other month (n≧4 / group). (C) Representative images (scale bar = 100 μm) of Masson's trichrome staining of livers from mice fed a WDF diet for 16 weeks (left), mice fed a WDF diet for 24 weeks and injected with IgG from weeks 16 to 24 (center), and mice fed a WDF diet for 24 weeks and treated with X209 from weeks 16 to 24 (right) are shown, along with (D) the quantification. The dotted line indicates the mean value for mice fed a NC diet. (E) Relative mRNA expression levels of pro-inflammatory genes in the liver are shown (n ≥ 5 / group). (B, D) Data are shown as mean ± SD; (E) Data are shown as box-and-whisker plots showing the median (center line), 25th to 75th percentiles (box), and range from lowest to highest percentile (whiskers). (D, E) Two-tailed Student's t-test with Tukey's correction.
[0400] [Figures 30A-30G]We demonstrate that anti-IL-11 or anti-IL11RA neutralizing antibodies can reverse HFMCD diet-induced liver fibrosis and hepatic stellate cell transformation to myofibroblasts. (A-D) Data from Figure 5G (HFMCD diet-induced liver fibrosis recovery experiment) are shown. Mice were treated with IgG, X203, or X209 for 1, 3, or 6 weeks. (A) Western blot showing the activation status of ERK in the liver. (B) Representative images (scale bar = 100 μm) of Masson's trichrome staining of livers from mice treated with IgG, X203, or X209 for 6 weeks, and (C) its quantification. (D-G) Data from the hepatic stellate cell transformation recovery experiment shown in Figures 21K-21L are shown (TGFβ1 (5 ng / ml), PDGF (20 ng / ml), IgG, X203, and X209 (2 μg / ml)). (D) Representative immunofluorescence images of ACTA2-positive cells incubated with TGFβ1 or PDGF before or after the addition of X203, X209, or IgG (scale bar = 200 μm). The amount of collagen secreted by hepatic stellate cells stimulated with (E) TGFβ1 or (F) PDGF before or after the addition of IgG, X203, or X209 is shown (n = 5 per group). (G) Western blots showing the ERK activation status of TGFβ1-treated hepatic stellate cells after treatment with X203 or X209. (C) Data are shown as mean ± SD; (E-F) Data are shown as box-and-whisker plots showing the median (center line), 25th-75th percentiles (box), and range from lowest to highest percentile (whiskers). (C, E-F) Two-tailed Student's t-test with Tukey's correction. FC: fold change; NC: normal chow; HFMCD: high-fat methionine-choline deficient diet.
[0401] [Figures 31A-31H]These results demonstrate that anti-IL-11 and anti-IL11RA neutralizing antibodies protect HFMCD-fed mice from liver fibrosis and inflammation. (A) ELISA results for CCL2 in supernatants of hepatic stellate cells (n = 4 / group) were obtained after unstimulated (-), IL-11-stimulated (5 ng / ml), or TGFβ1-stimulated (2 μg / ml) in the presence of IgG, X203, or X209. (B-I) Data from the therapeutic treatment experiment shown in Figure 22B are shown. (B) Representative macroscopic photographs of livers, (C) Western blots showing the activation status of ERK in livers, and (D) representative images of Masson's trichrome staining of livers (scale bar = 100 μm) and (E) quantification of ERK activation after 5 weeks of early treatment with X203 or X209. (F) Hydroxyproline content in liver (values for mice fed NC or HFMCD diets for 1 week are the same as those used in Figure 25C, and values for IgG-treated mice at 3 or 6 weeks are the same as those used in Figure 22F (n ≥ 5 / group)). (G) Relative expression levels of fibrosis marker RNA in liver after 5 weeks of treatment with X203 or X209 were measured by qPCR, confirming the RNA-seq data (values for Col1a1, Col1a2, Col3a1, and Acta2 in mice fed NC diets for 6 weeks are the same as those used in Figure 28D (n ≥ 5 / group)). (H) Serum ALT levels (values for mice fed NC or HFMCD diets for 1 week are the same as those used in Figure 25D, and values for IgG-treated mice at 3 or 6 weeks (2 or 5 weeks of treatment, respectively) are the same as those used in Figure 22G (n ≥ 5 / group)). (A, E–F, H) Data are shown as mean ± SD; (G) Data are shown as boxplots showing the median (center line), 25th–75th percentiles (boxes), and range from lowest to highest percentile (whiskers). (A, E, G) Two-tailed Student's t test with Tukey's correction; (F, H) Two-way ANOVA. FC: fold change; NC: normal chow; HFMCD: high-fat, methionine-choline-deficient diet.
[0402] [Figures 32A-32D] This shows that anti-IL-11 or anti-IL11RA neutralizing antibodies restore the NASH molecular signature to a normal liver profile. (A-D) Data from RNA-seq and gene set enrichment analyses of the early therapeutic treatment experiment shown in Figure 22A are shown (n=3 / group). (A-B) Heat maps of gene expression levels (assessed by reads mapped as transcripts per million (TPM)) for all genes that were statistically significantly differently expressed between IgG and (A) X209 treatment, or between IgG and (B) X203 treatment in each sample. Clustering analysis of the expression profile of the anti-IL-11 treatment group revealed a similar expression pattern to that of the NC diet group, suggesting a near-complete recovery from the transcriptional effects of the HFMCD diet. (C) Heatmaps of lipogenesis and β-oxidation gene expression showed that X209 improved hepatic lipid metabolism compared with IgG, and X203 improved hepatic lipid metabolism even more than X209. (D) Bubble maps showing the results of gene set enrichment analysis (GSEA) of differentially expressed genes at week 6 after antibody treatment with either the NC or HFMCD diet. Each dot represents the normalized enrichment score (NES) of each gene set, color-coded, and its magnitude indicates its significance level, corrected by FDR. Gene sets for enrichment analysis were selected from the "H (Hallmark)" set published in MSigDB. FC: fold change; NC: normal chow; HFMCD: high-fat, methionine-choline-deficient diet.
[0403] [Figures 33A-33K]Scatter plots, boxplots, histograms, and photographs of IL-11 receptor and IL-6 receptor expression and the effects of IL-11 and IL-6 signaling in human primary hepatocytes. (A) Representative flow cytometry forward scatter (FSC) and fluorescence intensity plots of hepatocytes stained for IL11RA, IL6R, and gp130. (B) The abundance of IL11RA1 and IL6R reads (transcripts per million (TPM)) in basal hepatocytes based on RNA-seq (left) and Ribo-seq (right) analyses. (C and D) Read coverage of (C) IL11RA1 transcripts and (D) IL6R transcripts based on RNA-seq and Ribo-seq analyses of human hepatocytes (n=3). (E and F) Western blots showing the activation status of ERK, JNK, and STAT3 in hepatocytes stimulated with a dose range of hyperIL11 or hyperIL6 (E), and the secretion of ALT (F). (G) ALT levels in the supernatants of hepatocytes stimulated with hyperIL11 alone or in the presence of increasing amounts of soluble gp130 (sgp130). (H and I) Western blots of hepatocyte lysates showing the expression levels of phosphorylated ERK and phosphorylated JNK, as well as total ERK and JNK, in response to stimulation with hyperIL11 alone or in the presence of sgp130 (H). (I) Western blots of hepatocyte lysates showing the expression levels of phosphorylated STAT3 and total STAT3 in response to stimulation with hyperIL6 in the presence or absence of sgp130. (J) Representative FSC plots of propidium iodide (PI) staining of hepatocytes stimulated with IL11 in the presence of sgp130 or soluble IL11RA (sIL11RA). (K) Western blots showing the expression levels of p-ERK and p-JNK, as well as total ERK and JNK, in hepatocytes in response to stimulation with IL11 alone or in the presence of sgp130 or sIL11RA.(A-K) Human primary hepatocytes; (E-K) 24-hour stimulation; (E-K) hyper IL11, hyper IL6, IL11 (20 ng / ml), sgp130, sIL11RA (1 μg / ml). (B, F-G) Data are shown as boxplots showing the median (center line), 25th-75th percentiles (boxes), and minimum-maximum range (whiskers).
[0404] [Figures 34A-34K] Graphs, scatter plots, and images show that lipid-loaded hepatocytes secrete IL11 and induce various lipotoxic phenotypes through autocrine IL11 cis-signaling. (A-K) Data from palmitate-loaded human primary hepatocytes in the presence of IgG (2 μg / ml), anti-IL11RA (X209, 2 μg / ml), or sgp130 (1 μg / ml). The concentrations of (A) IL11, (B) IL6, (C) CCL2, and (D) CCL5 proteins secreted into the supernatant were measured by ELISA. (E and F) Representative FSC plots and quantification of PI-positive hepatocytes stimulated with palmitate are shown. (G) ALT concentration in the supernatant is shown. (H) Glutathione (GSH) concentration in hepatocytes is shown. (I) Representative fluorescent image of DCFDA staining (detection of ROS; scale bar = 100 μm). (J) Western blot analysis of pERK, ERk, pJNK, JNK, cleaved caspase-3, caspase-3, NOX4, FASN, and GAPDH. (K) Representative images of Oil Red O staining (scale bar = 100 μm). (A-D, F-H) Mean ± SD; Student's t test with Tukey's correction.
[0405] [Figures 35A-35P]Schematic diagram, images, and boxplots show that suppression of IL6 family cytokine trans-signaling in mice fed a fructose-supplemented Western diet had no effect on NASH or metabolic phenotypes. (A) Schematic diagram of the experiment in which mice expressing sgp130 specifically in hepatocytes were fed a WDF diet to obtain the data shown in (B–P). Three weeks after injection of AAV8-Alb-Null or AAV8-Alb-sgp130, mice were fed a WDF diet for 16 weeks. (B) Western blots showing liver sgp130, IL11, and IL6 concentrations, as well as GAPDH concentrations as an internal control. (C) Serum IL11 levels. (D) Serum IL6 levels. (E) Representative liver macroscopic photographs and H&E staining images. (F) Liver weight. (G) Liver triglyceride content. (H) Serum ALT levels. (I) Serum AST levels. (J) Collagen concentration in the liver. (K) Fasting blood glucose level. (L) Serum triglyceride level. (M) Serum cholesterol level. (N) GSH content in the liver. (O) Heat map showing the expression of pro-inflammatory and pro-fibrotic genes in the liver (values are shown in Figures 41D and 41E). (P) Western blot of p-ERK, ERK, p-JNK, JNK, p-STAT3, and STAT3 in the liver. (C-N) Data are shown as boxplots showing the median (center line), 25th-75th percentiles (boxes), and minimum-maximum range (whiskers); Student's t-test with Tukey's correction; conditions, from left to right, are NC Null, WDF Null, and WDF sgp130.
[0406] [Figures 36A-36K]Schematic diagrams, images, graphs, and boxplots are shown, demonstrating that hepatocyte-specific suppression of IL11 cis-signaling protects mice from cachexia and NASH in HFMCD-fed mice. (A) Schematic diagram showing the experimental design for the experiments shown in (B-K) in Il11ra1loxP / loxP (conditional knockout; CKO) mice injected with AAV8-Alb-Cre and fed an HFMCD diet. Three weeks before the start of HFMCD-fed feeding, Il11ra1loxP / loxP mice were intravenously injected with AAV8-Alb-Null or AAV8-Alb-Cre to specifically omit Il11ra1 in hepatocytes. (B) Western blots of IL11RA and GAPDH in the liver. (C) Body weight (expressed as a percentage of initial body weight). (D) Representative macroscopic and H&E-stained liver images. (E) Triglyceride content in the liver. (F) Serum ALT levels. (G) Serum AST levels. (H) Liver GSH content. (I) Liver collagen concentration. (J) Heatmap showing mRNA expression of pro-inflammatory markers (TNFα, Ccl2, Ccl5) and fibrotic markers (Col1a1, Col1a2, Col3a1, Acta2) in the liver. Values are shown in Figures 43A and 43B. (K) Western blot showing ERK and JNK activation status in the liver. (C) Data are presented as mean ± SEM and were analyzed by two-way ANOVA with Tukey's multiple comparison test. Statistical significance is shown as P values between HFMCD WT and HFMCD CKO; (E-I) Data are shown as boxplots showing the median (center line), 25th–75th percentiles (boxes), and minimum–maximum range (whiskers); Student's t test with Sidak's correction; conditions, from left to right, are NC WT, NC CKO, HFMCD WT, and HFMCD CKO.
[0407] [Figures 37A-37M]Schematic diagrams, images, graphs, and boxplots show that hepatocyte-specific inhibition of IL11 cis-signaling protects mice from obesity and NASH induced by a WDF diet. (A) Schematic diagram showing the experiment to generate control and CKO mice fed a WDF diet to obtain the data shown in (B-M). Three weeks after injection of AAV8-Alb-Null or AAV8-Alb-Cre virus into CKO mice, they were fed a WDF diet for 16 weeks. (B) Western blots showing IL11RA and GAPDH concentrations in the liver. (C) Body weight (expressed as a percentage of initial body weight). (D) Fat mass. (E) Representative macroscopic and H&E-stained liver images. (F) Triglyceride content in the liver. (G) Liver weight. (H) Serum ALT level. (I) Serum AST level. (J) GSH content in the liver. (K) Collagen concentration in the liver. (L) Heatmap showing the expression of pro-inflammatory and pro-fibrotic genes in the liver (values are shown in Figures 44A and 44B). (M) Western blot showing the activation status of ERK and JNK in the liver. (C and D) Data are shown as mean ± SEM and were subjected to two-way ANOVA with Tukey's multiple comparison test. Statistical significance is indicated as P values between WDF WT and WDF CKO. (F-K) Data are shown as boxplots showing the median (center line), 25th-75th percentiles (boxes), and minimum-maximum range (whiskers). Student's t-test with Sidak's correction. Conditions, from left to right, are NC WT, NC CKO, WDF WT, and WDF CKO.
[0408] [Figures 38A-38N]Schematic diagram, images, and boxplots showing that hepatocyte-specific IL11 cis-signaling, but not trans-signaling, induces steatohepatitis in mice fed a WDF diet. (A) Schematic diagram showing the experimental design for the experiments shown in (B-N) in Il11ra1+ / + (WT) and Il11ra1- / - (KO) mice fed a WDF diet. KO mice were injected with AAV8-Alb-Null, AAV8-Alb-mbIl11ra1 (full-length membrane-bound Il11ra1), or AAV8-Alb-sIl11ra1 (soluble form of Il11ra1) and fed a WDF diet for 16 weeks, starting 3 weeks after viral administration. (B) Western blots showing the concentrations of IL11RA and GAPDH in the liver. (C) Representative macroscopic photographs and H&E stained images of livers. (D) Liver weight. (E) Liver triglyceride content. (F) Serum ALT level. (G) Serum AST level. (H) Liver GSH content. (I) Liver collagen content. (J) Heat map showing the expression of pro-inflammatory and fibrotic genes in the liver (values are shown in Figures 45C and 45D). (K) Western blot showing the activation status of ERK and JNK in the liver. (L) Fasting blood glucose level. (M) Serum triglyceride level. (N) Serum cholesterol level. (D-I, L-N) Data are presented as box plots showing the median (center line), 25th-75th percentile (box), and minimum-maximum range (whiskers); Student's t-test with Tukey's correction. The conditions, from left to right, are NC Null WT, WDF Null WT, WDF Null KO, WDF mbIl11ra1 KO, and WDF sIl11ra1 KO.
[0409] [Figure 39]A schematic diagram of the proposed IL11 signaling mechanism in NASH is shown here. Excessive lipid accumulation in hepatocytes leads to lipotoxicity, generating reactive oxygen species and inducing the translation and secretion of IL11 protein. IL11 binds to IL11RA and gp130 on hepatocytes, autocrinely initiating the activation of ERK, JNK, and caspase 3, leading to lipoapoptosis. IL11 also acts paracrinely to transform quiescent hepatic stellate cells (HSCs) into activated myofibroblasts. Cytokines and chemokines released from lipotoxic hepatocytes and HSCs induce immune cell activation and recruitment, leading to inflammation. Therefore, autocrine IL11 cis-signaling in hepatocytes is a key initiating event in the pathogenesis of all NASH diseases.
[0410] [Figures 40A-40I]Scatter plots, boxplots, histograms, photographs, and graphs are shown for the expression of IL-11 receptor and IL-6 receptor in human primary hepatocytes and the effects of IL-11 signaling and IL-6 signaling. (A) Representative FSC plots of IL11RA, IL6R, and gp130 staining in activated THP-1 cells. (B) The transcript expression levels (transcripts per million (TPM)) of gp130 in human primary hepatocytes based on RNA-seq and Ribo-seq analysis are shown. (C) Read coverage of gp130 transcripts based on RNA-seq and Ribo-seq analysis of human primary hepatocytes (n=3). (D) Immunofluorescence images showing the expression of IL11RA, IL6R, gp130, and albumin in human primary hepatocytes and activated THP-1 cells (scale bar = 100 μm). (E) Basal soluble IL6R concentration in hepatocyte culture medium. (F) Quantification of PI staining of human primary hepatocytes (PI-positive cells) stimulated with IL11 in the presence of sgp130 or sIL11RA. (G) Dose-dependent effect of IL11 on the concentration of ALT secreted by human primary hepatocytes in the presence of increasing concentrations of IL11 in the presence of 1 μg / ml of sgp130 or sIL11RA. (H) Dose-dependent effect of increasing concentrations of sgp130 or sIL11RA on IL11-induced ALT secretion. (I) Triglyceride levels in palmitate-stimulated hepatocytes in the presence of IgG (2 μg / ml), anti-IL11RA (X209, 2 μg / ml), or sgp130 (1 μg / ml). (B, G-H) Data are shown as box-and-whisker plots, showing the median (center line), 25th-75th percentiles (boxes), and minimum-maximum range (whiskers). (E-F, I) Data are shown as mean ± SEM. (F-I) Student's t test with Tukey's correction. (G) For each concentration of IL11, the following conditions are shown, from left to right: baseline, sgp130-added, and sIL11RA-added.(H) For IL11+sgp130 / IL11RA at each concentration, the conditions in which sgp130 was added and the conditions in which sIL11RA was added are shown from left to right, respectively.
[0411] [Figures 41A-41E] These are a diagram, boxplot, and graph showing that expression of sgp130 fails to protect mice from liver and obesity phenotypes induced by a WDF diet. (A) A schematic diagram showing the structure and amino acid positions of each domain of the gp130 protein (left) and the domains used to construct sgp130 in this study (right). (B-E) Data from an in vivo experiment using a WDF diet and sgp130, following the experimental procedure shown in Figure 35A, are shown. (B) Serum gp130 levels are shown in control mice fed an NC diet and in mice injected with AAV8-Alb-Null or AAV8-Alb-sgp130 and then fed a WDF diet. (C) The effect of feeding a WDF diet for 16 weeks on body weight in mice injected with AAV8-Alb-Null or AAV8-Alb-sgp130 is shown. Data are shown as mean ± SEM. (D and E) The mRNA expression levels of (D) pro-inflammatory markers (TNFα, Ccl2, Ccl5) and (E) fibrotic markers (Col1a1, Col1a2, Col3a1, Acta2) in the liver are shown in Figure 35O. (B, D-E) Data are shown as box-and-whisker plots showing the median (center line), 25th-75th percentiles (boxes), and minimum-maximum range (whiskers); Student's t-test with Tukey's correction. Conditions, from left to right, are NC Null, WDF Null, and WDF sgp130.
[0412] [Figures 42A-42N]Schematic diagram, images, and boxplots show that inhibition of putative IL6 family member trans-signaling pathways in mice fed an HFMCD diet had no effect on the NASH phenotype. (A) Schematic diagram of the experiment in which sgp130 was expressed in hepatocytes specifically in mice fed an HFMCD diet to obtain the data shown in (B–N). Mice were intravenously injected with AAV8-Alb-Null or AAV8-Alb-sgp130 and fed an HFMCD diet for 4 weeks. (B) Western blots showing the concentrations of sgp130, IL11, and IL6 in the liver, as well as GAPDH as an internal control. (C) Serum gp130 levels. (D) Serum IL11 levels. (E) Serum IL6 levels. (F) Representative macroscopic photographs and H&E stained images of livers. (G) Triglyceride content in the liver. (H) Serum ALT levels. (I) Serum AST levels. (J) GSH content in the liver. (K) Collagen concentration in the liver. (L and M) mRNA expression levels of (L) pro-inflammatory markers (TNFα, Ccl2, Ccl5) and (M) fibrotic markers (Col1a1, Col1a2, Col3a1, Acta2) in the liver. (N) Western blot analysis of p-ERK, ERK, p-JNK, JNK, p-STAT3, and STAT3 in the liver. (C-E, G-M) Data are shown as boxplots showing the median (center line), 25th-75th percentiles (boxes), and minimum-maximum range (whiskers); Student's t-test with Tukey's correction. Conditions, from left to right, are NC Null, HFMCD Null, and HFMCD sgp130.
[0413] [Figure 43A-43B]Box plots showing that hepatocyte-specific Il11ra1 deficiency protects mice from HFMCD diet-induced gene dysregulation. (A and B) mRNA expression levels of (A) pro-inflammatory markers (TNFα, Ccl2, Ccl5) and (B) fibrotic markers (Col1a1, Col1a2, Col3a1, Acta2) in the livers of control or CKO mice fed NC or HFMCD diets, as shown in Figure 36J. (A-B) Data are shown as box plots showing the median (midline), 25th-75th percentiles (boxes), and minimum-maximum range (whiskers); Student's t-test with Sidak's correction. Conditions for each gene are, from left to right, NC WT, NC CKO, HFMCD WT, and HFMCD CKO.
[0414] [Figures 44A-44E] Box and whisker plots showing that hepatocyte-specific Il11ra1 deficiency in mice protects against the WDF diet-induced NASH phenotype. (A-E) Data are shown for control and CKO mice fed NC and WDF diets according to the experimental procedure described in Figure 37A. (A and B) mRNA expression levels of (A) pro-inflammatory markers (TNFα, Ccl2, Ccl5) and (B) fibrotic markers (Col1a1, Col1a2, Col3a1, Acta2) in the liver, as shown in Figure 37L. (C) Fasting blood glucose levels. (D) Serum triglyceride levels. (E) Serum cholesterol levels. (A-E) Data are shown as box and whisker plots showing the median (center line), 25th-75th percentiles (boxes), and minimum-maximum range (whiskers); Student's t-test with Sidak's correction. (A and B) The conditions for each gene are, from left to right, NC WT, NC CKO, WDF WT, and WDF CKO. (C-E) The conditions for each gene are, from left to right, NC WT, NC CKO, WDF WT, and WDF CKO.
[0415] [Figures 45A-45D]A schematic diagram and boxplots are shown showing that hepatocyte-specific IL11 cis-signaling, but not IL11 trans-signaling, induces WDF diet-induced steatohepatitis in mice. (A) Schematic diagram showing the structure and amino acid positions of each domain of the full-length membrane-bound IL11RA (left) and the domains used to construct soluble IL11RA (right). (B-D) Data obtained by injecting AAV8-Alb-Null, AAV8-Alb-mbIl11ra1 (full-length membrane-bound Il11ra1), or AAV8-Alb-sIl11ra1 (soluble Il11ra1) into Il11ra1+ / + (WT) mice or mice lacking extensive Il11ra (Il11ra1- / -; KO mice) and feeding them a WDF diet, according to the experimental procedure described in Figure 38A. (B) Serum IL11RA levels in KO mice injected with AAV8-Alb-Null or AAV8-Alb-sIl11ra1 and fed a WDF diet. (C and D) Liver mRNA expression levels of (C) pro-inflammatory markers (TNFα, Ccl2, Ccl5) and (D) fibrotic markers (Col1a1, Col1a2, Col3a1, Acta2). (B–D) Data are shown as boxplots showing the median (center line), 25th–75th percentiles (boxes), and minimum–maximum range (whiskers); Student's t-test with Tukey's correction. (C and D) The conditions for each gene are, from left to right, NC Null WT, WDF Null WT, WDF Null KO, WDF mbIl11ra1 KO, and WDF sIl11ra1 KO.
[0416] [Figures 46A-46L]Schematic diagram, images, and boxplots show that steatohepatitis is induced by hepatocyte-specific IL11 cis-signaling, but not by IL11 trans-signaling, in mice fed an HFMCD diet. (A) Schematic diagram showing the experiments shown in (B–L) in which WT and KO mice were fed an HFMCD diet. KO mice were intravenously injected with AAV8-Alb-Null, AAV8-Alb-mbIl11ra1, or AAV8-ALB-sIl11ra1, while WT mice were administered AAV8-Alb-Null as a control. Starting 3 weeks after administration of each virus, mice were fed an HFMCD diet for 4 weeks. (B) Western blots showing IL11RA and GAPDH concentrations in the liver. (C) Serum IL11RA levels. (D) Representative macroscopic photographs and H&E stained images of livers. (E) Triglyceride content in the liver. (F) Serum ALT levels. (G) Serum AST levels. (H) Liver GSH levels. (I) Liver collagen content. (J and K) Liver mRNA expression levels of (J) pro-inflammatory markers (TNFα, Ccl2, Ccl5) and (K) fibrotic markers (Col1a1, Col1a2, Col3a1, Acta2). (L) Western blot analysis showing the activation status of ERK and JNK in the liver. (C, E-K) Data are shown as box plots showing the median (center line), 25th-75th percentiles (boxes), and minimum-maximum range (whiskers); Student's t-test with Tukey's correction. (E-I) Conditions, from left to right, are NC Null WT, HFMCD Null WT, HFMCD Null KO, HFMCD mbIl11ra1 KO, and HFMCD sIl11ra1 KO. (J and K) The conditions, from left to right, are NC Null WT, HFMCD Null WT, HFMCD Null KO, HFMCD mbIl11ra1 KO, and HFMCD sIl11ra1 KO.
[0417] [Figure 47A-47B]Graphs and images showing that pancreatic stellate cells (PSCs) express IL-11Rα and gp130, but not IL-6Rα. (A) Single-cell RNA sequencing analysis of Il6st (encoding gp130), Il11ra1, and Il6ra expression in mouse pancreatic stellate cells and pancreatic duct cells. (B) Immunofluorescence analysis of gp130, IL11RA, and IL6RA protein expression in human pancreatic stellate cells.
[0418] [Figure 48A-48B] Boxplots and images show the activation of pancreatic stellate cells (PSCs) into a collagen-expressing, αSMA-positive, fibrotic phenotype. (A) High-content imaging assays were performed in vitro to quantify the percentage of ACTA2-positive cells and the fluorescence intensity of type I collagen per unit area. (B) Representative images are shown for high-content imaging assays in vitro to quantify the fluorescence intensity of type I collagen per unit area. Pancreatic stellate cells were stimulated in vitro with the indicated factors in the presence or absence of an anti-IL-11RA neutralizing antibody or an IgG isotype control antibody for 24 hours.
[0419] [Figures 49A-49C] Schematic diagrams, boxplots, and images are shown for an experiment in which pancreatic fibrosis was induced in vivo in transgenic mice capable of inducing IL-11 expression specifically in fibroblasts. (A) Schematic diagram of an experiment in which IL-11 expression was induced in fibroblasts by treating Col1a2-CreER Rosa26Il11 / + (IL11 Tg) transgenic mice with tamoxifen. (B) Hydroxyproline content in pancreatic tissue from control and IL11 Tg mice after 24 days. (C) Representative images of Masson's Trichrome staining of pancreatic tissue from control and IL11 Tg mice after 24 days.
[0420] [Figures 50A-50C] Schematic diagrams, boxplots, and images are shown for the effect of antagonism on IL-11-mediated signaling in a pancreatic duct ligation (PDL) pancreatic injury model. (A) A schematic diagram of an experiment in which pancreatic injury was induced in mice by pancreatic duct ligation followed by treatment with an anti-IL-11RA neutralizing antibody or an IgG isotype control antibody is shown. (B) The weight of the ligated pancreatic lobes in mice treated with an anti-IL-11RA neutralizing antibody or an IgG isotype control antibody 14 days after treatment is shown. (C) Representative images of Masson's Trichrome staining of pancreatic tissue from mice treated with an anti-IL-11RA neutralizing antibody or an IgG isotype control antibody 14 days after treatment are shown. [Example]
[0421] In the following examples, the present inventors demonstrate that inhibiting IL-11-mediated signaling can reduce the severity of and ameliorate the symptoms of various metabolic diseases.
[0422] Example 1: General Methods for Examples 1-4 IL-11RA knockout mice Mice on a C57Bl / 6J genetic background (B6.129S1-Il11rα tm1Wehi Il11rα (Il11rα) from the Jackson Laboratory (J. / J.) - / - We generated mice lacking a functional allele of .
[0423] Treatment with anti-IL-11 or anti-IL-11Rα antibodies Mice were intraperitoneally injected with 10 mg / kg of anti-IL-11 or anti-IL-11Rα antagonist antibodies or an equivalent amount of isotype-matched IgG control antibody. Anti-IL-11 antibodies inhibit IL-11-mediated signaling by binding to mouse IL-11, and anti-IL-11Rα antibodies inhibit IL-11-mediated signaling by binding to mouse IL-11Rα.
[0424] More specifically, the anti-IL-11 antibody used in this example is mouse anti-mouse IL-11 IgG X203, described, for example, in Ng et al., Sci Transl Med. (2019) 11(511) pii: eaaw1237 (also reported in Ng, et al., "IL-11 is a therapeutic target in idiopathic pulmonary fibrosis." bioRxiv 336537; doi: https: / / doi.org / 10.1101 / 336537). X203 is also known as "Enx203" and comprises a VH region set forth in SEQ ID NO: 92 in WO 2019 / 238882(A1) (SEQ ID NO: 22 in the present disclosure) and a VL region set forth in SEQ ID NO: 94 in WO 2019 / 238882(A1) (SEQ ID NO: 23 in the present disclosure).
[0425] The anti-IL-11Rα antibody used in this example is mouse anti-mouse IL-11Rα IgG X209, described, for example, in Widjaja et al., Gastroenterology (2019) 157(3):777-792 (also reported in Widjaja, et al., "IL-11 neutralizing therapies target hepatic stellate cell-induced liver inflammation and fibrosis in NASH," bioRxiv 470062; doi: https: / / doi.org / 10.1101 / 470062). X209 is also known as "Enx209" and comprises a VH region set forth in SEQ ID NO: 7 in WO 2019 / 238884(A1) (SEQ ID NO: 24 in the present disclosure) and a VL region set forth in SEQ ID NO: 14 in WO 2019 / 238884(A1) (SEQ ID NO: 25 in the present disclosure).
[0426] feed Using a fructose-supplemented Western diet (WDF), we established metabolic disorders that closely resemble those seen in humans with obesity, type 2 diabetes, or nonalcoholic fatty liver disease (NAFLD) (Baena et al., Sci Rep (2016) 6: 26149, Machado et al., PLoS One (2015) 10:e0127991).
[0427] Specifically, to establish metabolic diseases such as obesity and type 2 diabetes, mice were fed a Western diet (WDF) (D12079B, Research Diets) for 16 weeks, starting at 12 weeks of age, supplemented with 15% wt / vol fructose dissolved in drinking water.
[0428] We also established a cachexia-like metabolic disorder using a high-fat, methionine- and choline-deficient diet (HFMCD). Specifically, C57BL / 6N mice were fed a methionine- and choline-deficient diet (HFMCD) supplemented with 60 kcal of fat (A06071301B, Research Diets) to establish the weight loss and lean body mass loss seen in cachexia.
[0429] Control subjects were fed normal chow (NC, Specialty Feeds) and drinking water.
[0430] Body composition analysis using EchoMRI Total body fat mass and lean body mass were measured every 2 weeks by EchoMRI analysis using the 4in1 Body Composition Analyzer for Live Small Animals.
[0431] Measuring fasting blood glucose levels To measure fasting blood glucose levels, mice were fasted for 6 hours, then blood was collected (by snipping the tip of the tail) and fasting blood glucose levels were measured using an Accu-Chek blood glucose meter.
[0432] Intraperitoneal glucose tolerance test (ipGTT) Mice were fasted for 6 hours before undergoing the intraperitoneal glucose tolerance test. Basal fasting blood glucose levels were measured by cutting the tip of the tail and using an Accu-Chek blood glucose meter. Two grams of glucose per kilogram of lean body mass was injected intraperitoneally, and blood glucose levels were measured every 15 minutes for up to two hours. The area under the curve (AUC) was calculated and plotted as a bar graph.
[0433] Histological analysis of islets of Langerhans, glucagon, and insulin in the pancreas For histological analysis, pancreatic samples were excised, fixed in 4% neutral buffered formalin (NBF) for 24 hours at room temperature, and stored in 30% sucrose. Five-micrometer-thin frozen sections were stained by overnight incubation with glucagon or insulin antibodies according to standard protocols, visualized with the ImmPRESS HRP IgG Polymer Detection Kit (Vector Laboratories) containing ImmPACT DAB Peroxidase Substrate (Vector Laboratories), and observed under a light microscope.
[0434] Example 2: Antagonism of IL-11-mediated signaling in obesity-related disorders To investigate the effects of antagonism on IL-11-mediated signaling in obesity and obesity-related disorders (e.g., type 2 diabetes), we performed IL-11 receptor α chain knockout (IL11-RA) mice. - / - ) mice were used to perform in vivo experiments in diet-induced mouse models of these metabolic diseases, as well as in vivo experiments in which mice were treated with anti-mouse IL-11 antagonist antibody or anti-mouse IL11RA antagonist antibody.
[0435] IL11RA knockout mice fed normal chow diet (NCD) or fructose-supplemented Western diet (WDF) displayed an improved metabolic phenotype compared with IL11RA-expressing wild-type littermates.
[0436] Figures 1A and 1B show that wild-type mice gained more weight than IL11RA knockout mice. Figures 2A and 2B show that IL11RA knockout mice had significantly less total body fat than wild-type mice. Figure 3 shows that IL11RA knockout mice had significantly lower fasting blood glucose levels than wild-type mice. Figure 4 shows that IL11RA knockout mice had significantly lower serum triglyceride levels than wild-type mice. Figures 5A and 5B show that IL11RA knockout mice had significantly lower serum cholesterol levels than wild-type mice.
[0437] These results suggest that reducing IL-11-mediated signaling has beneficial metabolic effects.
[0438] Next, the present inventors examined the effects of an anti-IL-11RA antagonist antibody or a control IgG antibody on mice fed a WDF diet.
[0439] Surprisingly, mice fed a WDF diet and treated with anti-IL-11RA antibody showed significantly reduced body weight compared with mice fed a WDF diet and treated with an IgG control antibody (Fig. 6A).Furthermore, mice fed a WDF diet and treated with anti-IL-11RA antibody showed significantly reduced fat mass (Fig. 6B), similar to IL11RA KO mice (Fig. 3).
[0440] Interestingly, the anti-IL-11RA antibody-treated mice had increased lean body mass compared with the IgG control antibody-treated mice, suggesting that suppressing IL-11 signaling in the WDF diet-induced metabolic disease restored muscle mass. Furthermore, intraperitoneal glucose tolerance test (ipGTT) showed that the anti-IL-11RA antibody-treated mice had significantly improved glucose tolerance along with improved fasting blood glucose levels (Figures 7A and 7B).
[0441] Furthermore, we also examined the effects on the pancreas using the aforementioned assay. Surprisingly, we found that mice fed a WDF diet and treated with anti-IL-11RA antibody exhibited significant protection against the loss of pancreatic weight induced by the WDF diet compared with mice treated with an IgG control. This protective effect was observed both when treated between weeks 8 and 16 (to protect against metabolic disease-related effects) and between weeks 16 and 24 (to reverse metabolic disease-related effects) (Figure 8).
[0442] Figure 9A shows that serum cholesterol levels in WDF-fed mice treated with anti-IL-11RA antibody were significantly lower than in WDF-fed mice treated with control IgG antibody. Figure 9B shows that serum triglyceride levels in WDF-fed mice treated with anti-IL-11RA antibody were significantly lower than in WDF-fed mice treated with control IgG antibody. Figure 9C shows that fasting blood glucose levels in WDF-fed mice treated with anti-IL-11RA antibody were significantly lower than in WDF-fed mice treated with control IgG antibody.
[0443] Furthermore, immunohistochemical analysis of the pancreas revealed increased islet glucagon and insulin staining and islet hyperplasia in WDF-fed and IgG-treated mice (Figures 10A and 10B), features commonly seen in type 2 diabetes (Bonner-Weir and O'Brien Diabetes (2008) 57:2899-2904). Treatment of WDF-fed mice with anti-IL-11RA antibody at 16–24 weeks significantly reduced islet hyperplasia and glucagon staining and improved islet insulin expression (Figures 10A and 10B), suggesting that antagonism of IL-11-mediated signaling may be useful in improving and reversing metabolic disorders caused by a Western diet.
[0444] Example 3: Antagonism against IL-11-mediated signaling and cachexia The effect of anti-IL-11 therapy on a mouse model of cachexia was evaluated.
[0445] Feeding mice a methionine-choline-deficient (MCD) diet induces severe nonalcoholic steatohepatitis (NASH), liver inflammation, and fibrosis, leading to severe and persistent weight loss (up to 30% body weight loss after 3 weeks on the MCD diet). Mice fed the MCD diet have a 36% higher metabolic rate than mice fed a normal chow diet (NCD) and a strong appetite-stimulating environment (lower leptin, blood glucose, triglyceride / cholesterol, and insulin levels), yet do not increase food intake (Rizki et al. J. Lipid Res. (2006) 47:2280-2290). Therefore, the MCD diet model is a well-known model of cachexia, sharing many characteristics with cancer-associated cachexia. Steatohepatitis has been frequently reported in experimental and human cancer cachexia and is important in the wasting syndrome, but its role is not fully understood.
[0446] Five-week-old male mice were fed a methionine- and choline-deficient (MCD) diet (A06071301B, Research Diets) supplemented with 60 kcal of fat. This diet, called a high-fat methionine- and choline-deficient diet (HFMCD), induces more severe NASH than a methionine- and choline-deficient diet alone. Control mice were fed a regular chow diet (NC; Specialty Feeds). For the same treatment period, mice were intraperitoneally injected twice weekly with 10 mg / kg of anti-IL-11 or anti-IL-11RA antibodies, or the same concentration of IgG isotype control, starting one week after starting the HFMCD diet. Body weight was measured weekly.
[0447] The results are shown in Figures 11A and 11B. Anti-IL-11 therapy was found to have a significant beneficial effect on body weight, indicating that suppressing IL-11-mediated signaling can alleviate cachexia-associated weight loss. All mice (n ≥ 5 / group) fed the HFMCD diet lost approximately 15% of their body weight after the first week of the steatohepatitis-inducing HFMCD diet. However, those treated with anti-IL-11 or anti-IL-11RA therapy quickly regained weight, returning to normal or near-normal weight by week 5 (Figure 11A). While mice fed the NC diet gradually gained weight, mice fed the HFMCD diet and treated with the IgG control lost weight over the treatment period, with a weight loss of over 30%. An example of a comparison of mouse body size is shown in Figure 11B. Thus, in vivo suppression of IL-11-mediated signaling was found to ameliorate cachexia in a mouse model of anorexia / cachexia.
[0448] To further explore the effects of inhibiting IL-11-mediated signaling on cachexia, we tested various doses of anti-IL-11 therapy in the MCD diet model. Similar to previous experiments, cachexia was induced in 5-week-old male mice by feeding either an HFMCD diet or an NC diet for 1 week. This resulted in a 15% weight loss in the MCD-fed mice. After the first week, mice were intraperitoneally injected twice weekly with anti-IL-11 or anti-IL-11RA antibodies at doses of 0.5 mg / kg, 1 mg / kg, 5 mg / kg, or 10 mg / kg. Three antibodies were tested in this experiment: two anti-IL-11 antibodies ((1) and (2)) and one anti-IL-11RA antibody. An IgG isotype antibody was used at 10 mg / kg as a control.
[0449] Body weight and food intake were measured weekly. Food intake was measured as the average food intake (g / animal / week) from the feeder in each cage (n = 3 animals per cage).
[0450] Body weight measurements are shown in Figures 12A-12C. All three anti-IL-11 therapies were found to increase body weight in a dose-dependent manner, indicating reversal of cachexia. The highest dose had the greatest reversal effect on cachexia. Mice fed the NC diet gradually gained weight, while mice fed the HFMCD diet and treated with the IgG control lost approximately 30% of their body weight during the treatment period.
[0451] Food intake measurements are shown in Figures 13A-13C. All three anti-IL-11 therapies were found to increase food intake in a dose-dependent manner. The highest dose had the greatest effect on food intake, while mice treated with the IgG control showed a slight decrease in food intake. Treatment with anti-IL-11RA antibody was found to be most effective in reversing weight loss and produced the greatest increase in food intake.
[0452] Given that acute illnesses such as trauma and sepsis can also be associated with anorexia and cachexia, we next investigated the effect of antagonizing IL-11-mediated signaling on anorexia and cachexia in a mouse model of acute kidney injury.
[0453] Renal injury was induced in 10-week-old male mice by intraperitoneal injection of folic acid (180 mg / kg) dissolved in vehicle (0.3 M NaHCO3). Control mice received vehicle alone. Mice were sacrificed 28 days after injection. From 1 hour before folic acid administration until sacrifice, mice were intraperitoneally injected every 3 days with 20 mg / kg of anti-IL-11 antibody, anti-IL-11RA antibody, or the same concentration of IgG isotype control.
[0454] The results are shown in Figure 14A. Folic acid induction of renal injury resulted in severe, acute-phase renal injury bilaterally, accompanied by rapid anorexia / cachexia and weight loss. Mice (n=7 / group) treated with anti-IL-11Rα or anti-IL-11 therapy at the time of induction and throughout renal injury recovered weight more rapidly than IgG controls, returning to normal or near-normal weight by 3 weeks.
[0455] In the second experiment, kidney damage was induced by intraperitoneal injection of folic acid in the same manner as in the previous experiment. Starting 21 days after the induction of kidney damage, mice were treated with anti-IL-11 antibody or IgG control alone. Mice were weighed before and after antibody treatment. Normal mice that did not receive folic acid were used as controls.
[0456] The results are shown in Figure 14B. Mice treated with anti-IL-11 antibody began to regain weight from the start of treatment, indicating that weight loss associated with wasting can be ameliorated in the later stages of the disease.
[0457] In additional experiments, mice underwent unilateral ureteral obstruction (UUO) to induce acute kidney injury. Unilateral ureteral obstruction was performed on 12-week-old mice. Briefly, mice were anesthetized with an intraperitoneal injection of ketamine (100 mg / kg) / xylazine (10 mg / kg). Sufficient anesthesia was confirmed by the loss of the interdigital reflex. The left flank of each mouse was then shaved. A longitudinal incision was made in the skin with a scalpel, and a second incision was made in the peritoneum to expose the kidney. The kidney was then brought to the surface of the body using forceps, and the ureter below the kidney was ligated twice with surgical silk suture. The ligated kidney was gently returned to its anatomical position and refilled with sterile saline to replace fluid loss. The incision was then sutured. Mice were treated with the antibiotic enrofloxacin (15 mg / kg, subcutaneously) and the analgesic buprenorphine (0.1 mg / kg, subcutaneously) for three consecutive days after surgery. Ten days after ligation, mice were sacrificed. From day 4 after surgery until sacrifice, mice were intraperitoneally injected with 20 mg / kg of anti-IL-11 antibody (twice weekly) or the same concentration of IgG isotype control.
[0458] The results are shown in Figure 15. Mice in both groups initially lost a similar amount of weight (approximately 6%) due to anorexia associated with surgical trauma. Mice treated with anti-IL-11 therapy (20 mg / kg twice weekly from day 4 after unilateral ureteral obstruction until sacrifice) regained weight more quickly than mice treated with the IgG control, returning to normal weight within 4 days.
[0459] Thus, antagonism of IL-11-mediated signaling can promote therapeutic weight restoration in acute disease models.
[0460] Next, we examined the effect of IL-11 overexpression on mouse body weight by injecting recombinant mouse IL-11 or inducing expression of an IL-11 transgene.
[0461] Recombinant murine IL-11 (rmIL11) was reconstituted in saline to a concentration of 50 μg / ml. Ten-week-old wild-type male C57BL / 6J mice were injected subcutaneously daily for 21 days with 100 μg / kg rmIL11 in saline (n = 19) or an equivalent volume of saline (n = 15).
[0462] The results are shown in Figure 16A. Administration of rmIL11 was found to slow the progression of normal weight gain. Mice injected with rmIL11 daily for 21 days gained less weight during the treatment period than mice administered saline alone.
[0463] IL-11 transgenic (IL-11-Tg) mice were generated. Heterozygous Rosa26-IL11 mice were crossed with Col1a2-CreER mice to generate double heterozygous Col1a2-CreER:Rosa26-IL11 offspring mice (IL-11-Tg mice) expressing the IL-11 transgene in fibroblasts. To induce the IL-11 transgene via Cre, 6-week-old IL-11-Tg mice were intraperitoneally injected with 50 mg / kg of tamoxifen (Sigma-Aldrich) for 10 consecutive days and sacrificed on day 21 (n = 14). As a control, Rosa26:Il11 mice (which do not carry the Col1a2-CreER allele) were injected with the same dose of tamoxifen for 10 consecutive days (n = 10).
[0464] The results are shown in Figure 16B. IL-11-Tg mice showed early signs of cachexia, stopped gaining weight, and lost weight over time, indicating that IL-11-mediated signaling promotes weight loss associated with wasting.
[0465] Example 4: Antagonism of IL-11-mediated signaling in a non-alcoholic steatohepatitis (NASH) mouse model We investigated the role of IL-11 signaling in the pathogenesis of nonalcoholic steatohepatitis (NASH).
[0466] 4.1 Method Hepatic stellate cells (HSCs) or hepatocytes were stimulated with IL-11, and the effects were assessed using high-content cell imaging, immunoblotting, ELISA, and invasion assays. IL-11 gain-of-function and loss-of-function experiments were performed in vitro and in vivo using genetic and pharmacological approaches. IL-11 signaling was examined using an ERK inhibitor. Furthermore, the effects of anti-IL-11 or anti-IL11RA therapy were evaluated in three preclinical NASH models using a methionine- and choline-deficient diet or a Western diet supplemented with fructose water. Furthermore, phenotypic analysis was performed using hydroxyproline assays, qPCR, RNA-seq, Western blot, histological analysis, Cytofluor, lipid biomarkers, and metabolic biomarkers.
[0467] Animal experiments All animal experiments were approved by the SingHealth Institutional Animal Care and Use Committee (IACUC) and were performed in accordance with the IACUC guidelines. All mice were provided with food and water ad libitum.
[0468] NASH mouse model Wild-type mice fed a high-fat, methionine-choline-deficient (HFMCD) diet Five-week-old male C57BL / 6N mice were fed a methionine-choline-deficient diet (A06071301B16, Research Diets) supplemented with 60 kcal% fat. Control mice were fed a normal chow diet (NC, Specialty Feeds). The duration of diet feeding and antibody therapy is described herein.
[0469] db / db mice fed a methionine-choline-deficient (MCD) diet Male BKS.Cg-Dock7 mice on a C57BL / 6J genetic background m + / +Lepr db J(db / db) mice were fed a methionine- and choline-deficient diet (MCD, A02082002BRi, Research Diets) for 8 weeks, resulting in hepatic steatosis at 12 weeks of age. Mice of the same genotype served as controls. The duration of diet feeding and antibody therapy was described herein.
[0470] Wild-type mice fed a fructose-supplemented Western diet (WDF) To mimic a NAFLD / NASH-like condition in humans, 10-week-old male C57Bl / 6J mice were fed a Western diet (D12079B, Research Diets) supplemented with 15% wt / vol fructose dissolved in drinking water. 17,18 Control mice were fed regular chow and tap water. The duration of diet feeding and antibody therapy is described herein.
[0471] Il11ra-deficient mice Mice lacking a functional allele of Il11rα (Il11ra - / - ) was in the C57Bl / 6J genetic background (B6.129S1-Il11ra tm1Wehi / J, Jackson Laboratory). - / - mice and their wild-type littermates (Il11ra + / + (1) Starting at 5 weeks of age, mice were fed a HFMCD diet for 10 weeks or a WDF diet for 16 weeks starting at 12 weeks of age to develop NASH. Control mice were fed a normal chow diet (NC) for the same period.
[0472] In vivo administration of IL-11 10-week-old male Col1a1-GFP reporter mice 19 Alternatively, wild-type C57BL / 6J mice were subcutaneously injected daily with 100 μg / kg of recombinant mouse Il-11 (rmIl-11) or an equivalent volume of saline for 21 days.
[0473] In vivo administration of anti-IL-11 monoclonal antibody or anti-IL11RA monoclonal antibody Mice were intraperitoneally injected with anti-IL-11 antagonist antibody, anti-IL11RA antagonist antibody, or an equivalent amount of IgG isotype control for the treatment period indicated in each figure.
[0474] Measuring fasting blood glucose levels Mice were fasted for 6 hours, then blood was collected (by snipping the tip of the tail) and fasting blood glucose levels were measured using an Accu-Chek blood glucose meter.
[0475] cell culture Cells (atrial fibroblasts, hepatic stellate cells, and hepatocytes) were grown and maintained at 37°C and 5% CO2. Growth medium was changed every 2–3 days, and cells were passaged at 80–90% confluence using standard trypsinization techniques. All experiments were performed using low-passage cells (P1–P2). Cells were serum-starved for 16 hours before stimulation. Stimulated cells were compared to unstimulated cells grown under the same conditions (serum-free medium) for the same period in the absence of stimulation.
[0476] Primary human atrial fibroblasts Human atrial fibroblasts were used in the same manner as previously reported. 11 The cells were prepared and cultured according to the method described above.
[0477] Primary human hepatic stellate cells (HSCs) Primary human hepatic stellate cells (5300, ScienCell) were cultured on poly-L-lysine coated plates (2 μg / cm 2The cells were cultured in complete medium for hepatic stellate cells (5301, ScienCell) in a 2000-well plate (0403, ScienCell).
[0478] Human primary hepatocytes Human hepatocytes (5200, ScienCell) were grown and maintained in hepatocyte medium (5201, ScienCell) supplemented with 2% fetal bovine serum (FBS) and 1% penicillin-streptomycin.
[0479] THP-1 cells THP-1 cells (ATCC) were cultured in RPMI 1640 medium (A1049101, Thermo Fisher Scientific) supplemented with 10% FBS and 0.05 mM β-mercaptoethanol. Differentiation of THP-1 cells was then induced by stimulation with 10 ng / ml phorbol 12-myristate 13-acetate (PMA, P1585, Sigma) in RPMI 1640 medium for 48 hours.
[0480] Operetta high-throughput phenotyping assay The Operetta assay was performed as previously reported with minor modifications as described below. 11 5 × 10 hepatic stellate cells or hepatocytes were placed in a 96-well black CellCarrier plate (PerkinElmer). 3Cells were seeded at a density of 1000 cells / well. For each experimental condition, cells were fixed with 4% paraformaldehyde (PFA) (28908, Thermo Fisher Scientific), permeabilized with 0.1% Triton X-100 (Sigma), and nons...
Claims
1. A pharmaceutical for the treatment or prevention of a metabolic disease, comprising as an active ingredient an agent capable of inhibiting interleukin-11 (IL-11)-mediated signal transduction, the metabolic disease is or comprises obesity, type 2 diabetes mellitus (T2D), pre-diabetes, overweight, metabolic syndrome, pregnancy-related hyperglycemia, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, pancreatic insufficiency, pancreatitis, acute pancreatitis, chronic pancreatitis, steatosis, lipotoxicity, non-alcoholic fatty liver disease (NAFLD), non-alcoholic fatty liver (NAFL), insulin resistance or hyperglucagonemia; The pharmaceutical agent, wherein the agent capable of inhibiting IL-11-mediated signal transduction is (i) an anti-IL-11 antagonist antibody or an antigen-binding fragment thereof against IL-11-mediated signal transduction, or (ii) an anti-IL-11Rα antagonist antibody or an antigen-binding fragment thereof against IL-11-mediated signal transduction.
2. The pharmaceutical product according to claim 1 , wherein the drug is capable of preventing or reducing binding of interleukin-11 (IL-11) to the interleukin-11 receptor (IL-11R).
3. The pharmaceutical agent of claim 1 or 2, wherein the pharmaceutical agent is administered to a subject in which expression of interleukin-11 (IL-11) or IL-11 receptor (IL-11R) is upregulated.
4. The pharmaceutical composition of any one of claims 1 to 3, wherein the pharmaceutical composition is administered to a subject in which expression of interleukin-11 (IL-11) or interleukin-11 receptor (IL-11R) is known to be upregulated.
Citation Information
Patent Citations
Treatment of fibrosis
JP2019502689A
Il-11 antibodies
WO2018109174A2
